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Abstract 
 
The recent growth in the biopharmaceutical industry is remarkable due to the 
introduction of many new therapeutic proteins for the treatment of different 
diseases. The production processes of the biotherapeutics are complicated 
and have to be maintained under strict and regulated conditions. Therefore, 
the development of rapid, sensitive and cost-effective analytical assays is 
highly demanded for monitoring the biofermentation processes and the key 
parameters that could affect the final product quality and production 
consistency. 
 The overall aim of this research is to develop sensitive and selective 
analytical methods for the determination of raw material components in 
highly complex samples supplied from the biopharma industry based on 
solid phase extraction (SPE) and rapid resolution liquid chromatography 
(RRLC). This development includes the use of narrow-bore columns packed 
with sub-2 µm silica particles or made of monolithic materials. The 
developed methods were applied for the qualitative and quantitative analysis 
of common monosaccharides, including sialic acid, and cysteine/cystine ratio 
in a range of biopharmaceutical production samples such as raw material 
yeast extract powders, fermentation feedstocks, chemically defined media 
and in-process fermentation broth samples in which they were taken from 
different lots in order to estimate lot-to-lot variability. For evaluation 
purposes, standard analytical performance criteria were examined for all the 
developed methods. In addition, a novel solid phase microextraction in a 
pipette tip for selective enrichment of galactosylated proteins is presented. 
The extraction device is fabricated by in-situ photopolymerisation of ethylene 
dimethacrylate porous polymer monolith within the confines of 20 µL 
polypropylene pipette tip. Then the surface of the monolith was significantly 
enhanced by immobilising gold nano-particles (AuNPs) which was 
functionalised with Erythrina cristagalli lectin (ECL) afterwards. The ECL-
modified tip was successfully applied for the enrichment of galactosylated 
  ii 
proteins versus non-galactosylated proteins from different sample matrices 
including Escherichia coli cell lysate. Reversed-phase capillary LC was used 
to validate the efficiency and selectivity of the developed extraction device 
which resulted in an increase in extraction recovery of ~95 % due to the 
AuNPs enhanced surface area. 
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Chapter 1 
An introduction to column stationary phase 
developments in liquid chromatography  
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1.1. An introduction to liquid chromatography 
 
Chromatography is a powerful analytical method that is widely used for the 
separation, identification and determination of the chemical components in 
complex mixtures [1]. It was first demonstrated by the Russian botanist 
Mikhail Tswett in 1906 when he separated different plant pigments by 
passing an extract of the leaves through a glass column packed with calcium 
carbonate [2]. The term chromatography came from the Greek words, 
chroma meaning "colour" and graphein meaning "to write" [3]. Tswett's 
invention went virtually unnoticed for several decades [2]; however, the 
application of chromatography has grown incredibly since then because of 
the great need for analytical methods for characterising complex mixtures 
[3].  
Chromatography may be defined as the separation of a mixture of 
components based on the distribution coefficients for each component 
between two phases; a stationary phase and a mobile phase as shown in 
Figure 1.1 [1]. In liquid chromatography, the mobile phase is liquid consisting 
of a solvent or mixture of solvents and the stationary phase is a solid 
support. Chromatographic separations can be classified based on the 
interaction mechanism of the solute with the stationary phase according to 
the following: (i) Adsorption chromatography; this is the traditional separation 
mode in which the stationary phase is solid and the mobile phase is liquid. 
The mixture components adsorb on the surface of the solid phase. The more 
strongly a solute is adsorbed, the slower it travels through the column [2]. (ii) 
Partition chromatography; the stationary phase is liquid bonded to a solid 
support and the mobile phase is a liquid. The separation of the mixture 
components is based on their equilibration between the liquid on the 
stationary phase surface and the mobile phase. In the liquid-liquid partition 
chromatography, if a polar stationary phase with a non-polar mobile phase is 
used, polar compounds are retained and separated. This is called "normal-
phase chromatography". If a non-polar stationary phase with a polar mobile 
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phase is used, non-polar compounds are retained and separated. This is 
called "reversed-phase chromatography" [2]. (iii) In ion exchange 
chromatography, the stationary phase consists of either cationic exchange 
or anionic exchange groups attached to polymeric or silica materials and the 
mobile phase consists of an electrolyte. The separation of the mixture 
components is based on the exchange of ionic analytes with the counter-
ions on the stationary phase [4]. (iv) In size exclusion chromatography, the 
separation of a mixture of components is based on the size of the analyte 
molecules. Large molecules are excluded from the pores of the stationary 
phase particles and eluted first, whereas small molecules are retained in the 
pores for a while before elution [4]. 
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 Figure 1.1: Schematic of the chromatographic process showing the separation of 
sample components during their passage through the column. Adapted from [3].  
 
Until the late 1960s, the passage of the mobile phase through the 
solid phase in the column was driven by its own weight preventing any 
attempts for efficient and fast separations. In the late 1950s, the substantial 
  4 
developments in gas chromatography (GC), which had led to a system with 
a pump to deliver and control the flow rate of the mobile phase and a 
detector for on-line monitoring of analytes, were extended to liquid 
chromatography leading to High Performance Liquid Chromatography 
(HPLC) [5, 6]. 
Thus, HPLC is the term used to describe liquid chromatography in 
which the separation of sample components is accomplished by pumping 
the liquid mobile phase through a column that contains the stationary phase. 
The HPLC instrument, as illustrated in Figure 1.2, consists of a pump to 
deliver the mobile phase through the system, an injector to introduce the 
sample, a column to separate the sample components, a detector to monitor 
the separated components and a data collection device for interpretation and 
storage of results [4, 7]. 
 
 
 
Figure 1.2: Schematic of the major modules of the HPLC instrumentation. 
 
 
In the last 30 years, HPLC has become one of the most popular 
analytical instruments for the quantitative analysis of a wide range of 
pharmaceutical compounds [8, 9]. One of the main objectives of analytical 
laboratories is to develop rapid and efficient methods for qualitative and 
quantitative analysis due to a continuously growth in the number of samples 
[10]. In addition, high-throughput separations are highly demanded in 
common applications within the pharmaceutical industry such as purity 
assays, pharmacokinetic studies, and quality control [11] since faster 
separations are required to enhance productivity and reduce costs [12].  
Pump 
Injector / 
autosampler 
Column 
Column oven 
Detector 
Mobile phase 
reservoirs 
Data  
controller 
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1.2. Column stationary phase developments 
 
1.2.1. Particle-based stationary phases 
 
The column is the heart of the chromatographic system as it contains the 
most important part, the stationary phase, in which the separation of sample 
components is achieved. The column chromatographic performance 
depends on the selectivity and efficiency of the stationary phase where the 
improvement efforts have been made to achieve faster and more efficient 
separations since the introduction of HPLC. Typically, the column is 
constructed from stainless steel for rigidity at high pressures [1, 7] or it can 
be replaced by titanium or polyetheretherketone (PEEK) for more corrosion 
resistance [4]. The quality of the packed column and its backpressure, and 
therefore the separation efficiency are determined by the particle size and its 
distribution and the quality of the packing of the particles within the column 
[4, 13]. Most analytical HPLC columns range from 2 to 5 mm in internal 
diameter and from 30 to 300 mm in length [7]. The most common stationary 
phases in HPLC columns are those in which the functional group is bonded 
to silica, which has excellent physical characteristics and chromatographic 
performance [4, 7].  
In theory, it has been known since the early development of 
chromatography that packing the column with small size particles leads to 
reduced mass transfer effects and thus high efficiency with reduced analysis 
time [14, 15]. Great reduction in the size of the particles has been achieved 
in the last sixty years. For example, the size of the first particles used in the 
1950s was approximately 100 µm which has been reduced since then up to 
the development of sub-2 µm [16]. These small particles were introduced by 
Horváth and co-worker in 1988 [17] but they were not commercially available 
until 2004, due to the lack of adequate instrumentations which contain 
pumps compatible with columns packed with such small particles [10, 18]. 
Accordingly, column efficiency has been improved significantly. The plate 
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numbers per column have been increased from 200 to over 30,000 for the 
columns packed with 100 µm and sub-2 µm respectively [10, 16].  
The efficiency of a column is a number that describes peak 
broadening as a function of retention. Two major theories have been 
developed to describe the column efficiency. Plate theory was proposed by 
Martin and Synge, and the rate theory was developed by van Deemter et al. 
[7]. The chromatographic column, as proposed in the plate theory, is 
considered to consist of a number of thin sections or "plates", each of which 
allows a solute to equilibrate between the stationary phase and mobile 
phase [7]. The number of theoretical plates or plate number (N) is a measure 
of the efficiency of the column. N is defined as the square of the ratio of the 
retention time divided by the standard deviation of the peak (σ). Since the 
Wb is equal to 4σ for a Gaussian peak, 
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Since it is more difficult to measure σ or Wb, a relationship using width at half 
height (W1/2) is often used to calculate N, since W1/2 is equal to 2.355σ for a 
Gaussian peak [4], therefore: 
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The greater the number of theoretical plates (N), the more efficient the 
column is considered to be [7]. 
The movement of a solute along the column is viewed as a stepwise 
transfer from one theoretical plate to the next. The thinner the theoretical 
plates, the greater the number that can be envisaged within a given length of 
column. These terms are related as follows: 
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NLH /=                                                                                     (Eq. 1.3) 
 
Where L is the length of the column (mm). Thus, the smaller the height 
equivalent to a theoretical plate (HETP, or H), the greater is the efficiency of 
the column. In general, the H value is smaller for small size stationary phase 
particles, low mobile phase flow rates, less viscous mobile phases [7]. 
The van Deemter equation was developed in 1950s to explain band 
broadening in chromatography by correlating HETP or H with linear flow 
velocity (µ) and describes the contributions to HETP of a column: [4]. It 
considers the diffusional factors that contribute to band broadening in the 
column [7]. The contributions of these three parameters to the column 
efficiency are graphically shown in Figure 1.3. The van Deemter equation 
may be written as the following: 
 
CµB/µAH ++=                                                                 (Eq. 1.4) 
 
Where H represents the efficiency of the column and µ is the average linear 
velocity of the mobile phase. The A term is "eddy diffusion or multi-path 
effect". When the sample is introduced to the head of the column, the 
analyte molecules reach the end of the column at different times due to the 
different paths that they travelled through the stationary phase particles 
(Figure 1.4). The A term is proportional to particle size dp and is smaller in 
well-packed columns [4]. The B term represents "longitudinal diffusion" of 
the solute band in the mobile phase (Figure 1.4) and is proportional to 
diffusion coefficient (Dm) [4]. The contribution of longitudinal diffusion to plate 
height becomes significant only at low mobile phase velocities [7]. The C 
term is "resistance to mass transfer" which arises from the time lags caused 
by the slower diffusion of the solute band in and out of the stationary phase 
(Figure 1.4). It is proportional to (dp
2/Dm) and contribution from the C term is 
important at high flow rates [4]. The minimum point on the van Deemter 
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curve in Figure 1.3 indicates the minimum plate height, Hmin, and the 
optimum flow velocity at maximum column efficiency [4]. 
 
 
 
 
Figure 1.3: Hypothetical van Deemter curve showing the relationship between 
efficiency and average linear velocity. Adapted from [4]. 
 
 
 
 
Figure 1.4: Diagrams illustrating the mechanism of various van Deemter terms 
contributions. Reproduced from [4]. 
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Based on the van Deemter equation, the use of small particles leads 
to improvements in the column efficiency with reduced analysis time. The 
main advantage of reducing the size of the particles is the low mass transfer 
resistance associated with these particles in which high resolution with short 
analysis time can be achieved at higher and over a wider range linear 
velocities [10, 18]. The van Deemter plot in Figure 1.5 shows the height 
equivalent to the theoretical plate (H) versus the linear velocity for different 
particle sizes. It shows that higher column efficiencies were obtained when 
the size of the particles decreased. Therefore, columns packed with sub-2-
µm particles may obtain better resolution and reduced analysis time whereas 
the columns packed with larger particles produced a much steeper curves at 
high linear velocities as the C term in Eq. (1) is proportional to dp
2 [18]. 
 
 
 
Figure 1.5: Theoretical van Deemter curves plotted for 10, 5, 3 and 1.7 µm 
particles. Reproduced from [18]. 
 
Even though using columns packed with small particles leads to 
better resolution and rapid analysis time, the high back pressures generated 
from such columns prevent the use of conventional HPLC instruments. The 
increase in the pressure is proportional to the cube of the particle diameter 
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used. For example, a column packed with 1.7 µm particles generates a 
pressure 27 times higher than that packed with 5 µm particles under the 
same conditions [10]. Therefore, HPLC instrumentations capable of pumping 
the mobile phase at high backpressures are required for operating such 
columns.   
 
1.2.2. Introduction to monolithic stationary phases 
 
Porous monolithic materials are a relatively new class of column stationary 
phase materials that have proven to be a very good alternative to particle-
based columns. The development of monolithic materials for the purpose of 
chromatographic separation has increased significantly in the last two 
decades. Monolithic materials are constructed of a porous single piece that 
contains pores in which the liquid phase flows through and can be compared 
to a single large “particle” that does not contain interparticular voids typical of 
packed beds [19-22].  
The word “monolith” comes from the Greek and means literally “single 
stone”. It first appeared as a description of a single piece of functionalised 
cellulose sponge used for protein separation in 1993 [23] whereas this 
expression was used afterwards to describe rigid macroporous polymers 
prepared by bulk polymerisation in a closed mould [24]. Since this stage, this 
term became standard as it is an easy-to-use word compared to the early 
names such as “continuous polymer bed” [25], “continuous polymer rod” 
[26], “porous silica rod” [27] and “continuous column support” [28], which 
were previously used to describe different porous polymers. 
The concept of using monolithic materials as stationary phases in 
chromatography was first proposed by Mould and Synge in the early 1950s 
[29, 30]. Later, Kubín et al. from the Institute of Macromolecular Chemistry in 
Prague tested a methacrylate-based polymeric matrix for the purpose of 
chromatographic separations in size-exclusion mode. However, the low 
degrees of crosslinking they used led to very low permeability [31]. Even 
  11 
though the considerable potential advantages of monolithic materials had 
been proposed a relatively long time ago [32], they were not demonstrated 
until the introduction of the monolithic stationary phases in the late 1980s 
and the early 1990s as suitable materials for chromatographic separations, 
which marked a significant improvement in the column technology [33]. 
In 1992, a report was published by Svec and Fréchet [26, 34], which 
described for the first time a much simpler procedure for the in-situ 
fabrication of rigid macroporous polymers. It was prepared by filling a 
column housing with a mixture consisting of monomers, a free-radical 
initiator and porogenic solvents and heated in order to form a rigid porous 
polymer. At the same time, Soga and Nakanishi [35-37] developed a method 
to synthesise inorganic continuous beds made of porous silica. These 
materials were then utilised by Tanaka as monolithic columns in HPLC in 
which he functionalised the surface with octadecyldimethyl-(N,N-
diethylamino)silane and applied them to the separation of polypeptides [38] 
and alkylbenzenes [27]. Since the publication of these reports and the 
promising results obtained, more attention has been drawn towards these 
materials. Today rapid advances in the development of monolithic materials 
continue to appear and they now hold an impressively strong position in 
separation science and other areas of chemistry, achieved due to the 
tunable properties that lead to broad applications [39-42]. 
Depending on the nature of the material, monoliths can be divided 
into two groups: (i) organic polymer-based monoliths, such as acrylamide-
based, acrylate- or methacrylate-based, and styrene-based polymers, and 
(ii) inorganic polymer-based monoliths such as silica, which are prepared by 
sol-gel technology [13, 43].    
The idea of using the monolithic materials as an alternative to packed 
beds arose from the need to overcome some of the drawbacks associated 
with particle-based beds, based upon their physical and chemical structures 
and a number of features and benefits that they possess; mainly, the 
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achievement of rapid separation with low backpressures and low mass 
transfer resistance [44, 45].   
In general, the fabrication of the monolithic materials is relatively 
simple; the polymerisation process of a mixture consisting of monomers and 
porogenic solvents is initiated either thermally or by photo-induction [46]. 
Monoliths are formed in-situ and can be constructed to any shape or 
confined mould without the requirement for frits to retain the phase. 
Therefore, some of the problems associated with the manufacture of 
particle-based stationary phases are avoided, in particular that associated 
with the use of retaining frits, particularly in capillary column formats [46].  
As a result of this high porosity, columns made of monolithic materials 
can be operated at high flow rates (up to 10 mL.min−1 in conventional column 
formats) using conventional HPLC instruments without generating 
excessively high backpressures. Figure 1.6 shows a comparison of column 
backpressures at different flow rates obtained for a monolithic column and 
particle-based columns packed with 3.5 and 5 µm particles. Obviously, the 
backpressure obtained by the monolithic column is much lower than that for 
packed columns [13, 18]. Gaining this advantage, the separation of five β-
blocking drugs has been carried out at different flow rates using a silica-
based monolithic column (Chromolith Performance RP-18e, 100 mm × 4.6 
mm). A baseline separation of the five drugs was achieved within one minute 
at a flow rate of 9 mL.min-1 compared to 12 minutes when the flow rate was 
1 mL.min-1 without losing the efficiency [13, 18].  
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Figure 1.6: Comparison of back pressure in the monolithic and particle-based 
columns packed with 3.5 and 5 µm particles at different flow rates. Reproduced 
from [13]. 
 
 
Moreover, monolithic columns require a relatively short-time for 
column equilibration when a mobile phase gradient is used as well as the 
easy application of flow-rate gradients and the coupling of several columns 
together (L >1 m) in order to increase separation efficiency (N >100,000 
theoretical plates). This property is important for some applications such as 
proteomics and metabolomics in which high peak capacity and separation 
efficiency is required [10, 49].  
Furthermore, the structure of the monolithic materials differs from 
particle-based supports. Monolithic materials consist of continuous rods of 
interconnected channels totally filling the column. Therefore, all of the mobile 
phase must flow through the pores of the monoliths rather than around and 
between the particles in the packed columns due to the lack of interparticular 
voids in the column [50]. When the van Deemter plots of plate height versus 
mobile phase linear velocity for particle-based and monolithic columns are 
compared, one major difference is occurred, the contribution of C term. The 
contribution of the C term in the monolithic columns is much lower than that 
in particle-based columns even at high linear velocities. This is owing to 
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accelerated mass transfer as a result of convection [50]. Consequently, fast 
separations with high efficiency can be obtained with such materials [46]. 
Figure 1.7 shows the van Deemter curves for uracil on a particle-based 
packed with 5 µm particles and a monolithic column indicating that the 
monolithic column can afford operation at high flow rates without losing 
efficiency [51].  
  
 
Figure 1.7: Van Deemter plots for uracil obtained for the monolithic ( ) and 
conventional column packed with 5 µm particles ( ). Reproduced from [51]. 
 
However, monolithic columns have several disadvantages that need 
to be mentioned which may reduce their applicability. In general, the 
commercially available monolithic columns do not have a wide range of 
surface chemistries. In addition, even though it is an advantage to run the 
monolithic columns (especially with large internal diameters) at high flow 
rates with low backpressures, this could be a disadvantage at the same time 
as it consumes large volumes of mobile phase and may not be fully 
compatible with mass spectrometry [18].     
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Moreover, silica-based monoliths, in particular, have restricted pH 
stability. They are only stable at the pH range from 2 to 8 because of the 
solubility of silica in alkaline solution [52]. Also, the significant shrinkage of 
the silica-based monoliths that occurs after the preparation of these 
materials restricts their in-situ preparation in typical analytical sizes. For 
example, if a 4.6 mm rod is desired, a 6 mm rod is prepared first, removed 
from the mould and then encased within a PEEK tube [13].   
  In contrast to silica-based monoliths, organic polymer monoliths suffer 
from significantly lower peak efficiencies in most cases, particularly for small 
molecules, probably due to the micropores in their structure which negatively 
affect the efficiency and peak symmetry [53]. 
 
1.2.3. Silica-based monolithic stationary phases 
 
1.2.3.1. Introduction 
The sol-gel technology, used for the preparation of porous silica-
based monoliths, was first invented in the late 1800s [54, 55]. Later, in the 
early 1990s, a new sol-gel process was developed by Nakanishi and Soga 
for the production of such materials [35-37]. Based on that, in 1996, Tanaka 
et al. reported the first paper describing the preparation and the application 
of these materials in HPLC [27], in which they prepared the column based 
on the hydrolysis and polycondensation of tetramethoxysilane (TMOS) in the 
presence of water-soluble organic polymers, polyethylene oxide (PEO). The 
resulting silica monolith is shown in Figure 1.8. Then, the surface chemistry 
of the column was subsequently modified with C18 functionality and then the 
resulted column was compared with particle-based C18 columns packed with 
5 µm silica particles. For the separation of alkylbenzenes, the silica-based 
monolithic column showed a slight tailing with 8000 theoretical plates 
produced compared to >10,000 produced by the particle-based column. 
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Figure 1.8: SEM image of a porous silica-based monolith. Reproduced from [27]. 
 
 
Simultaneously, an alternative way for the preparation of silica-based 
monoliths was reported by Fields based on xerogel [28]. The silica xerogel 
was prepared from a potassium silicate solution. After washing and purging, 
the surface of the resulting column was derivatised in a subsequent step 
using a solution of dimethyloctadecylchlorosilane. The column was analysed 
by scanning electron microscopy (SEM) and the image obtained showed the 
inhomogeneous continuous structure of the xerogel, which was chemically 
bonded to the fused silica wall via the surface silanols, as shown in Figure 
1.9. For evaluation purposes, the column efficiency was studied using a test 
mixture consisting of ethyl benzoate and naphthalene with on-line UV 
detection. The results obtained showed the very low efficiency that the 
column possesses (5000 plates/m). The efficiency of the column could have 
been improved by fabricating more homogeneous structures with narrower 
pore size distributions, since the irregular structure of the stationary phase 
lead to a subsequent wide distribution of flow paths.   
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Figure 1.9: SEM image of silica xerogel column end. Reproduced from [28].  
 
 
In 1998, Asiaie et al. [56] published a report describing a different 
method for preparing silica-based monoliths. The method was based on 
packing fused silica capillary with octadecylated (ODS) 6 µm particles as the 
first step. Then, the packed column was thermally treated to form a 
monolithic structure. In a final step, the column was reoctadecylated in-situ 
with dimethyloctadecylchlorosilane. The resulted monolithic structure is 
shown Figure 1.10. The column efficiency was evaluated utilising micro-
HPLC and capillary electrochromatography (CEC) for the separation of small 
aromatic compounds. The efficiency of the sintered monolithic column was 
similar to the column freshly packed with the same particles.  
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Figure 1.10: SEM image of packed fused silica capillary sintered at 360 oC with 
NaHCO3 flux. Reproduced from [56].  
 
 
The preparation of silica-based monoliths within the fused silica 
capillaries is relatively straightforward and does not suffer from the shrinkage 
that occurs after their preparation in conventional analytical sizes, due to 
attachment between the capillary wall and the monolithic bed. However, 
capillary columns cannot be operated using the conventional HPLC 
instrumentations, they require special instrumentation. Silica-based 
monoliths have become commercially available from Merck KGaA Company 
(Darmstadt, Germany) in 2000. Based on the work of Nakanishi and co-
workers, the company has developed a proprietary technology for the 
preparation and cladding of 4.6 mm i.d. silica rods with a resistant PEEK 
polymer. 
 
1.2.3.2. Properties of silica-based monoliths 
The essential feature of the silica-based monolithic materials is their 
unique pore structure. Silica-based monoliths possess a bimodal pore 
structure which means that the monolithic bed has two kinds of pores; 
macropores (or through-pores) and mesopores [13]. The macropores size 
ranges from 1 to 8 µm and allows mobile phase flow through the monolithic 
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bed, whereas the mesopores on the surface of the macropores range from 
10 to 400 nm [57-59]. However, silica-based monoliths with 2 µm 
macropores and 13 nm mesopores in size are the most widely used [13]. 
Figure 1.11 shows typical SEM images of the silica-based monolithic 
structure illustrating the porous structure and the macropores and 
mesopores. The size of the macropores and mesopores can be controlled 
independently by controlling the composition of the starting mixture or the 
concentration of the silanes, such as TMOS, during the preparation process 
[60]. The porosity of silica-based monoliths is much higher than that of 
particle-based columns [61]. The total porosity of the silica-based monoliths 
is about 85 %. This is about 15 - 20 % higher than that for particle-based 
columns packed with 5 µm particles [13] whereas the external porosity is 65 
- 70 % for silica-based monoliths compared to 40 % for particle-based 
columns [62]. Conventional silica-based monolithic columns that are 
commercially available have an external porosity of 60 % and 85 % total 
porosity [27, 63].  
 
 
Figure 1.11: SEM images showing the typical porous structure of silica-based 
monolithic columns. Reproduced from [13].  
  20 
As a result, the presence of the macropores and mesopores leads to 
a high permeability with high surface area providing good chromatographic 
efficiencies comparable to particle-based columns at low backpressures. 
The permeability of the silica-based monolithic columns has been found to 
be as much as 30 times higher than a particle-based column packed with 5 
µm particles [64] and equivalent to a particle-based column backed with 11 
µm particles [65]. Moreover, the column efficiency produced by the 
commercial silica-based monolith is similar to that produced by a column 
packed with 3.5 µm particles with a backpressure half of that caused by a 
column packed with 5 µm particles [13]. These features of the silica-based 
monoliths allow the coupling of several columns which in turn lead to an 
efficient separation of complex samples. For example, Cabrera et al. have 
coupled fourteen silica-based monolithic columns to give a total length of 1.4 
m. The resulted series has been used for the separation of six 
alkylbenzenes. The separation was carried out a flow rate of 1 mL.min-1 
giving a backpressure of 11.7 MPa and plate number of 108,000 [66].  
 
1.2.3.3. Preparation of silica-based monoliths 
Silica-based monoliths are produced via sol-gel technology with 
phase separation. The preparation process mainly involves three reactions: 
(i) catalysed hydrolysis of an alkoxysilane, (ii) condensation of hydrated 
silica to form siloxane bonding, and (iii) polycondensation of the linkage of 
an additional silanol group to form cyclic oligomers as shown in Figure 1.12. 
[54, 55]. The structure properties of the silica-based monoliths depend on 
different factors that can be tuned to produce a monolith with desired 
properties. These factors involve the nature and concentrations of the 
starting reagents, the nature of the catalyst, pH, temperature, reaction time 
and the rate of hydrolysis and condensation [54, 55]. The reaction mixture 
contains silica precursors as starting reagents distributed in a solvent in the 
presence of water-soluble polymers such as polyethyleneglycols (PEG). The 
silica precursors are normally alkoxides and the most widely used are 
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alkoxysilanes such as tetraethoxysilane (TEOS) or TMOS [20, 54, 55, 67]. 
The average macropores size and skeleton can be controlled by the 
PEG/silica ratio as this ratio determines the phase separation tendency [60]. 
The morphology of the monolith is influenced by the additive molecular 
weight; the larger the additive, the larger the throughpores and mesopores 
[68]. After the synthesis of the monolith, its surface can be tailored in the 
ageing step which deals with the enlargement of the mesopores utilising a 
process called Ostwald Ripening [67].  
 
OH OH
OH
OH
Si OH
OH
OH
SiRO OR
OR
OR
Si O OH
OH
OH
Si
O
O
O
Si O Si
O O
O
O
Si
O O
O
O
Si
O O
O
O
Si
1. Hydrolysis 2. Condensation
3.
 P
oly
co
nd
en
sa
tio
nalkoxysilane dimer
gel
OH OH
OH
OH
Si+
 
Figure 1.12: Schematic reaction showing typical sol-gel reaction. Adapted from 
[54]. 
 
1.2.4. Organic polymer-based monolithic stationary phases 
 
1.2.4.1. Introduction 
In the late 1960s, Kubín et al. produced a highly swollen continuous 
polymeric matrix for chromatographic separations in size-exclusion mode 
using a redox free-radical initiating system [31]. The fabrication process 
involves placing 100 mL of the polymerisation mixture that consisted of 22 % 
aqueous solution of 2-hydroxyethylmethacrylate which contained 0.2 % 
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ethylene dimethacrylate in a 25 mm i.d. glass tube for 24 h at room 
temperature [69]. The resulting column was used for the separation of water-
soluble polymers. Unfortunately, the permeability of the column was very 
poor and efficiency was too low for really useful practical separations [21, 
41]. In the early 1970s, more permeable open-pore polyurethane foams 
were developed. They were prepared in-situ in large chromatographic 
columns allowing the separation of small analytes [70-73]. However, none of 
these early efforts were progressed at the time and the interest in monolithic 
phases faded for almost two decades [21, 41].  
In 1989, Hjertén et al. [25, 74] published a report for the first time 
describing a preparation of highly swollen crosslinked continuous beds by 
polymerising a dilute solution of N,N’-methylenebisacrylamide and acrylic 
acid in the presence of ammonium sulfate. The next step was compression 
of the resulting polymer to about 17 % of its original length within the 
confines of a chromatographic column. The compressed bed completely 
filled the cross section of the column and allowed high flow rates due to its 
very good permeability. The resulting column was successfully applied to the 
fast ion-exchange separation of a mixture of proteins (Figure 1.13). 
 
Figure 1.13: HPLC chromatograms of model proteins in cation-exchange mode 
using compressed continuous gel at different indicated flow rates. Conditions: gel 
plug 3 × 0.6 cm, linear gradient from 0.01 mol.L-1 sodium phosphate buffer pH 6.4 
to 0.25 mol.L-1 sodium chloride in the buffer, gradient volume 5 mL. Peaks: alcohol 
dehydrogenase (1), horse skeletal myoglobin (2), whale myoglobin (3), 
ribonuclease (4), and cytochrome c (5). Reproduced from [25]. 
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This work was followed by another approach published by Svec and 
Fréchet in 1992 describing the manufacture of macroporous methacrylate-
based monolithic columns for the first time. In their work, the monolith was 
polymerised in-situ in a 30 mm × 8 mm i.d. stainless steel column. The 
column was filled with the polymerisation mixture consisting of glycidyl 
methacrylate (GMA) and ethylene glycol dimethacrylate, as monomer and 
crosslinker, respectively, cyclohexanol and dodecanol as porogens and 
azobisisobutyronitrile (AIBN) as initiator. The polymerisation was carried out 
thermally at 70 oC for 6 hours. The epoxide groups of the GMA were 
functionalised and the resulting column was applied to the separation of a 
mixture of proteins in an ion-exchange mode [26]. Even though the 
chromatogram showed a relatively long run time (~ 35 minutes) as shown in 
Figure 1.14, it indicated the applicability of such materials as stationary 
phases for high-performance chromatographic separations and opened the 
window to the subsequent development of the monolithic materials.  
 
 
 
Figure 1.14: Ion-exchange chromatograph of model protein mixture in the porous 
polymer rod column. Conditions: column 30 × 8 mm i.d., poly(glycidyl methacrylate-
co -ethylene dimethacrylate) modified with (diethylamino)hydroxypropyl groups. 
Mobile phase: 10 min 0.01 mol.L-1 Tris-HCI buffer solution at pH 7.6, followed by 10 
min gradient of the same buffer from 0 to 7 mol.L-1 NaCI, flow rate 0.5 mL.min-1, UV 
detection: 218 nm, injection 2 pL of a solution containing total 16 mg.mL-1 proteins. 
Reproduced from [26].  
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1.2.4.2. Preparation of polymer-based monoliths 
In comparison to silica-based monoliths, the fabrication of organic 
polymer-based monoliths by a “moulding” process is simple and relatively-
straightforward [75, 76]. The fabrication is achieved by employing a one-step 
polymerisation approach in which the following components are required: 
functional monomers (with one or more double bonds) and crosslinkers (with 
two or more double bonds) to form the monolith skeleton and determine the 
polarity of the final monolith, porogenic solvents to determine the pores size 
and distribution, and an initiator to initiate the polymerisation. These 
components are mixed together in an appropriate ratio, sonicated and 
deoxygenated with nitrogen [21, 43, 77, 78]. The structural properties of the 
monoliths can be influenced by different factors such as the polymerisation 
conditions, e.g. the polymerisation temperature, the content of the 
crosslinkers, the thermodynamic quality of the porogenic solvents [24, 79, 
80].  
The fabrication of the organic polymer-based monolithic columns 
follows the simple scheme illustrated in Figure 1.15. The mould is sealed at 
one end, filled with the oxygen-free polymerisation mixture and sealed at the 
other end afterwards. The polymerisation is then initiated. When the 
polymerisation is finished, the seals are removed and replaced with fittings 
and then the column is attached to a pump for washing the monolithic 
column with copious amounts of organic solvent to remove the porogenic 
solvents and any other unreacted components from the pores of the 
monolithic column [50, 69]. The mould used for the preparation of the 
organic polymer-based monolith is typically a tube. A wide range of tube 
sizes and materials have been used as moulds, such as stainless steel, 
PEEK, and glass tubes [81-84]. Apart from tubes, polymer-based monoliths 
could be also prepared in different mould shapes, such as microfluidic chips, 
syringes, pipette-tips, etc. The preparation of cylindrical monoliths with a 
homogeneous porous structure and diameter up to about 10 - 25 mm is 
readily achieved in a single-step polymerisation, whereas larger sizes are 
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more difficult to prepare [76]. The mould may require a proper pretreatment 
for its inner-wall for subsequent attachment between the mould and the 
monolithic bed. This step is crucial to stabilise the monolithic bed inside the 
mould and to prevent the mobile phase from bypassing the bed and to force 
it to flow through the monolithic bed. For example, a fused silica capillary 
surface is first treated with 3-(trimethoxysilyl)propyl methacrylate (TMSPM) 
before the polymerisation takes place. The reaction between the methoxy 
groups in TMSPM and silanol groups on the fused silica capillary results in 
the successful attachment of the ethylene moieties to the capillary inner-wall 
which participate in the attachment between the monolithic bed and the 
inner-wall of the capillary afterwards [20, 43].  
 
 
 
Figure 1.15: Schematic of preparation of macroporous polymer monoliths using 
“moulding” process. Reproduced from [69].  
 
 
The mechanism of the monolith formation is as follows. First, the 
polymerisation is initiated by the decomposition of the initiator forming a free 
radical. During the polymerisation, the solubility of the polymer chains in the 
reaction mixture decreases as they grow. Then the polymer chains 
precipitate to form nuclei. The monomers are thermodynamically better 
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solvents for the nuclei than the porogens which result in the nuclei being 
swollen with the monomers. As the polymerisation continues to proceed, the 
nuclei size increases leading to form microglobules which then cross-link 
among each other to form the final morphological structure of the monolith, 
whereas the macropores are filled with the porogens which determine the 
volume of the macropores [22].  
The formation of polymer-based monoliths utilising free-radical 
polymerisation can be initiated by a number of means such as heating, UV 
radiation, gamma rays and chemical agents. Thermal-initiation is the most 
common way for starting the polymerisation. The temperature has to be 
controlled carefully to obtain monoliths with reproducible and uniform porous 
structure due to the significant influence of temperature on the growth rate of 
nuclei. The initiator decomposition and the rate of propagation are faster at 
high temperatures leading to increase the number of growing nuclei and thus 
small pore size is obtained. In addition, faster polymerisation may lead to 
less uniform porous structure. Therefore, lower temperatures are preferred. 
However, this can be limited by the decomposition temperature of some 
initiators [22, 85]. The structural properties of the polymer-based monoliths 
can also be affected by changing the initiators. For example, the 
decomposition temperatures of di-nitrile or azo initiators such as AIBN are 
between 60 and 80 oC. Monoliths with larger pores were obtained when the 
polymerisation was initiated by di-benzoyl peroxide which decomposes at 
temperatures of 60 – 140 oC due to the slower decomposition rate of the 
initiator [86]. The replacement of AIBN by 2,2’-azobis(2,4-
dimethyl)valeronitrile (ADVN) results in a decrease in population of smaller 
pores which led to a decrease in the total surface area. [87]. Polymerisation 
can also be initiated utilising UV radiation, which is recommended for the 
preparation of homogeneous monoliths [88, 89]. UV-initiated polymerisation 
is usually carried out at room temperature and thus, in contrast to thermal-
initiation, volatile solvents with low boiling points can be used as porogens 
[22]. Moreover, the monolith can be synthesised in a very short time; usually 
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within few minutes. UV-initiated polymerisation is mostly affected, and thus 
the structural properties of the monoliths, by the light intensity as well as the 
nature and the concentration of the initiator [22]. However, UV-initiated 
polymerisation is limited to UV-transparent monomers and porogenic 
solvents; and moulds such as fused silica capillaries and UV-transparent 
microfluidic chips [88-91]. In addition to the above initiation means, gamma 
radiation is another option for initiating the polymerisation but it is less 
common than them as it requires strict safety measures [22, 78]. Gamma-
initiation has the advantage of direct generation of free radicals from the 
monomers, without the addition of initiators, which results in a cross-linked 
product [22, 92-94]. The structural properties of the monoliths are controlled 
by varying the dose rate. Increasing the dose rate leads to increase the rate 
of free radical formation and thus accelerates the polymerisation and the 
crosslinking, which results in monoliths with larger pores [22]. The optimum 
doses are ranged from 20 to 40 kGy, whereas the optimum dose rates are 
between 10 and 16 kGy/h [92]. Polymerisation initiation using chemical 
agents at room temperature is the oldest way [78]. A number of chemical 
agents have been used for monoliths preparation. For example, ammonium 
peroxodisulfate with N,N,N’,N’-tetramethylethylenediamine catalyst has been 
used for the preparation of poly(butyl methacrylate) [95]. 
 
1.2.4.3. Control of surface chemistry 
Several methods have been reported for the preparation of organic 
polymer-based monoliths with a wide variety of surface chemistries in which 
the application of such materials as chromatographic stationary phases 
depend on. For example, in reversed-phase mode chromatography, 
monoliths with hydrophobic moieties are used, while for the separation in 
ion-exchange mode, ionisable groups must be present on the surface of the 
monoliths, etc. The desired surface chemistry can be obtained by including 
the functional monomers in the polymerisation mixture, chemically modifying 
or photografting the surface of the preformed monoliths.  
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A) Preparation from functional monomers.  
A large variety of surface chemistries can be directly obtained for 
polymer-based monoliths, due to the large selection of available monomers 
that can be used for the preparation of such materials. The preparation of a 
monolith with a desired surface chemistry by inclusion of functional 
monomers that have the desired chemistry in the polymerisation mixture (i.e. 
direct copolymerisation) is the most convenient and simple way [21, 22]. 
Almost any monomer, including water-soluble hydrophilic monomers, can be 
used in the polymerisation mixture to form a monolith [39]. However, the 
polymerisation conditions optimised for preparation of a monolith cannot be 
transferred directly to another one without additional re-optimisation. Thus, 
the use of new monomer mixtures requires re-optimising the polymerisation 
conditions to obtain satisfactory permeability of the new resulting monolith 
[96]. A wide range of monomers and crosslinkers has been used for the 
preparation of polymer-based monoliths and examples are shown in Figure 
1.16. The list of monomers includes a variety of surface functionalities 
varying from very hydrophilic acrylamide (8) and 2-acrylamido-2-methyl-1-
propanesulfonic acid (6) (AMPS), through reactive monomers such as GMA 
(5), chloromethylstyrene (2), 2-vinyl-4,4-dimethylazlactone (7) (VAL) and 
protected functionalities 4-acetoxystyrene (3), to rather hydrophobic styrene 
(1) (ST) and butyl methacrylate (4) (BuMA), and even zwitterionic (9) (N,N-
dimethyl-N-methacryloyloxyethyl-N-(3-sulfopropyl)ammonium betaine). The 
examples of crosslinkers showed in Figure 1.16 include divinylbenzene 
(DVB) (10), N,N’-methylenebisacrylamide (11), ethylene dimethacrylate 
(EDMA) (12), and trimethylolpropane trimethacrylate (13) [50]. 
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Figure 1.16: Examples of monomers used for the preparation of rigid porous 
polymer monolithic columns. Reproduced from [50].  
 
 
Polymethacrylate-based monoliths are materials exhibiting medium 
polarity, as they contain carboxyl groups, and a hydrophobic framework as 
shown in Figure 1.17 [43]. The production of such materials can be readily 
achieved by polymerising a mixture consisting of methacrylate esters as a 
monomer and EDMA as a crosslinking agent. The monomers used for the 
production of methacrylate-based monoliths include BuMA, 2-hydroxyethyl 
methacrylate, GMA and other methacrylate esters [55]. Among them, GMA 
is often used as a monomer in the polymerisation mixture since it contains 
reactive epoxide groups which lead to readily subsequent surface 
modification for numerous applications, such as the extraction of neutral 
compounds [97] and peptides [98, 99]. The solvents used as porogens 
include toluene, cyclohexanol, dodecanol, propanol, methanol or acetonitrile. 
The polymerisation is usually initiated by AIBN, which is activated by heat or 
UV light. [55, 80, 100, 101].  
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Figure 1.17: Chemical structure of a medium polar poly(butyl methacrylate) 
monolith. Reproduced from [78]. 
 
 
Polystyrene-based monoliths, as shown in Figure 1.18, are strongly 
hydrophobic materials. They are prepared by polymerising a mixture 
consisting of ST or its derivatives, such as 4-(chloromethyl)styrene as 
monomers and DVB as a crosslinking agent. The polymerisation is carried 
out in the presence of a diluent which acts as the pore forming agent. It can 
be a solvent, a nonsolvent or a linear polymer. In the case of a solvating 
diluent, macroporous monoliths are only produced when the concentration of 
DVB is high and the monomer concentration is diluted. Whereas in the case 
of nonsolvating diluent, the macroporous monoliths are formed at lower 
concentrations of DVB and with less diluted monomers [55]. Since the 
polystyrene-based monoliths are hydrophobic, they can be used directly in 
reversed-phase chromatography. However, by using 4-
(chloromethyl)styrene as a monomer, reactive groups are obtained for 
further derivatisation. For example, the poly(chloromethyl)styrene monolith 
surface has been modified utilising the two-step strategy. It was first reacted 
with ethylenediamine and then reacted with γ-gluconolactone and 
chloroacetic acid to produce highly hydrophilic and weak cation-exchange 
surfaces respectively [102, 103].  
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Figure 1.18: Chemical structure of a strongly hydrophobic polystyrene monolith. 
Reproduced from [78].   
 
Polyacrylamide-based monoliths are highly polar materials with a 
hydrophilic framework as shown in Figure 1.19. They are prepared by 
polymerising a mixture including acrylamide or its derivatives as a monomer 
and N,N’-methylenebisacrylamide as a crosslinker [25, 104, 105]. The 
monomers involved in the polymerisation mixture are often acrylamide, 
piperazine diacrylamide, methacrylamide in the presence of dimethyl 
sulfoxide (DMSO) and dodecanol as the porogens. In addition, either AMPS 
or vinylsulfonic acid could be added to the polymerisation mixture for the 
production of a charged surface, while other monomers such as stearoyl 
methacrylate or BuMA are used to provide a surface suited to hydrophobic 
interaction chromatography [55]. The polymerisation reaction is initiated by a 
catalyst-initiator system of N,N,N’,N’-tetramethylethylenediamine (TEMED) 
for the breakdown of ammonium sulfate to form persulfate radicals. The 
polymerisation is usually carried out overnight at room temperature since it is 
not thermally-initiated [55]. Polyacrylamide-based monoliths have been used 
for the extraction of phenols and other acidic species [106-108] as well as in 
the preparation of molecularly imprinted polymer (MIP) extraction devices 
[109, 110]. 
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Figure 1.19: Chemical structure of a highly polar polyacrylamide monolith. 
Reproduced from [78]. 
 
 
B) Chemical modification of the monolith surface.  
Chemical modification is another approach that allows the 
introduction of various functionalities while preserving the original porous 
structure of the monolithic materials. It increases the number of available 
chemistries providing stationary phases for various separation modes. The 
surface modification is readily performed using monoliths prepared from 
monomers containing reactive groups [21, 39, 50]. For example, GMA is a 
very popular functional monomer used for monolith preparation. Because of 
the presence of epoxide groups, it can be readily derivatised for extensive 
applications [43]. Typically, the pores of the monolith containing reactive 
groups are filled with the reagent and allowed to react under certain 
conditions. Then, once the reaction is completed, the monolith is rinsed with 
a solvent to remove all unreacted components [39]. Examples of chemical 
surface modifications are shown in Figure 1.20 in which the GMA monolith is 
treated with diethylamine to obtain a monolith for anion exchange 
separations [26], while the poly(chloromethylstyrene-co-DVB) polarity is 
converted from hydrophobic to hydrophilic by its treatment with 
ethylenediamine and then with γ-gluconolactone. [102].  
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Figure 1.20: Examples of modification of typical porous polymer monoliths 
containing GMA (A) and chloromethylstyrene (B) units. Reproduced from [39].  
 
 
 
C) Grafting the monolith surface.  
Grafting can also be utilised to modify the monolith surface chemistry 
leading to new functional groups without changing the original pore size of 
monolith morphology. However, in contrast to chemical modification, grafting 
may produce multiple functionalities by attaching chains of functional 
polymer to each surface site of the pores rather than introducing only a 
single functionality at each individual surface site, obtained by chemical 
modification as illustrated in Figure 1.21. Thus, the sorption capacity of the 
monolith is significantly increased [22, 39, 50, 111].  
 
 
 
Figure 1.21: Schematic representation of the growing polymer chains during 
photografting with increasing irradiation time from (a) to (c). Adapted from [90]. 
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Photografting is a photoinitiated method utilised for polymer surface 
modification using UV irradiation, hydrogen abstracting photoinitiators and 
reactive vinyl monomers [112]. The desired functionality is introduced in the 
monolith pore surface by the photoinitiated grafting of suitable polymer 
chains as shown in Figure 1.22, which can be obtained within a very short 
period of time [90, 113, 114]. Upon photoexcitation, the photoactive 
component (e.g. benzophenone (BP)) abstracts hydrogen atoms from the 
polymer surface and forms free radicals. The resulting surface radicals then 
initiate surface graft polymerisation [115]. The resulting polymer chains 
grafted to the surface also contain abstractable hydrogen atoms which also 
can be a base for new chains to grow, ultimately leading to a branched 
polymer architecture [39].  
 
 
 
 
Figure 1.22: Schematic picture of surface grafting onto a substrate with BP and a 
vinyl monomer, irradiated with UV light. Adapted from [114]. 
 
In addition, one of the advantages of UV-initiated grafting is that the 
location of grafts can be precisely controlled using photomasks which allows 
the discrete modification of zones within the monolithic rod.  This is in 
contrast with using the chemical modification method in which the entire 
surface of the monolith is exposed to modification [115]. Rohr et al. grafted 
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distinct areas of the surface of a butyl methacrylate/ethylene glycol 
dimethacrylate-based monolith with chains of VAL through a mask. VAL 
amine-reactive groups were labeled with a fluorescent dye, Rhodamine 6G, 
by reaction with its secondary amine groups. The resulted labeled monolith 
was visualised by an optical fluorescence microscope and the images in 
Figure 1.23 show the fluorescent areas (bright spots) [90].  
 
 
 
 
Figure 1.23: Fluorescence microscope image of porous poly-(BuMA-co-EDMA) 
monolith in a 50 µm capillary photografted through a mask with polyVAL chains for 
1 (a) and 3 minutes (b) and subsequently reacted with Rhodamine 6G. Reproduced 
from [90].  
 
1.3. Monolithic solid phase extraction in a pipette-tip format (SPE-PT)  
 
In most cases, biological samples are not compatible with direct analysis 
utilising HPLC, capillary electrophoresis (CE), mass spectrometry (MS), etc., 
as such samples are very complex and may contain proteins, salts, acids, 
bases and other organic compounds with similar properties to the target 
analytes [116, 117]. Therefore, a pretreatment step is crucial prior to 
analysis in order to reduce the complexity of such samples. The demand for 
this is even more when the concentration of the target analyte in the sample 
is low and close to the detection limit of the analytical instrumentation, or 
when the detection sensitivity is influenced by the matrix of the sample, as 
typical in MS [118]. A selective sample preparation step is the front-end and 
often the key for successful subsequent analysis steps. Thus, the most effort 
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and a significant amount of time are given to this step. It typically takes 
about 80 % of the total analysis time [18, 116]. Depending on the desired 
task, sample preparation, in general, includes (i) concentration of the target 
analyte to adequate levels for measurement, (ii) removal of interfering-
compounds of the sample matrix from the target analyte as the presence of 
such compounds could complicate or inhibit analysis, and (iii) exchanging 
the solvent or buffer that the target analyte is dissolved in to be compatible 
with the analytical method [119]. The sample preparation technique can be 
considered successful if the following features are obtained: (i) low sample 
loss (i.e. high recovery), (ii) complete removal of coexisting components, (iii) 
convenient and fast sample treatment, and (iv) low-cost analysis [116, 117].  
Ultra-centrifugation, liquid–liquid extraction (LLE) and solid phase 
extraction (SPE) are the most common techniques that have been employed 
for sample preparation [18, 119]. Ultra-centrifugation is used to remove 
proteins from the biological samples. In contrast, LLE and SPE are useful 
techniques regularly employed for efficient sample clean-up based on 
partition or adsorption of the target analytes. These techniques are efficient 
and reliable for extracting the majority of pharmaceutical compounds from 
sample matrices and can produce clean extracts for subsequent analysis 
[116, 117]. Traditional LLE, however, suffers from a number of limitations. 
Specifically, difficulties in choosing a non-miscible solvent for polar and ionic 
compound extraction from water. The need for large volumes of organic 
solvents also results in a dilute extract [116].  
SPE, among others, is a simple, effective and versatile sample 
preparation technique that plays a crucial role in the analysis of biological 
matrices [120-122]. This is due to high analyte recovery, short extraction 
time, ease of operation, high enrichment factor and low consumption of 
organic solvents, together with ease of automation [123, 124]. It is a 
powerful tool applicable for purification, desalting, preconcentration and 
selective capturing prior to introducing the sample to advanced analytical 
techniques. [43, 119, 125]. 
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SPE first appeared in the late 1970s to avoid the use of 
environmentally unfriendly chlorinated solvents in LLE techniques. It has 
gained increased importance as a sample preparation technique utilised for 
reducing sample complexity, and has gradually replaced the position of LLE 
as the preferred sample preparation technique for biological samples [126-
128]. SPE is defined as “a method of sample preparation that concentrates 
and purifies analytes from solution by sorption onto a disposable solid-phase 
cartridge, followed by elution of the analyte with solvent appropriate for 
instrumental analysis” [121]. Therefore, the extraction of the target analytes 
is based on partitioning between two phases: a liquid phase (the sample) 
and a solid phase (the extraction bed). The sample solution is passed 
through the solid phase and the analyte of interest is retained and then 
eluted with another solvent. The analyte of interest must have greater affinity 
for the solid phase than for the sample matrix to be retained, which may 
involve polar, non-polar or ionic interactions with a wide range of solid phase 
chemistries that can be used for the extraction of various compounds from 
aqueous or organic matrices [18, 116]. The key factor in optimising an 
extraction method for the target analyte is choosing the solid phase in which 
the extraction is going to take place on. The choice depends on the analyte 
and its properties and the sample matrix [18, 116].  
The most popular format of SPE is a 1 – 6 mL open syringe-barrel or 
cartridge type containing a sorbent between frits. It is typically filled with 40 – 
60 µm packing materials [119, 128, 129]. The first SPE devices were made 
of stainless steel packed with porous poly(ST-co-DVB) beads and used as 
pre-columns. These expensive columns were then replaced with disposable 
column-like containers manufactured from polyethylene or polypropylene 
[127].  
However, one of the recent trends in sample preparation method 
development is the use of miniaturised extraction devices. Miniaturisation is 
driven by the limited availability of valuable samples, the requirement of fast 
and simple handling of small volumes (1 – 100 µL), and the need to 
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minimise sample dilution in the elution step. Therefore, studies have recently 
focused on the development of methods that reduce the sample volumes 
required for analysis, the analysis time, the organic solvent consumption or 
even elimination of chlorinated solvents [18, 117, 119]. Solid phase 
microextraction (SPME) is a successful miniaturised extraction technique 
that requires low sample and solvent volume, is simple and easily automated 
[43]. It was invented by Pawliszyn in the early 1990s as a one-step, simple, 
time-efficient and solvent-free sample preparation technique. The extraction 
is based on the partitioning of the target analyte between the sample matrix 
and a solid phase coating on a fused silica fibre and attached to a modified 
microsyringe [130-132]. This invention was a significant step towards the 
development of miniaturised sample preparation techniques and since then 
various miniaturised techniques such as chip-based microextraction [133], 
stir-bar-sorptive extraction (SBSE) [134], microextraction in a packed syringe 
(MEPS) [135], microextraction based on a monolithic spin column [136] have 
been described.  
Solid phase extraction in a pipette-tip (SPE-PT), in particular, is 
another approach towards miniaturisation which was introduced in the late 
1990s [129]. It is a simple and rapid method that has recently gained 
increased attention as a sample preparation tool within the field of 
bioanalytical chemistry and utilised for purification, desalting, 
preconcentration and selective capturing prior to introducing the sample to 
the advanced analytical techniques [137-139]. SPE-PT is an off-line sample 
pretreatment tool that can be utilised for processing one or several samples 
simultaneously either manually using multi-channel hand-held pipettors or 
automatically using commercially available robotic liquid handling systems 
[117]. Moreover, the operation process of this microextraction device is 
based on bi-directional flow in which the handling of the samples includes 
repeated smooth aspiration/desorption cycles [43, 140]. The extraction 
procedure is simple and easy as there is no special equipment required. As 
illustrated in Figure 1.24, the extraction sorbent is conditioned first and then 
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the sample solution is withdrawn through the sorbent and the analyte is 
adsorbed. Following that, the sorbent is washed and the analyte is eluted 
with a suitable organic solvent [141, 142]. The technique has several 
advantages, including the ease of use, faster extraction time, small sample 
and solvent consumption, low operating costs and inexpensive and 
disposable usage compared to conventional SPE [43, 128, 129, 143]. 
 
 
 
Figure 1.24: Extraction procedures for SPE-PT. Adapted from [142]. 
 
 
An SPE-PT device contains a chromatographic sorbent (solid phase), 
in which the extraction takes place, positioned at the bottom-end of a 
pipette-tip. The chromatographic materials used for the preparation of these 
devices are required to be (i) amenable to fluidic flow, which means low 
backpressure is produced, (ii) physically stable at the bottom-end of the 
pipette-tip, so no dead volume at the end of the tip or void between the solid 
phase and the wall of the tip is produced, (iii) able to eliminate any possible 
interference or carry-over that could arise as these devices are single-use, 
and (iv) available in different surface functionalities such as reversed-phase, 
ion exchange, immobilised metal affinity chromatography (IMAC), etc., in 
order to be applicable to as wide range of sample matrices as possible [117, 
128].  
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Among other sorbents, silica particles or silica-based and organic 
polymer-based monoliths are the most common chromatographic materials 
used for the fabrication of the SPE-PT devices. Regarding the fabrication of 
SPE-PT packed with silica beads, the key concerns associated with such 
devices are how the beads are going to be retained in the packing mold, 
how easy and reproducible is the packing procedure, and the robustness of 
the packed column, etc. [118, 144]. Packed SPE-PT devices have been 
reported before for the enrichment, purification, desalting and fractionation of 
different biological samples using either home-made or commercially 
available tips. Several reports have been published on packing a bottom-end 
squeezed GELoader tip (Eppendorf, Hamburg, Germany) with a slurry of 
chromatographic media (Figure 1.25) [139, 145-150]. The bottom-end of the 
tip was carefully squeezed using a pair of flat pliers to reduce the inner 
diameter of the lower end of the tip. This modification is necessary to 
prevent leakage of the chromatographic media, but still allows the passage 
of solvent. Then the modified tips were filled with a suspension of different 
chromatographic media for various purposes. For example, the tip was 
packed with reversed-phase media to form a purification column for clean-up 
and preconcentration of peptide mixtures [139, 145, 146], with and 
immobilised Fe(III) affinity media, TiO2 beads for purification, enriching and 
characterisation of phosphorylated peptides [147, 148], immobilised-trypsin 
for protein digestion [149]. In addition, Jiang and Lucy reported a method for 
the preparation of an off-line ion-exchange SPE-PT. They have packed a 
200 µL pipette-tip with 50 mg of Bio-Rad AG1-X8 anion exchanger beads 
which were stabilised with glass wool. The resulted tip was used for the 
enrichment of herbicide glyphosate from river water samples prior to CE 
analysis [150].  
‘ZipTip’ from Millipore (Billerica, MA, USA) was the first commercially 
available tip, developed in the late 1990s. It is a fritless SPE-PT consisting of 
beads incorporated into a matrix of supportive material [145].  It has been 
widely used for desalting, preconcentration and purification of different 
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sample matrices [137, 138, 151, 152]. For example, Bagshaw et al. have 
reported a method for desalting and sample clean-up using ‘ZipTip’ C18 tips 
prior to analysis with matrix-assisted laser desorption/ionisation time-of-flight 
mass spectrometry (MALDI-TOF-MS). The results obtained showed a great 
improvement in the signal-to-noise ratio of in-gel peptide digests leading to 
more reliable peptide mass fingerprinting [152]. Even though ‘ZipTip’ tips are 
very popular, their capacity is too small for quantitative studies [153] and 
their binding properties have been found to be unsatisfactory [154]. 
 
 
 
Figure 1.25: Image showing an example of a packed SPE-PT. Reproduced from 
[146]. 
 
However, there are some difficulties and limitations associated with 
the preparation of packed tips. The main issues are the need for frits for 
retaining the beads and the ease of packing these beads reproducibly within 
the confines of the polypropylene tip. Furthermore, the narrow pH stability 
range and low surface area because of large particles used in order not to 
produce high backpressures are some other limitations that restrict the use 
of packed SPE-PT [117, 142, 144, 155].  
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On the other hand, monolithic materials have shown great potential 
for the preparation of such extraction devices and can be an alternative to 
overcome many packed sorption material drawbacks. Both silica-based and 
organic polymer-based monoliths are becoming more common due to the 
advantages they posses compared to packed beads [155]. In general, these 
include the ease and low-cost of preparation, in particular, for microscale 
utilisation as there is no need for frits. Also, they take the shape of the mould 
in which they are prepared in. In addition, polymer monoliths are chemically 
stable over a wide pH range and can be synthesised with a wide variety of 
surface functionalities. They are also physically stable, as they are attached 
to the inner-wall of the tip providing no voids or dead volume. Moreover, the 
structure of the monoliths is highly permeable and thus operation at low 
backpressures and higher linear velocities is possible [117, 155, 156]. 
Furthermore, monoliths for bioanalytical applications, in particular for large 
molecules such as proteins and peptides, are gaining popularity due to the 
favourable mass transfer characteristics they possess [127, 157].   
Silica-based monoliths are manufactured by sol–gel technology when 
the continuous sol–gel network is created by the gelation of sol solution.  
These materials have been previously used as sorbents in SPE-PT. 
Miyazaki et al. prepared a monolithic silica bed fixed in a 200 µL pipette-tip 
in which the silica surface was modified with a C18 phase or coated with a 
titania phase. The C18-bonded tip was used for sample concentration, 
desalting and removal of detergents, whereas the titania-coated tip was 
applied for purification and concentration of phosphorylated peptides from β-
casein tryptic digestion [158]. The commercially available silica-based tips 
‘MonoTip’ from GL Sciences Inc. (Tokyo, Japan) have also been extensively 
used for the pretreatment of various biological samples for drugs analysis. 
For example, Kumazawa et al. [159, 160] and Hasegawa et al. [161, 162] 
used ‘MonoTip’ C18 for the extraction of antihistamines from human plasma 
[159, 161] as well as methamphetamine and amphetamine from human 
urine [160] and human whole blood [162]. In addition, Ota et al. reported a 
  43 
successful method for the preparation of the trypsin-immobilised silica-based 
tip which was achieved via an aminopropyl group. The effectiveness of the 
tip was shown through its ability to rapidly digest reduced and alkylated 
proteins prior to chromatographic analysis [163].  
Although monoliths, in general, have the advantages mentioned 
above, the preparation of silica monoliths, however, is time-consuming in 
comparison with organic polymer monoliths. It manufactured by sol-gel 
technology with phase separation and takes over 64 hours, whereas the 
polymer monolith takes less than 2 hours. In addition, the shrinkage of silica 
monoliths which occurs during the preparation cannot be completely avoided 
and it needs special apparatus to be overcome which may not be available 
in every lab [43]. In contrast, polymer-based monoliths can be readily 
prepared in-situ in polypropylene pipette-tips as shrinkage is not serious in 
the preparation of such materials [43]. The inner-wall of the tip is pretreated 
in order to get subsequent bonding to the monolithic bed. This treatment is 
required to stabilise the bed and to prevent sample loss due to the void 
between the bed and the inner-wall of the tip [164]. Organic polymer 
monoliths are produced by a one-step polymerisation of a mixture consisting 
of organic monomers, crosslinkers, porogenic solvents and initiators. The 
mixture is typically sonicated, purged under nitrogen, filled into the tip itself 
and in most cases polymerised using UV irradiation. In addition, a wide 
range of the monolith surface functionalities can be obtained either by 
copolymerisation of a suitable functional monomer or by post-modification 
utilising simple modification or photografting. Although polymer-based 
monolithic SPE-PT has drawn attention recently as an off-line sample 
preparation tool for bioanalysis, they have not yet been extensively applied 
for large biomolecules analysis.      
Hsu et al. [118] described a preparation of an ‘EasyTip’, which is an 
EDMA-based polymer monolith fabricated in a 20 µL polypropylene pipette-
tip by photopolymerisation. Instead of bonding the monolithic bed to the wall 
of the pipette-tip, they used a 1 mm ring that was cut from the sharp end of 
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the tip to stabilise the bed. Due to high backpressure originated from the 
small porosity of the monolithic bed which prevents using the manual 
micropipettors, the authors created a main flow-through channel by inserting 
a piece of fused capillary-silica during the polymerisation which was 
removed afterwards. The surface of the monolith was functionalised with C18 
beads and IMAC beads by blending the beads with the polymerisation 
mixture and then the suspended slurry was photopolymerised in-situ. The 
effectiveness of the C18 beads functionalised tip was evaluated by applying it 
to desalt and preconcentrate the tryptic-digested hemoglobin and in-gel 
digest of epidermal growth factor receptor (EGFR) protein from A431 cell 
lysate. Whereas the IMAC beads functionalised monolith was applied to 
extract the signal of tryptic phosphopeptides of β-casein prior to MALDI-MS. 
Later, they prepared the SPE-PT device by an oil-in-water emulsion 
technique in order to increase the pore size and permeability of the 
monolithic bed and therefore overcome the high backpressure preventing 
the use of the manual micropipettors and facilitate the sample handling with 
low backpressures. By using this technique, they increased the pore size of 
the bed over five times compared to conventional photopolymerisation [165].  
Hsieh et al. [166] developed a SPE-PT device following the same 
preparation strategy described by Hsu et al. [118] in which they 
functionalised the surface of the polymer monolith with titanium dioxide 
(TiO2) nanoparticles for entrapping phosphorylated peptides. The TiO2-
embedded tip coupled with MALDI-MS was successfully applied to 
selectively identify phosphorylated peptides from tryptic-digested α-casein 
and β-casein spiked into bovine serum albumin (BSA) nonphosphorylated 
peptides. The same target analytes, phosphorylated peptides, were 
analysed by Rainer and co-workers [167] utilising a SPE-PT with a DVB 
backbone. The selectivity of the device towards the target analytes was 
achieved by incorporating TiO2 and zirconium dioxide (ZrO2) nanoparticles in 
the polymer monolith skeleton. The selectivity was demonstrated by 
enriching a digest of the in vitro phosphorylation of extracellular signal 
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regulated kinase prior to identification by MALDI-MS-MS. In addition, the 
sample handling was automated using a 12-channel robotic system allowing 
a highly reproducible process and analysis of many samples simultaneously.  
Recently, Hahn et al. [168] immobilised trypsin on GMA-co-DVB 
monolith for in-tip digestion of proteins. In their method, the protein solution 
was aspirated into the trypsin-immobilised tip and then the tip was placed in 
a microwave oven for highly efficient and time saving digestion. Then the 
protein digests were eluted from the tip and injected in the MALDI-TOF-MS 
and liquid chromatography electrospray ionization mass spectrometry (LC-
ESI-MS) for analysis. The method was fully automated using a robotic 
system for fast and reproducible sample handling. Myoglobin, bovine serum 
albumin and α-casein were used as test proteins for evaluation purposes 
whereas the method was applied for the analysis of in-tip trypsin-digested 
serum sample and the results were good in comparison with in-solution 
digestion. 
Altun et al. [164, 169-171] carried out a series of experiments 
developing a high-throughput methacrylate polymer-based SPE-PT for drug 
analysis using 96-well pipette-tips (Figure 1.26) allowing the handling of the 
samples in 2 minutes by a Personal Pipettor robot (PP-550N-MS, Apricot 
Designs, Monrovia, CA, USA). The inner-wall of the tip was modified using 
BP as photoinitiator to generate radicals at the surface for subsequent 
covalent attachment between the monolithic bed and the tip inner-wall [164]. 
The sampling procedures include passing the sample through the tip to 
target analyte, washing the bed with water to remove the interferences, and 
then eluting the analyte with organic solvent. The tips were successfully 
applied to extract different drugs from human plasma samples. 
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Figure 1.26: UV-polymerised 96-tips packed with monolithic methacrylate polymer. 
Reproduced from [143].  
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2.1. Introduction  
 
Since the United States Food and Drug Administration (FDA) approval of 
recombinant insulin more than two decades ago [1], there has been an 
accelerated drive towards the development and manufacturing of therapeutic 
proteins. This is due to the high specificity and effectiveness of such drugs 
for the treatment of various diseases, including several types of cancer, 
diabetes, anemia and hepatitis [2-5]. Up to 2009, nearly 100 proteins with 
human therapeutic applications have entered the market [6] and more than 
370 are currently under development [7]. The biopharmaceutical industry 
has grown significantly in the last decade and continues to grow at a rapid 
rate with a predicted annual growth of 12 % [8]. The global market value has 
increased in the last decade from $12 billion to $99 billion [9, 10] and is 
expected to reach $125 billion by the year 2015 [11]. Therefore, due to the 
increase in demand for therapeutic proteins, there is a growing need to 
develop technologies to achieve better productivity [12].  
Quality by Design (QbD) is a framework that ensures better 
understanding of biofermentation processes and the various parameters 
which affect product quality and process consistency [13]. QbD is gaining 
industry acceptance as an approach towards development and 
commercialisation of bio-therapeutic products expressed via microbial or 
mammalian cell lines [14]. Manufacturers who submit New Drug Applications 
(NDA) for novel bio-therapeutic products have an obligation to clearly 
demonstrate the application of the QbD approach, which is defined as: ‘a 
systematic approach to development that begins with predefined objectives 
and emphasises product and process understanding and process control, 
based on sound science and quality risk management’ [15-17]. Some of the 
key activities that are performed during QbD implementation include: (i) 
identification of the quality target product profile and the critical quality 
attributes based on impact on product safety and/or efficacy, (ii) design of 
the process and a robust control strategy to deliver consistently the desired 
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product quality, (iii) validation and filing of the process to demonstrate the 
effectiveness of the control strategy, and (iv) ongoing monitoring to ensure 
robust process performance over the life cycle of the product [18, 19].  
Process Analytical Technology (PAT) has been defined by the United 
States FDA as ‘a system for designing, analysing, and controlling 
manufacturing through timely measurements of critical quality and 
performance attributes of raw and in-process materials and processes, with 
the goal of ensuring final product quality’ [20]. The main goal of this 
approach is to design and develop well-characterised processes which will 
consistently ensure a predefined quality at the end of the manufacturing 
process.  
In contrast to small molecule medicines (i.e. < 1 kDa), which are 
typically synthesised by chemical means, therapeutic proteins are 
macromolecules composed of long chains of amino acid subunits and 
usually produced in living systems through microbial fermentation or by 
mammalian cell culture. The structure and functionality of the protein is 
determined by its sequence of amino acids which determines its three 
dimensional structure [21, 22]. Producing such therapeutics is a 
complicated, time-consuming and expensive process. Many years can be 
spent in just identifying the proteins, determining its gene sequence and 
developing the process to produce the molecule in commercial quality. Once 
the production process is optimised and scaled up, large batches can be 
produced [22]. Most of the therapeutic proteins are produced in bacteria 
(Escherichia coli), yeast (Saccharomyces cerevisiae) or mammalian cell 
culture (Chinese hamster ovary cells, CHO) [23-25], beside other production 
systems under development which include the yeast (Pichia pastoris), insect 
cell culture and transgenic animals and plants [1]. However, cultivated 
mammalian cells have become the dominant production system due to their 
capacity for proper protein folding and their ability to perform extensive post-
translational modification [26]. Therefore, the quality and effectiveness of a 
protein can be superior when expressed in mammalian cells compared to 
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other hosts such as bacteria, plants and yeast. Today, about 60 - 70 % of all 
recombinant protein pharmaceuticals are produced in mammalian cells [27].  
In addition, glycosylation, which refers to the covalent attachment of 
carbohydrate to the protein surface, is required for most of the therapeutic 
proteins to ensure proper folding, biological function and activity. At the 
moment about 60 % of the therapeutic proteins market are glycoproteins [4, 
28, 29]. The production of therapeutic proteins that are glycosylated has 
mostly required mammalian cells that have the ability to mimic human 
glycosylation, and cannot be produced in standard prokaryotic expression 
systems because of the lack of proper glycosylation machinery. Prokaryotic 
hosts, e.g. E. coli, do not glycosylate proteins and lower eukaryotic 
expression systems such as yeast and insect cells are typically unable to 
provide mammalian glycosylation [21, 29]. 
A number of mammalian cell lines are used for recombinant protein 
production including CHO, mouse myeloma (NS0), baby hamster kidney 
(BHK), human embryo kidney (HEK-293) and human retinal cell lines [27]. 
Among them, CHO cells, which are derived from a partially inbred female 
adult Chinese hamster [30], are widely used in combination with the 
dihydrofolate reductase (DHFR)-selectable and amplifiable marker to 
produce therapeutic proteins [31], due to the high viability and the high 
densities achieved by these cells [32]. The number of licensed therapeutic 
proteins produced in CHO cells between the years 1987 and 2006 was 27, 
out of 38 drugs produced by mammalian cells [24]. CHO cells have gained 
their popularity from their ability to modify the protein products with 
glycosylation patterns similar to those in humans as well as their ability to 
grow to high densities in bioreactors [32, 33].  
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2.2. Cell culture media and yeast extract samples 
2.2.1. Introduction 
 
In vitro cell cultivation techniques play a key role in the production of 
therapeutic proteins [34-36]. Thus, mammalian cells (e.g. CHO cells) are 
cultivated in bioreactors under strictly controlled conditions in an aqueous-
based media formulated for this task. Cell culture media used for the 
cultivation of mammalian cells is more complex and costly than that used for 
bacteria or yeast [37]. The cell culture media is very important to produce the 
correct physiological environment and allow effective in vitro culturing of 
mammalian cells as it provides survival and growth requirements [38]. The 
formulation of suitable culture media is critical and requires accurate 
selection of different components since the physiological environments of 
most cells are not fully defined and the exact compositions vary significantly 
based on the cell line used. In addition, different parameters are required for 
growth promotion and protein production enhancement, depending on the 
cell line used [39, 40]. The cell culture media must provide an energy source 
and all of the cell nutrients required for growth, while maintaining pH and 
osmolarity. Therefore, the cell culture media tend to be highly complex 
mixtures, containing a variety of amino acids, inorganic salts, organic acids, 
buffers, carbohydrates, vitamins, cofactors, and other materials [41].  
Research on hosts for producing therapeutic proteins is focusing 
increasingly on the development of more cost-effective and high 
performance novel expression systems with improved characteristics to 
meet the increased demands for therapeutic proteins [21, 29]. Therefore, 
increasing the yield of the final product and improving the stability of the 
protein expression are of considerable value to the manufacturer. Such 
improvements have been mainly obtained, over recent years, from 
optimising downstream processes and media development [27].  
An example of cell culture media development is shown in the 
following. The final product titers in CHO cells have been increased to reach 
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the gram per liter range, representing a 100-fold increase. In the late 1980s, 
a maximum cell density of 1 - 2 million cells.mL-1 yielding 50 - 100 mg.L-1 
with a typical batch culture production run lasted about 7 days. By 
comparison, the recent fed-batch production run can last up to 21 days with 
a maximum cell density of 10 - 15 million cells.mL-1 yielding 1 - 5 g.L-1 [27, 
42]. This significant improvement in the yield has been achieved mostly by 
reformulation of the serum-free medium and development of the cell culture 
feeding process, and in bioprocess modifications [27, 43]. The components 
of the cell culture media can be complex or chemically-defined (CD) 
mixtures.  
 
2.2.2. Media with complex components 
 
There are two types of cell culture media that contain complex components: 
basal media or feed media. Basal media, in addition to other important 
growth factors, are added at the initial bioreactor inoculation step to provide 
specific cell nutrients, whereas feed media are used in fed-batch processes. 
Media supply is strictly controlled to optimise growth rate, product yield, and 
quality, while preventing the formation of unwanted metabolites [38]. In 
addition, the presence of metabolisable materials in the cell culture media is 
a key to the production. Originally, serum was used to promote growth and 
enhance protein production. However, the risks of using serum as 
supplements are high, and include the possible presence of large proteins 
that may be difficult to remove and the possibility of infectious agents [44, 
45]. Moreover, not having serum in the cell culture media offers improved 
biosafety and makes regulatory approval simpler but that can limit the cell 
growth and protein production. Instead, a digest of biological materials, such 
as yeast extracts or plant hydrolysates, have become popular as a substitute 
for serum in cell culture to increase productivity [39]. Supplementing the 
culture media with these hydrolysates have been shown to improve protein 
production by twofold or more [39, 46, 47]. However, the drawback of such 
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supplements is that these hydrolysates contain unknown materials and 
undefined levels of nutrients, which can result in lot-to-lot variation in fed-
batch performance and protein production consistency [39, 48].  
 
2.2.3. Chemically defined media 
 
CD media is made of chemically defined ingredients added to purified water 
in which the identity and quantity of every component in the CD media is 
known. It contains no biogenic ingredients such as proteins, hydrolysates, or 
constituents of unknown composition. It is composed of only a carbon 
source, essential and non-essential amino acids, vitamins, and trace 
elements [39, 49, 50]. CD media are well suited for fundamental studies of 
metabolism which could greatly help the success of prospective commercial 
fermentation processes. CD media have become more popular for 
therapeutic protein production in the industrial scale, although complex 
media continue to be dominant in this field because of lower cost and higher 
productivity [51, 52]. There are some advantages related to using CD media 
instead of complex media. The major one is the absence of animal-derived 
components which is desirable from a regulatory point of view. Another 
important advantage and desired characteristic for any industrial 
fermentation process is greater reproducibility in the production of the target 
protein. This is due to the reduced performance variability of the cells in such 
media, since all the components and their amount in the media are known. 
In addition, CD media offer cleaner downstream processing steps and 
simplicity in the analysis of the end product. Also, as the CD media is more 
easily characterised compared to the complex media, it offers the potential 
for improved process control and monitoring [49, 51].  
However, despite the advantages of the CD media, it must be 
optimised to meet the specific nutritional requirements of each individual 
expression system. This can be a lengthy process and expensive, limiting 
their use in the commercial processes, since each system has specific 
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nutritional requirements and expensive growth factors such as L-amino acids 
and vitamins. Even following these significant efforts, the optimised CD 
media may still produce lower yields than complex media [49, 51].  
Therefore, semi-defined media can provide a balance for high 
productivity with reduced downstream processing. Semi-defined media are 
composed mostly of CD media supplemented with a small amounts (0.05 - 
0.5 %) of complex nutrients such as yeast extracts. Such small amount may 
provide enough nutrients to enhance microorganisms’ growth and protein 
production by over twofold without interfering with recovery or analysis of 
products [39, 49, 51].  
 
2.2.4. Yeast extracts 
 
Yeast extract is a highly filterable extract of autolysed baker’s or brewer’s 
yeast (S. cerevisiae) that includes the water-soluble components of the 
yeast cell. Yeast extract, which has good nutritional characteristics, is a non 
animal-derived powder consisting of peptides, free amino acids, nitrogen, 
carbohydrates, nucleotides, vitamins, especially vitamin B complex, trace 
elements, growth factors and salts, in addition to a significant amount of 
unknown materials [39, 51-56].  
Yeast extract is generally manufactured from the baker’s yeast, S. 
cerevisiae via a controlled autolysis process which releases the intracellular 
components. S. cerevisiae is allowed to grow to a high cell density for a 
designated period of time optimised for the particular yeast strain. Then the 
batch is exposed to a controlled temperature or osmotic shock that causes 
the yeast cells to die. However, even though these conditions lead to the 
death of the cells, the yeast’s endogenous enzymes are still active and the 
autolysis is begun. The cells are allowed to autolyse for a predetermined 
period of time. Autolysis of yeasts causes the release of amino acids, 
proteins, nucleic acid and other products. Moreover, yeast’s own digestive 
enzymes (particularly proteases and nucleases) are responsible for the 
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degradation of yeast proteins and nucleic acids which are broken down into 
peptides and amino acid derivatives and nucleotides, respectively. Once the 
autolysis is finished, the insoluble materials are centrifuged and filtered and 
the filtrate is concentrated and spray dried [49, 57-59].   
Yeast extract is a typical raw material used as a supplement in the 
culture media for the cultivation of cells which are used in the production of 
therapeutic proteins. It is a low-cost valuable source of various substances 
and a key medium component providing much of the nutritional 
requirements, particularly amino acids and vitamins, for growing CHO cells, 
and has shown a significant positive influence on cell growth and protein 
production [39, 49, 60-64].  
However, since yeast extracts are complex, ill-defined mixtures of 
natural origin, they exhibit significant lot-to-lot variability or variability 
between different vendors [65-67]. A variation by almost 50 % in biomass 
and growth-promoting activity was reported when different lots from the 
same manufacturing process were used [68]. This variability is due to the 
complex substrates and less controlled fermentation conditions used for 
yeast cultivation and to the variations in downstream processes [53]. As a 
result, the variability of such raw materials may have a significant impact on 
CHO cell growth and performance which could adversely affect the final 
product quality and yield [55, 64]. Therefore, such variation in the raw 
materials requires a development of extensive ‘use testing’ of different lots to 
ensure the invariability of such materials which, in turn, is reflected on the 
growth and performance of the cells and consistency of the final product [53, 
55, 69].  
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2.3. Characterisation of cell culture media and yeast extract samples  
 
2.3.1. Introduction 
 
Cell culture productivity plays a major role in reducing the overall 
manufacturing costs, whereas variability could lead to problems in 
downstream processes. Therefore, it is desirable to have a better 
understanding of cellular metabolism to understand the factors that 
contribute to productivity and variability [70, 71]. Process control is a critical 
factor in regulating cellular metabolism during cell cultivation to increase cell 
performance and productivity [72]. The presence of optimal concentrations 
of nutrients and the reduction of accumulating waste lead to successful cell 
growth, viability and protein production [73]. However, cell culture media and 
fermentation broths are complex mixtures of nutrients and other undefined 
components sourced from supplements, such as yeast, and limited 
information is available on the complex metabolisms of these cell lines. 
Thus, a variation in the fermentation performance may occur due to the lot-
to-lot variation inherently associated with these ill-defined components [51, 
74, 75]. Therefore, these exists a need to develop rapid, efficient and 
sensitive analytical methods to observe compositional changes and to 
ensure efficient and reliable process control for improving the yield and 
consistency of the target product [38, 41]. 
It is important to determine the concentration of specific components 
of the cell culture media, such as the main carbon and energy sources, and 
to monitor other factors, such as pH, when developing and optimising cell 
culture processes [76]. For example, characterisation of amino acid 
composition and concentrations in the cell culture and fermentation broth 
media is important because the presence or absence of specific amino acids 
could affect the yield and the quality of the desired products. Also, each cell 
line demands specific media compositions for obtaining maximum 
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productivity. Furthermore, monitoring of such nutrients during the 
fermentation is demanded since amino acids in the media might be 
consumed or released by the cells [75, 76]. Carbohydrates, which serve as 
carbon sources for many microorganisms, are essential for cell growth and 
product synthesis. It is desirable to characterise the carbohydrates, in these 
cell cultures and fermentation broths to avoid any adverse influence on the 
yield or quality of the target product [77]. Metabolism of glutamine and 
glucose produces ammonia and lactate, respectively. The concentrations of 
such metabolites should be monitored since the cell growth and productivity 
are inhibited at higher concentrations [78].  
 
2.3.2. Characterisation of amino acids and carbohydrates  
 
Amino acids and carbohydrates have been characterised in a number 
complex media such as mammalian cell culture media and fermentation 
broths [70, 71, 74-76, 79-83] utilising different analytical techniques such as 
high performance anion exchange chromatography with pulsed 
amperometric detection (HPAE-PAD) [70, 75, 76, 80, 81, 83], gas 
chromatography with flame ionisation detection (GC-FID) [71], ultra 
performance liquid chromatography (UPLC) [82] and MALDI-TOF-MS [74]. 
Genzel et al. developed a method for direct separation and detection 
of amino acids based on anion exchange chromatography with integrated 
pulsed amperometric detection [76]. The optimised method was applied for 
the analysis of typical mammalian cell culture broth samples taken over the 
entire process time. In their method, the samples had to be analysed at two 
dilutions due to the wide range of amino acid concentrations in the samples 
as a result of the medium composition and cell metabolism. Using the same 
separation technique, Hanko and Rohrer reported a direct method for 
quantitative analysis of tryptophan content of bovine serum albumin (BSA). 
The method was also used to monitor free tryptophan of E. coli cell culture 
and Bacto Yeast Peptone Dextrose (YPD) Broth and during an E. coli 
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fermentation [80]. Hanko et al. also published the successful use of anion 
exchange chromatography to simultaneous determination of carbohydrates 
and all common amino acids in cell culture and fermentation broth media 
[75, 83]. In their method, the separation between carbohydrates and amino 
acids was achieved by varying the initial NaOH eluent concentration and its 
duration.  
 Mohabbat and Drew developed a rapid (< 7 minutes) GC-FID for the 
simultaneous identification and quantification of 33 amino acids and 
dipeptides in cell culture media. The complex media samples were 
pretreated using the EZ:faastTM (Phenomenex) amino acid sample testing kit 
[71].  
Using UPLC with fluorescence detection, Fiechter and Mayer have 
developed a method for the separation of 21 amino acids utilising a sub-2 
µm C18 column [82]. Amino acids were derivatised with 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate and the derivatives were separated within 12 
minutes. The method was applied to characterise changes in the free (FAA) 
as well as total amino acid (TAA) profiles specific to culture media at three 
distinctive stages of fermentation: starting medium (before fermentation), 
inoculated fermentation broth after cell mass production prior to induction 
and after product expression at the end of fermentation.  
Free amino acids in mammalian cell culture media have also been 
quantified using MALDI-TOF-MS [74]. The technique was capable of 
quantifying 12 amino acids without derivatisation using α-cyano-4- 
hydroxycinnamic acid as the internal standard. It was applied for the analysis 
of bioreactor samples from five time points in the process.  
Krömer et al. have compared four common detection systems 
coupled to reversed-phase high performance liquid chromatography (RP-
HPLC) for the determination of L-alanyl-L-glutamine, a stable source of L-
glutamine, in cell culture media [84]. They used fluorescence detection 
(FLD) after precolumn derivatisation with o-phthaldialdehyde, direct 
quantification using ultraviolet detection (UVD), evaporative light scattering 
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detection (ELSD), and liquid chromatography electrospray ionisation tandem 
mass spectrometry (LC-ESI-MS/MS). The direct quantification of L-alanyl-L-
glutamine using UVD or ELSD was prevented by sample matrix effects, 
whereas FLD allowed the quantification over a wide concentration range and 
ESI-MS/MS showed the highest sensitivity.  
Giuffrida et al. studied the effect of genetic modification on the 
autolysis of yeast [85]. In their study, they determined L- and D-forms of the 
major amino acids released from yeast. The determination method of the 
released amino acids includes a pre-column derivatisation with fluorescein 
isothiocyanate.  The derivatives were identified and quantified using chiral 
micellar electrokinetic chromatography with laser-induced fluorescence 
detection (chiral-MEKC-LIF). The results obtained from comparing 
conventional and transgenic yeasts showed that higher amounts of L-amino 
acids were released to the medium as a result of the genetic modification 
which had lead to a faster autolysis of the yeast.  
Rao and co-workers simultaneously determined six of the critical 
cellular thiols in the sulfur metabolic pathway using a liquid chromatographic 
method with mass spectrometric detection [86]. Sample preparation included 
the extraction of thiols from yeast using water in an ultrasonic bath for 10 
minutes with an extraction recovery of more than 97 %. The extracted 
disulfides were treated with tris(2-carboxyethyl)phosphine (TCEP) to reduce 
the disulfide bond and then thiols were derivatised with p-
(hydroxymercuri)benzoate. The determined thiols were cysteine, 
homocysteine, glutathione, cysteinyl-glycine, γ-glutamyl-cysteine, and S-
adenosyl-homocysteine.  
The carbon sources, carbohydrates, and the metabolism products, 
sugar alcohols and glycols, were analysed simultaneously in growing yeast 
(S. cerevisiae) cultures and their final fermentation broths using HPAE-PAD 
[77]. The changes of carbohydrate concentrations in the yeast culture media 
during fermentation were monitored over 1 day. The results obtained 
showed a drop in glucose concentration over time and an increase in 
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glycerol. Male et al. also developed a method for on-line monitoring of 
glucose during mammalian cell cultivation. The method was based on a flow 
injection analysis (FIA) mediated-biosensor system, using immobilised 
glucose oxidase and the mediator 1,1’-dimethylferricinium (DMFe+)-
cyclodextrin [78].   
 
2.3.3. Characterisation of nucleotides and metabolism intermediates 
 
Cordell et al. developed a method utilising ion-pair HPLC tandem 
electrospray ionisation-mass spectrometry for the quantitative profiling of 
over twenty nucleotides and related phosphorylated species [87]. The 
method was applied to profile changes in intracellular nucleotides in cultured 
CHO cells and to study their response to drug treatments. VanDusen and 
co-workers reported a method for the measurement of free adenine content 
in yeast extracts or the adenine concentrations found in CD and complex 
fermentation samples [88]. The method used for the quantitation of adenine 
was RP-HPLC with fluorescence detection. Adenine was derivatised with 
chloroacetaldehyde to form the fluorescent adenine adduct 1,N6-
ethenoadenine. The method was utilised to study the adenine nutritional 
requirements of adenine auxotrophs of recombinant S. cerevisiae. The 
adenine content of individual yeast extracts was determined in relation to the 
cell mass (dry cell weight, DCW) achieved in culture media formulated with 
these extracts. As a result, a general increase in DCW was observed with 
increasing adenine concentration in the yeast extract. Jérôme et al. 
determined the concentration of methylamine, an intermediate in 
biopharmaceutical industry, in fermentation broths using a developed GC 
assay [89]. The validated method was used for monitoring methylamine 
concentration in a fed-batch bioprocess producing a dye-linked 
formaldehyde dehydrogenase in Hyphomicrobium zavarzinii ZV 580 
cultures. 
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2.3.4. Characterisation of vitamins 
 
Cataldi et al. and Nardiello et al. reported a developed method based on 
capillary electrophoresis coupled with laser-induced fluorescence (CE-LIF) 
for the analysis of water-soluble riboflavin, or vitamin B2, in baker’s yeast as 
it is a good source for riboflavin. Since riboflavin has an intrinsic fluorescent 
nature, it was selectively detected in such complex samples without 
interference [90]. In the same sample matrix, Gliszczyńska et al. quantified 
and identified riboflavin and its derivatives utilising HPLC with fluorescence 
detection [91].  
 
2.3.5. Characterisation using spectroscopic methods  
 
The use of spectroscopic methods in biopharmaceutical industry has been 
increased and their applications could exist at all manufacturing stages such 
as raw materials characterisation, monitoring of product formation and 
quality control in packaging [55]. In addition, they are suitable for online, in-
situ and in vivo measurements [38]. Kasprow et al. used near-infrared 
spectroscopy as a rapid screening method for yeast extract qualifying. NIR 
spectroscopy was performed by scanning yeast extract samples at the 
wavelengths in the range 1100 - 2500 nm. Mathematical treatment of the 
raw spectra was performed utilising chemometric methods for correlation 
between yeast extract variations and fermentation product yields [55]. 
However, since the samples under investigation in this field are prepared in 
water, much of the analyte spectral detail is masked in a technique such as 
near-infrared (NIR) spectroscopy due to the very strong water signals [41]. 
Ryan et al. [38] and Li et al. [41, 92, 93] have investigated the use of rapid 
‘holistic’ analytical methods for routine screening of cell culture media and 
yeast extracts used in industrial biotechnology. Due to the insufficient 
spectra obtained for characterising complex samples such as culture media 
by conventional single excitation wavelength spectroscopy, they used 
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excitation-emission matrix (EEM) fluorescence and Raman spectroscopy. In 
combination with chemometric methods, rapid and efficient assays were 
demonstrated for the qualitative and quantitative characterisation and quality 
assessment of complex and CD cell culture media and yeastolate 
components used for CHO cells cultivation for the purpose of recombinant 
proteins production.  
 
2.4. Thesis objectives  
 
Biotherapeutic drugs are very effective for treating different diseases such as 
cancer, diabetes, etc. This effectiveness has accelerated their development 
and manufacturing and the growth in the biopharmaceutical industry in the 
last decade is remarkable due to the introduction of many new therapeutic 
proteins. The production processes of such drugs are complicated and have 
to be maintained under strict and regulated conditions to ensure the 
consistency of the processes and to produce high quality drugs. Therefore, 
the development of rapid, sensitive and cost-effective analytical assays is 
highly demanded for monitoring the biofermentation processes and the key 
parameters that could affect the final product quality and production 
consistency. 
Chromatography is a powerful analytical technique that is widely used 
for the separation, identification and determination of the chemical 
components in complex mixtures. In the last 30 years, HPLC has become 
one of the most popular analytical instruments for the quantitative analysis of 
a wide range of pharmaceutical compounds. One of the main objectives of 
analytical laboratories is to develop rapid and efficient methods for 
qualitative and quantitative analysis. In addition, high-throughput separations 
are highly demanded in common applications within the pharmaceutical 
industry such as purity assays, pharmacokinetic studies, and quality control 
since faster separations are required to enhance productivity and reduce 
costs. 
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The aim of this thesis was to develop selective, rapid and efficient 
analytical methods based on solid phase extraction (SPE) and rapid 
resolution liquid chromatography (RRLC) for the analysis of real samples 
sourced from the biopharma industry and to evaluate lot-to-lot variability. 
The samples include fermentation feedstocks, CD cell culture media, raw 
materials (i.e. yeastolate) and in-process samples. The samples are 
complex and comprised a variety of components. The challenge is to 
develop methods for the determination of the target analytes with minimal 
interference from sample matrices. The development of the chromatographic 
methods includes the use of narrow-bore columns packed with sub-2 µm 
silica particles or the use of columns made of monolithic materials. The aim 
was also to develop a novel solid phase microextraction in a pipette tip for 
selective enrichment of galactosylated proteins by immobilising gold nano-
particles on the surface of the preformed monolith. 
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Chapter 3 
Application of rapid resolution liquid 
chromatography with fluorescence detection to 
the analysis of monosaccharides in bio-
fermentation media samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  79 
3.1. Introduction 
 
The development of robust quality control assays for key components in the 
raw materials and during production process is absolutely critical, since 
yeastolate raw materials and other cell hydrosylates exhibit significant lot-to-
lot variability, or variability between different vendors [1-3]. 
Several analytical methods of varying degrees of complexity have 
been developed for the determination of monosaccharides in aqueous 
samples and sample extracts, including GC [4], HPAEC-PAD [5-10], 
capillary zone electrophoresis (CZE) [11-15] RP-HPLC [11, 16-23]. Methods 
developed specifically for the characterisation of biofermentation broth 
samples for monosaccharide profiles are relatively few, and most are limited 
to two or three monosaccharides, present at relatively high concentrations 
[24-27]. In RP-HPLC, monosaccharides cannot be determined using direct 
UV absorbance or FLD, due to the lack of suitable chromophores and 
fluorophores. Some methods on complex media samples have been 
described using HPAEC-PAD [5], although this particular detection approach 
is prone to interference, especially with samples like yeastolates, which 
contain excess concentrations of undefined components. Alternative 
detection options, such as refractive index detection and related methods, 
suffer from limited concentration sensitivity and lack of specificity [28]. For 
these reasons, pre-column derivatisation of monosaccharides is crucial for 
highly sensitive and selective detection [29]. There are a variety of reagents 
developed for this application, including 2-aminobenzoic acid (AA) [11, 17], 
benzamidine [18], FMOC-hydrazine (9-fluorenylmethylchloroformate) [19] 
and aminopyrazine [20] for FLD, and p-aminobenzoic ethyl ester (ABEE) 
[21, 22] and 1-phenyl-3-methyl-5-pyrazolone (PMP) [23] for UV absorbance 
detection. Of the above options, labelling monosaccharides with AA has 
several advantages, not least the high sensitivity compared to the others. 
Additionally, AA can be used for quantitation of both neutral and amino 
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monosaccharides without N-acetylation, whereas using other labelling tags 
requires monosaccharides to be N-acetyled [30].  
This Chapter describes a selective and robust RPLC-FLD based 
method developed specifically for the profiling of up to 10 monosaccharides, 
with a chromatographic run-time of approx. 20 minutes, for a range of 
complex biological samples originating from a biopharmaceutical CHO 
based process. Specifically, the assay was developed to allow selective 
quantification of glucosamine, mannosamine, galactosamine, galactose, 
mannose, glucose, ribose, xylose, fucose and sialic acid, without 
interferences from the extracts of yeastolate feedstock, basal media 
preparations and fermentation process samples.  
 
3.2. Experimental 
 
3.2.1. Reagents and materials 
 
Galactose (Gal, 99 %), glucose (Glc, 99.5 %), mannose (Man, Sigma-Ultra), 
glucosamine (GlcN, 99 %), galactosamine (GalN, 98 %), ribose (Rib, 99 %), 
fucose (Fuc, 98 %), sodium cyanoborohydride (95 %), sodium acetate (99 
%), boric acid (99.5 %) and diethyl ether were purchased from Sigma-Aldrich 
(Tallaght, Dublin, Ireland). Xylose (Xyl, 99 %), mannosamine (ManN, 98 %), 
and anthranilic acid (AA, 98 %) were purchased from Fluka (Buchs, 
Switzerland). Methanol (MeOH) and acetonitrile (ACN) were of HPLC grade 
from Labscan (Tallaght, Dublin, Ireland). Acetic acid (96 %) was from Riedel-
de-Haen (Seelze, Germany). All chemicals were used as received, without 
any further purification. 
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3.2.2. Instrumentation 
 
The chromatographic separation was performed using an Agilent 1200 
Series Rapid Resolution Liquid Chromatography (RRLC) system (Agilent 
Technologies, CA, USA), which comprised an on-line degasser, a binary 
pump, an autosampler with temperature control, a column oven and a UV-
Vis detector. The AA-monosaccharide derivatives were separated on a 2.1 
mm × 50 mm, 1.8 µm ZORBAX Eclipse XDB-C18 column (Agilent 
Technologies, CA, USA) at a flow rate of 0.4 mL.min-1 and a column 
temperature of 20 oC. Mobile phase A was 50 mmol.L-1 sodium acetate 
buffer (pH 4.3) and mobile phase B was ACN. The gradient program was: 0-
12 minutes (2 % B), 12.1-17 minutes (10 % B) and 17.1-25 minutes (2 % B). 
The injection volume was 700 nL with FLD (Waters 470 fluorescence 
detector, Waters Corporation, MA, USA) at excitation: 360 nm and emission: 
424 nm. Sample preparation prior to derivatisation was achieved with a C18 
solid phase extraction cartridge (Phenomenex Strata C18-E, 55 µm, 70 Å, 50 
mg/mL, Phenomenex, Macclesfield, UK). A GFL water bath model 1013 
(GFL, Burgwedel, Germany) was used for derivatisation and the balance 
used was a Sartorius Model ED124S (Sartorius, Goettingen, Germany). The 
pH meter used (Orion 2 Star) was purchased from Thermo Electron 
Corporation (Thermo, PA, USA). The water used for preparations was 
purified using Millipore Direct Q 5 system (Millipore, France).  
 
3.2.3. Sample preparation 
 
The samples analysed originate from an actual industrial scale 
biofermentation process facility for a commercial biotherapeutic drug and 
were supplied by Bristol–Myers Squibb.  
Yeastolate samples were supplied as solid materials and stored in the 
fridge at 4 oC. Cell culture media were sampled and aliquotted under sterile 
conditions and shipped from the US to Ireland at low temperature. These 
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samples were then aliquotted to smaller volumes and stored frozen at -70 
oC. The samples were further transferred from Galway to Dublin at low 
temperature and stored at -70 oC. When analysed, the samples were 
removed from the freezer and defrosted at room temperature (~ an hour). 
The desired sample volume was aliqotted and then treated as described 
below, whereas the remaining sample was retuned to the freezer until further 
use. Samples identities are listed in Table 3.1. 
 
Table 3.1 
Identification and description of different sample types  
Sample#  Sample ID Description 
Yeastolate samples 
Sample 1 ITP-2006-000113 Bacto TC Yeastolate 
Sample 2 ITP-2006-000567 Bacto TC Yeastolate 
Sample 3 ITP-2006-000566 Bacto TC Yeastolate 
Sample 4 ITP-2006-000528 Bacto TC Yeastolate 
Sample 5 ITP-2006-000527 Bacto TC Yeastolate 
Sample 6 ITP-2006-000112 Bacto TC Yeastolate 
Sample 7 ITP-2006-000114 Bacto TC Yeastolate 
Basal media samples (Lot A) 
Sample A1 ITP-2006-000615 Lonza Initial After Load 
Sample A2 ITP-2006-000616 Lonza Initial After Load 
Sample A3 ITP-2006-000617 Lonza Initial After Load 
Sample A4 ITP-2006-000618 Lonza Initial After Load 
Sample A5 ITP-2006-000619 Lonza Initial After Load 
Sample A6 ITP-2006-000620 Lonza Initial After Load 
Sample A7 ITP-2006-000621 Lonza Initial After Load 
Basal media samples (Lot B) 
Sample B1 ITP-2006-000025 Bioreactor 4 Initial After Load 
Sample B2 ITP-2006-000091 Bioreactor 4 Initial After Load 
Sample B3 ITP-2006-000308 Bioreactor 4 Initial After Load 
Sample B4 ITP-2006-000401 Bioreactor 4 Initial After Load 
Sample B5 ITP-2006-000234 Bioreactor 4 Initial After Load 
Sample B6 ITP-2006-000186 Bioreactor 4 Initial After Load 
Sample B7 ITP-2006-000447 Bioreactor 4 Initial After Load 
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Table 3.1 (continued) 
Identification and description of different sample types  
Sample#  Sample ID Description 
In-process samples (Lot A) 
Sample A1  ITP-2006-000137 Bioreactor 1 Media Start (Day 0) 
Sample A2  ITP-2006-000238 Bioreactor 1 Media End 
Sample A3  ITP-2006-000239 Bioreactor 1 End Passage 7 
Sample A4  ITP-2006-000223 Bioreactor 2 Initial After Load 
Sample A5  ITP-2006-000253 Bioreactor 2 Prior to Transfer 
Sample A6  ITP-2006-000232 Bioreactor 3 Initial After Load 
Sample A7  ITP-2006-000246 Bioreactor 3 Prior to Transfer 
Sample A8  ITP-2006-000255 Bioreactor 4 Initial After Load 
Sample A9  ITP-2006-000247 Bioreactor 4 After Inoculation 
Sample A10 ITP-2006-000268 Bioreactor 4 Day 5 Post Inoculation 
Sample A11  ITP-2006-000297 Bioreactor 4 Day 10 Post Inoculation 
Sample A12  ITP-2006-000310 Bioreactor 4 Prior to Transfer 
In-process samples (Lot B) 
Sample B1 ITP-2005-000002 Bioreactor 1 Media Start (Day 0) 
Sample B2 ITP-2005-000003 Bioreactor 1 Media End 
Sample B3 ITP-2006-000001 Bioreactor 1 End Passage 7 
Sample B4  ITP-2006-000005 Bioreactor 2 Initial After Load 
Sample B5  ITP-2006-000004 Bioreactor 2 Prior to Transfer 
Sample B6 ITP-2006-000003 Bioreactor 3 Initial After Load 
Sample B7 ITP-2006-000018 Bioreactor 3 Prior to Transfer 
Sample B8 ITP-2006-000014 Bioreactor 4 Initial After Load 
Sample B9  ITP-2006-000017 Bioreactor 4 After Inoculation 
Sample B10  ITP-2006-000036 Bioreactor 4 Day 5 Post Inoculation 
Sample B11 ITP-2006-000038 Bioreactor 4 Day 10 Post Inoculation 
Sample B12  ITP-2006-000043 Bioreactor 4 Prior to Transfer 
 
 
All samples were dissolved and diluted using GlcN as an internal 
standard. A number of representative samples had previously been tested 
and found to contain no detectable levels of GlcN. Therefore, for yeastolate 
analysis (received as dry powders) 15 mg of yeastolate was dissolved in 1 
mL of 150 mmol.L-1 GlcN. For the analysis of basal media samples, 50 mL of 
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the sample was diluted by a factor of 5 using spiking solution (175 mmol.L-1 
GlcN). For the determination of Glc levels in these samples, 20 mL of the 
above diluted sample was further diluted by a factor of 80 using the spiking 
solution. In-process samples were collected at specific time-points during a 
commercial biofermentation process and were provided after removal of 
CHO cells by centrifugation. These samples were diluted by a factor of 5 
using spiking solution (175 mmol.L-1 GlcN). A further dilution of the diluted 
sample was carried out by a factor of 20, 50 or 60 depending on the relative 
levels of Gal and Glc which were present at high levels in many of these 
samples.  
 
3.2.4. Sample cleanup by solid phase extraction (SPE) 
 
A C18 SPE cartridge was conditioned with 1 mL of methanol followed by 1 
mL of water. A volume of diluted sample (200 µL) was passed through the 
cartridge and collected in a clean polypropylene centrifuge tube, followed by 
a further 100 µL water wash; the unretained hydrophilic monosaccharides 
were subsequently derivatised with AA as described is Section 3.2.5. 
 
3.2.5. Fluorescent labelling of monosaccharides 
 
3.2.5.1. Preparation of derivatisation reagent 
A methanol acetate borate solution (MABS) was prepared by 
dissolving 240 mg sodium acetate and 200 mg boric acid in 10 mL methanol. 
This solution was stable for one week at 4 oC. The derivatisation reagent 
was prepared by dissolving 30 mg of amino benzoic acid (AA) and 20 mg of 
sodium cyanoborohydride in 1 mL of MABS, which was prepared fresh prior 
to use [17].  
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3.2.5.2. Derivatisation of monosaccharides 
Pre-column derivatisation was achieved by mixing 100 µL of 
sample/standard with 100 µL of the AA reagent in a 2 mL screw-top 
polypropylene plastic tube. The mixture was heated in a water bath at 80 oC 
for 80 minutes followed by dilution with 800 µL of mobile phase A. The 
mixture was centrifuged and the supernatant was transferred for further use. 
The reaction scheme is shown in Figure 3.1. 
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Figure 3.1: Reaction scheme for the labelling of monosccharides with AA [30]. 
 
3.2.6. Liquid-liquid extraction of excess derivatisation reagent 
 
An aliquot of the derivatised sample (250 µL) was transferred to a 1.5 mL 
centrifuge tube and shaken with 1 mL of diethyl ether for 1 minute. The top 
layer (ether) was removed with a micropipette and another 1 mL of ether 
was added to the bottom layer and the procedure repeated. A total of three 
ether extractions were performed after which the bottom layer was 
transferred to a glass HPLC vial for injection. 
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3.2.7. SPE recovery of monosaccharide standards and real samples 
 
The recovery of monosaccharides standards from SPE was studied by 
comparing the peak areas of two different aliquots of the same standard 
solution. One of the aliquots was passed through the SPE cartridge as in 
Section 3.2.4., collected and derivatised, whereas the other was derivatised 
without SPE treatment. For spike recovery study, a yeastolate sample was 
spiked with known concentrations of monosaccharide standards prior to SPE 
and derivatisation. 
 
3.3. Results and discussion 
 
3.3.1. Optimisation of chromatographic conditions 
 
The method described here has its origin within the pioneering paper on the 
separation of AA monosaccharide derivatives by RPLC-FLD initially reported 
by Anumula [17]. However, the chromatographic method developed by 
Anumula utilising a 5 µm 0.46 mm × 25 cm C18 column was only capable of 
the separation of six to seven monosaccharides in a run-time of approx. 50 
minutes, with a large tailed reagent peak masking the elution window from 
20 to 35 minutes, and thus limiting the practical application of the method. In 
an effort to simultaneously reduce chromatographic run-time, mobile phase 
consumption and increase peak capacity to allow the separation of a larger 
suite of monosaccharides (including sialic acid), the method described 
herein utilised a short (2.1 mm × 50 mm) 1.8 µm, C18 column (ZORBAX 
Eclipse XDB), which under optimised conditions allowed the separation of all 
10 target AA-monosaccharide derivatives within 20 minutes. In addition, the 
method used considerably less solvent while running at lower flow rates (in 
this instance 0.4 mL.min-1).  
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The effect of the mobile phase pH was investigated in detail over two 
different pH ranges. ‘Range 1’ was from pH 3.6 to pH 5.2 at 0.4 unit 
intervals. The retention time of the last eluting peak decreased by about 50 
% when the pH was increased from 3.6 to 5.2, however, the overall 
resolution of the analyte peaks was almost lost at this pH (5.2), whereas a 
reasonable separation was obtained at pH 4.4 as shown in Figure 3.2(a). 
Therefore, a further investigation over a narrower range from pH 4.0 to pH 
4.5 at 0.1 unit intervals, i.e. ‘Range 2’, was carried out. There was no 
significant effect upon retention times across this range, as they only 
increased by approximately 7 %, when the pH was decreased from 4.5 to 
4.0, whereas a greater effect was seen on the resolution between Man, Glc 
and Rib peaks as shown in Figure 3.2(b). For example, at pH 4.0 the 
resolution of the Man/Glc pair was 1.9 and 0.92 for Glc/Rib, whereas at pH 
4.5 Man/Glc resolution was 0.96 and Glc/Rib was 1.55. However, at pH 4.3 
these were 1.5 and 1.4, respectively, as shown in Figure 3.3. The resolution 
between Glc and Rib was the highest at pH 4.8, although at this pH co-
elution of Man/Glc and ManN/GalN peak pairs was also observed, with lower 
resolution between sialic acid and a late eluting system peak. Therefore, it 
was concluded that the optimum working pH in terms of retention and 
resolution was pH 4.3. In addition, the effect of sodium acetate buffer 
concentration on the separation was also investigated in the range between 
10 and 50 mmol.L-1. However, there was no significant influence of the 
concentration either on the separation or on the retention time.  
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Figure 3.2: The effect of mobile phase pH on the separation of the ten AA-
monosaccharide derivatives at pH ‘Range 1’ (a) and pH ‘Range 2’ (b). Column: 2.1 
mm × 50 mm, 1.8 µm Zorbax Eclipse XDB-C18. Mobile phase A: 50 mmol.L
-1 
sodium acetate, mobile phase B: 100 % ACN. Gradient program: 0-4 minutes (2 
%), 5-8 minutes (4 %), 9-12 minutes (8 %), 12.1-20 (2 %). Flow rate: 0.43 mL.min-1. 
Column temperature: 20 oC. Injection volume: 700 nL. Detection: excitation @ 360 
nm and emission @ 425 nm. Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) excess AA, 
(5) Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and (12) blank 
peak.  
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Figure 3.3: The influence of mobile phase pH on the resolution of Man/Glc and 
Glc/Rib peak pairs. 
 
 
The effect of column temperature upon the separation of the 
derivatives was also examined in the range between 15 oC and 50 oC at 5 oC 
intervals and the results are shown in Figure 3.4. Even though the peaks 
were sharper and eluted earlier by over 50 % at 50 oC compared to 15 oC, 
the resolution between the peaks decreased significantly and, in particular, 
co-elution of ManN/GalN and sialic acid/system peak pairs was observed. 
Improved resolution was obtained when the separation was carried out at 
lower temperatures. However, column temperatures below 20 oC lead to 
broadened peaks and increased retention times and so 20 oC was selected 
for all sample analyses.  
Figure 3.5 shows the separation of the AA-monosaccharide 
derivatives under the optimised conditions. As it can be seen, the AA-
monosaccharide derivative peaks are well separated from each other and 
from the blank peaks. 
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Figure 3.4: The effect of column temperature on the separation of the ten AA-
monosaccharide derivatives. Chromatographic conditions are as descriced in 
Figure 3.2 except the following: Mobile phase A: 50 mmol.L-1 sodium acetate pH 
4.1. Gradient program: 0-4 minutes (2 %), 6-12 minutes (4 %), 13-20 minutes (8 %), 
21-25 (2 %). Flow rate: 0.3 mL.min-1.  Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) 
excess AA, (5) Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and 
(12) blank peak. 
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Figure 3.5: Optimum separation of the ten AA-monosaccharide derivatives overlaid 
with a blank. Column: 2.1 mm × 50 mm, 1.8 µm Zorbax Eclipse XDB-C18. Mobile 
phase A: 50 mmol.L-1 sodium acetate pH 4.3, mobile phase B: 100 % ACN. 
Gradient program: 0-12 minutes (2 %), 12.1-17 minutes (10 %), 17.1-25 minutes (2 
%). Flow rate: 0.4 mL.min-1. Injection volume: 700 nL. Column temperature: 20 oC. 
Detection: excitation @ 360 nm and emission @ 425 nm. Peaks: (1) GlcN, (2) 
ManN, (3) GalN, (4) excess AA, (5) Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, 
(11) sialic acid, and (12) blank peak. 
 
 
3.3.2. Labelling of monosaccharides with AA 
 
Figure 3.1 shows the reaction scheme for tagging the monosaccharides with 
AA. An investigation of the time required for formation of the AA-
monosaccharide derivatives was carried out by performing the derivatisation 
at 80 oC for different time periods ranging from 0 to 120 minutes. The 
optimum time for the derivatisation reaction which gave the highest peak 
areas for the AA-monosaccharide derivatives was 80 minutes as indicated in 
Figure 3.6. Peak areas for AA-monosaccharides derivatives were increased 
by 11.2 % for GlcN, 5.5 % for ManN, 4.2 % for GalN, 1.9 % for Gal, 3.8 % for 
Man, 4.0 % for Glc, 2.9 % for Rib, 3.1 % for Xyl, 3.3 % for Fuc and 33.3 % 
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for sialic acid compared to the original assay, [17] in which the derivatisation 
was carried out for 60 minutes in an oven.  
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Figure 3.6: The effect of the time of derivatisation on the peak area of standard 
monosaccharides derivatives. The other derivatisation conditions are as described 
in Section 3.2.5. Curve assignment: (1) sialic acid, (2) GlcN, (3) GalN, (4) ManN, (5) 
Gal, (6) Rib, (7) Man, (8) Glc, (9) Fuc, (10) Xyl. 
 
3.3.3. Liquid-liquid extraction of the excess derivatisation reagent 
 
The concentration of AA reagent used for the derivatisation of samples as 
first reported produced an unacceptably large tailed reagent peak within the 
centre of the chromatogram which interfered with the accurate determination 
of Gal and probably Man [17]. Within the sample set under investigation in 
this study, monosaccharide concentrations varied greatly, particularly for 
basal media samples and in-process samples, which both had been 
supplemented with additional Glc. Therefore, for practical application a 
method to reduce the excessive reagent concentration within the prepared 
sample was necessary. Since the intention of this study was to develop a 
single derivatisation protocol for all three sample types (i.e. yeastolate, basal 
media and in-process samples), no attempt was made to reduce the reagent 
peak size by optimising the concentration of AA (30 mg.mL-1) for each 
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individual sample type. Instead the excess reagent could be readily 
extracted into diethyl ether without adversely affecting either the separation 
or the recovery of monosaccharides. Figure 3.7 shows standard 
chromatograms of AA-monosaccharide derivatives before and after diethyl 
ether extraction. The peak area for the AA reagent peak(s) (including Peak 
12) was selectively reduced by a factor of ten, while the extraction recovery 
for all monosaccharides was not adversely affected as detailed in Table 3.2.  
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Figure 3.7: Separation of ten AA-monosaccharide derivatives before (pink) and 
after (dark blue) diethyl ether extraction of excess AA. Chromatographic conditions 
and peak assignment are as described in Figure 3.5.  
 
3.3.4. Method validation 
 
3.3.4.1. Solid phase extraction (SPE) recovery studies 
  Given the complex nature of the samples, SPE was used as an initial 
cleanup step for all samples under study. The samples were subjected to 
SPE to trap vitamins and peptides but to allow the unretained 
monosaccharides to run straight through for collection and derivatisation as 
such components could overload binding sites on the column. The SPE 
phase selected for study was a C18 bonded phase used in non-retentive SPE 
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mode, since monosaccharides were not expected to be retained due to their 
hydrophilic nature, relative to peptides and other hydrophobic small 
molecules. Thus the sample was passed through the SPE bed and 
unretained monosaccharides immediately collected for analysis. To recover 
any monosaccharides which were held up within the dead volume of the 
SPE cartridge, a water rinse was combined with the collected 
monosaccharide fraction. Rinse volumes ranging from 100 µL to 400 µL 
were investigated in an effort to maximise recovery while minimising 
unnecessary dilution effects. While an average recovery value of 62 % was 
obtained when no water rinse was used, a minimum rinse volume of 100 µL 
resulted in recovery values > 97 %, as detailed in Table 3.2. The recovery of 
a known concentration of monosaccharides spiked into a yeastolate sample 
prior to SPE and derivatisation was also examined and results are also 
detailed in Table 3.2. The spike recovery was > 90 % for all 
monosaccharides.  
 
Table 3.2 
Recovery (%) studies of monosaccharides from SPE and diethyl ether extractionsa 
Monosaccharide 
Solid phase 
extraction 
recovery 
(standards) 
Solid phase 
extraction 
recovery 
(spiked 
sample) 
Diethyl ether 
extraction 
recovery 
Average 
recovery 
(combined 
SPE and 
solvent 
extraction, 
n = 6 inj.) 
Glucosamine 100 112 114 108 
Mannosamine 98 102 111 104 
Galactosamine 98 105 118 107 
Galactose 102 103 122 109 
Mannose 100 91 115 102 
Glucose 97 102 117 105 
Ribose 98 90 110 99 
Xylose 101 91 113 102 
Fucose 97 94 104 98 
Sialic acid 102 122 109 111 
a Individual recovery data based upon duplicate injections for all monosaccharides. 
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3.3.4.2. Linearity 
The linear range of the method was examined using standard 
solutions of the ten monosaccharides. Each monosaccharide was prepared 
at five different concentrations (n = 5), derivatised and injected in duplicate. 
The method provided linear standard curves (R2 > 0.999) for each 
monosaccharide of interest over a wide concentration range (Table 3.3).  
 
3.3.4.3. Precision 
A mixture of ten monosaccharides was derivatised and injected seven 
times for testing peak area and retention time precision, resulting in % RSD 
values < 2.2 % and < 0.4 %, respectively as listed in Table 3.3. A yeastolate 
sample which had previously been found to contain detectable levels of 
Man, Glc, Xyl and Fuc was selected to study the reproducibility of sample 
preparation, i.e. SPE and subsequent derivatisation. The sample was 
divided into five aliquots, which were each individually treated as described 
in the Experimental section using GlcN as an internal standard. Duplicate 
injections of each individually processed sample aliquot resulted in peak 
area % RSD values of 1.9 % (Man), 3.1 % (Xyl), 3.0 % (Fuc) and 2.0 % 
(Glc). 
 
3.3.4.4. Sensitivity 
The limit of detection (LOD) was determined for each 
monosaccharide by injecting low concentrations of each analyte and 
extrapolating peak heights to a signal-to-noise (S/N) ratio of 3 (Table 3.3). 
Based upon a 700 nL injection volume, absolute detection limits were in the 
10-350 fmol range for the complete group of monosaccharides investigated. 
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Table 3.3 
Analytical performance criteria 
Monosaccharide 
Area 
precision  
% RSD 
(n = 7) 
RT 
precision  
% RSD 
(n = 7) 
LOD 
µ µmol.L
-1
 
(fmol)
a
 
Linear 
range 
(µmol.L
-1
) 
Linearity 
(n = 5) 
Glucosamine 0.7 0.4 0.56 (39) 4.2-83.3 0.999 
Mannosamine 0.7 0.4 0.19 (13) 1.4-41.7 0.999 
Galactosamine 0.7 0.3 0.37 (26) 1.9-55.6 0.999 
Galactose 0.8 0.2 0.37 (26) 1.9-55.6 0.999 
Mannose 0.8 0.2 0.37 (26) 2.8-83.3 0.999 
Glucose 1.2 0.1 0.37 (26) 2.8-55.6 0.999 
Ribose 2.2 0.1 0.37 (26) 1.9-55.6 0.999 
Xylose 0.6 0.1 0.14 (10) 1.4-41.7 0.999 
Fucose 1.0 0.1 0.14 (10) 1.4-27.8 0.999 
Sialic acid 1.3 0.1  0.50 (35) 5-500 0.999 
a Based on a 700 nL injection. 
 
3.3.5. Monosaccharide profile of yeastolate, basal media and in-process 
samples 
 
For evaluation purposes, the developed method was applied to the 
qualitative analysis of monosaccharide profiles in a variety of complex 
samples supplied from the biopharmaceutical industry. The samples were 
treated as described in the Experimental section and analysed with the 
developed method. The presence of monosaccharides in the samples was 
confirmed by a comparison with a standard chromatogram.  
 
3.3.5.1. Analysis of yeastolate samples 
The concentration of yeastolate used in this study was 15 mg.mL-1. 
The choice of this concentration was based on a preliminary study in which a 
series of yeastolate sample concentrations ranging from 10 to 100 mg.mL-1 
was prepared and injected. At the optimum concentration, the target analyte 
peaks were well separated from each other and from the other peaks. 
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Figure 3.8 shows the HPLC chromatograms obtained from the 
analysis of the yeastolate samples, seven samples in total. As it can be 
seen, all the AA-monosaccharide derivatives were well separated with no 
observed interference from unknown sample components. All samples were 
injected in duplicate and Man, Glc, Xyl and Fuc were found in all samples 
tested. As previously mentioned, GlcN was used as an internal standard in 
order to minimise possible quantification errors stemming from SPE or 
derivatisation procedures. Relative peak areas (relative to GlcN) are listed in 
Table 3.4 and shown graphically in Figure 3.9. From the results obtained the 
amount of most of the monosaccharides in the yeastolate samples lies within 
one standard deviation of the mean. The average % RSD for the seven 
yeastolate samples is 14 % (except for Xyl, % RSD = 37 %). Although the 
basic monosaccharide chromatographic profile for all batches was very 
similar (Figure 3.8), the variability in monosaccharide relative peak areas 
between different lots of yeastolate (particularly for the two high level 
monosaccharides, Man and Glc) was significant, since it could possibly have 
an impact on the consistency of product quality. Interestingly, the sample 
chromatograms showed a number of unidentified peaks eluting between 14 
and 17 minutes, which were not present in the standard or blank. Through 
sample spiking, both Xyl and Fuc could be seen in low levels within the 
yeastolate, but sialic acid could not be seen under these conditions.  
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Figure 3.8: HPLC chromatograms of yeastolate samples overlaid with a standard. 
Chromatographic conditions are as described in Figure 3.5. Peaks: (1) GlcN, (2) 
ManN, (3) GalN, (4) excess AA, (5) Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, 
(11) sialic acid, and (12) blank peak. 
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Table 3.4  
Semi-quantitative evaluation of monosaccharide levels in yeastolate samples. Date 
of analysis: 11/01/2008. 
Relative peak area* 
Sample 
number 
Man Glc Xyl Fuc 
Sample 1 2.98 7.73 0.05 0.11 
Sample 2 2.53 8.13 0.04 0.08 
Sample 3 2.71 7.71 0.04 0.01 
Sample 4 2.22 5.55 0.02 0.10 
Sample 5 2.21 5.41 0.020 0.1 
Sample 6 2.80 7.34 0.05 0.11 
Sample 7 3.32 8.29 0.055 0.12 
S.D.  
(% RSD) 
0.40 
(15 %) 
1.20 
 (16.7 %) 
0.01  
(36.8 %) 
0.01  
(10.2 %) 
*Relative peak areas w.r.t GlcN internal standard 
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Figure 3.9: Monosaccharide profiles in the yeastolate samples.  
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3.3.5.2. Analysis of basal media samples 
Fourteen samples of basal media were supplied from industry, in this 
case sourced from two different manufacturing facilities producing the same 
biotherapeutic (seven samples from each facility, referred to hereafter as 
‘‘Lot A’’ and ‘‘Lot B’’). Since the majority of samples were supplemented 
with relatively high levels of Glc, two dilution factors were employed for 
sample analysis (1/5 for all monosaccharides, except Glc for which 1/400 
dilution factor was used). Figures 3.10 and 3.11 (a and b) show an overlay 
of HPLC chromatograms for basal media (Lot A and Lot B) samples with 
small and large dilution factors, respectively. The samples were treated as 
described earlier and injected in the HPLC system in duplicate. The 
presence of the target analytes was confirmed by a comparison with a 
standard chromatogram. Relative peak areas of all monosaccharides 
existing in the samples were quantified with respect to GlcN internal 
standard and the results are listed in Table 3.5. Figures 3.12, 3.13 and 3.14 
show the intra- and inter-lot profile of each monosaccharide in these 
samples. All samples were found to contain Man, Glc and sialic acid. As 
shown in Table 3.5 and Figure 3.11(b), Sample B1 was the only sample 
containing detectable levels of Gal as well as over twice the amount of Glc 
relative to all other samples from Lot B. Although Glc levels were very high 
relative to Man for all samples tested, quantification of Man was still 
possible. Interestingly, mean Glc and Man levels were notably higher in the 
samples within Lot B relative to Lot A. The % RSD for Glc was 10 % in Lot 
A compared with 68 % in Lot B. Finally, there was a large variation in levels 
of free sialic acid present in both lots of samples (% RSD: 112 % for Lot A 
and 65 % for Lot B).  
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Figure 3.10(a): HPLC chromatograms of Lot A of basal media samples (diluted by 
a factor of 1/5) overlaid with a standard. Chromatographic conditions are as 
described in Figure 3.5. Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) excess AA, (5) 
Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and (12) blank peak. 
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Figure 3.10(b): HPLC chromatograms of Lot A of basal media samples (diluted by 
a factor of 1/400) overlaid with a standard. Chromatographic conditions are as 
described in Figure 3.5. Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) excess AA, (5) 
Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and (12) blank peak. 
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Figure 3.11(a): HPLC chromatograms of Lot B of basal media samples (diluted by 
a factor of 1/5) overlaid with a standard. Chromatographic conditions are as 
described in Figure 3.5. Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) excess AA, (5) 
Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and (12) blank peak. 
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Figure 3.11(b): HPLC chromatograms of Lot B of basal media samples (diluted by 
a factor of 1/400) overlaid with a standard. Chromatographic conditions are as 
described in Figure 3.5. Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) excess AA, (5) 
Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and (12) blank peak. 
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Table 3.5  
Semi-quantitative evaluation of monosaccharide levels in basal media samples. 
Date of analysis: 14-16/01/2008. 
Relative peak area* 
Sample number  
Gal Man Glc Sialic acid 
Basal media samples (Lot A) 
Sample A1 ND** 0.01 1.28 0.13 
Sample A2 ND** 0.02 1.33 0.03 
Sample A3 ND** 0.01 1.11 0.04 
Sample A4 ND** 0.01 1.07 0.07 
Sample A5 ND** 0.02 1.21 0.03 
Sample A6 ND** 0.01 1.17 0.03 
Sample A7 ND** 0.02 1.38 0.30 
S.D.  
(% RSD) 
 
0.0015 
 (10.7 %) 
0.116  
(9.5 %) 
0.10 
 (112 %) 
Basal media samples (Lot B) 
Sample B1 4.8 ND** 10.2 0.18 
Sample B2 ND** 0.03 3.69 0.11 
Sample B3 ND** 0.04 2.56 0.05 
Sample B4 ND** 0.04 2.84 0.08 
Sample B5 ND** 0.04 3.97 0.08 
Sample B6 ND** 0.03 1.99 0.03 
Sample B7 ND** 0.04 3.50 0.20 
S.D.  
(% RSD) 
 
0.0046 
 (12.8 %) 
2.77  
(67.5 %) 
0.07  
(64.7 %) 
*Relative peak areas w.r.t GlcN internal standard 
**None detected 
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Figure 3.12: Glc profile in the basal media samples.  
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Figure 3.13: Man profile in the basal media samples.  
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Figure 3.14: Sialic acid profile in the basal media samples.  
 
3.3.5.3. Analysis of in-process samples 
Figure 3.15 (a and b) shows chromatograms of in-process samples 
(24 samples in total). The samples sourced from two different manufacturing 
facilities producing the same protein. These in-process samples were 
collected from fed-batch CHO cell cultures at different time-points as 
described in Table 3.1. They were obtained prior to and after bioreactor 
inoculation as described earlier. The samples were treated and derivatised 
using the optimised procedure and injected in duplicate. The utility of the 
developed method for the in-process determination of monosaccharide 
levels in a bioreactor is clearly demonstrated in Figure 3.15. The displayed 
chromatograms demonstrate the potential of the method for monitoring 
changing levels of Gal and Glc over time. After the treatment of the samples 
under the optimised conditions, Glc was found in all samples tested and Gal 
and Man in some of them. Relative peak areas are listed in Table 3.6. 
Figures 3.16, 3.17 and 3.18 show the intra- and inter-lot profiles of each 
monosaccharide existing in the samples. The graphs show a close similarity 
between lots indicating a clearly well controlled process. In addition, Figure 
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3.19 illustrates that trace levels of Man can still be determined in in-process 
samples which contain significantly higher levels of Gal and Glc.   
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 5 10 15 20 25
Retention time (minutes)
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
1 11
7
6
4
Sample A1
Sample A5
Sample A6
Sample A7
Standard
Sample A4
Sample A3
Sample A2
85
3
2 12
10
9
a
 
Figure 3.15(a): HPLC chromatograms of Lot A of in-process samples (diluted to 
different extents) overlaid with a standard. Chromatographic conditions are as 
described in Figure 3.5. Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) excess AA, (5) 
Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and (12) blank peak. 
  109 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 5 10 15 20 25
Retention time (minutes)
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
1 117
6
4
Sample B1
Sample B5
Sample B6
Sample B7
Standard
Sample B4
Sample B3
Sample B2
85
3
2
12
10
9
b
 
Figure 3.15(b): HPLC chromatograms of Lot B of in-process samples (diluted to 
different extents) overlaid with a standard. Chromatographic conditions are as 
described in Figure 3.5. Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) excess AA, (5) 
Gal, (6) Man, (7) Glc, (8) Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and (12) blank peak. 
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Table 3.6 
Semi-quantitative evaluation of monosaccharide levels in in-process samples. Date 
of analysis: 05-06/03/2008. 
Relative peak area* 
Sample number (dilution factor) 
Gal Man Glc 
In-process samples (Lot A) 
Sample A1 (50) ND** 0.020 153.2 
Sample A2 (50) ND** 0.018 170.5 
Sample A3 (50) ND** 0.031 111.4 
Sample A4 (50) ND** 0.015 137.6 
Sample A5 (50) ND** 0.044 151.5 
Sample A6 (50) ND** 0.015 159.8 
Sample A7 (50) ND** 0.034 144.8 
Sample A8 (50) 0.025 0.020 149.8 
Sample A9 (50) 0.008 0.024 130.4 
Sample A10 (20) 1.96 0.058 131.5 
Sample A11 (20) 17.1 0.41 17.6 
Sample A12 (20) 16.9 0.43 15.1 
In-process samples (Lot B) 
Sample B1 (50) ND** 0.016 148.3 
Sample B2 (50) ND** 0.014 117.6 
Sample B3 (50) ND** 0.043 89.7 
Sample B4 (50) ND** 0.017 104.6 
Sample B5 (50) ND** 0.044 76.9 
Sample B6 (50) ND** 0.015 132.5 
Sample B7 (50) ND** 0.039 81.8 
Sample B8 (50) ND** 0.014 133.3 
Sample B9 (50) ND** 0.031 103.3 
Sample B10 (20) 2.25 0.091 14.1 
Sample B11 (20) 6.92 0.081 9.2 
Sample B12 (20) 7.78 0.094 5.8 
*Relative peak areas w.r.t GlcN internal standard 
**None detected 
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Figure 3.16: Glc profile for two different lots of biofermentetion in-process broth 
samples.  
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Figure 3.17: Gal profile for two different lots of biofermentetion in-process broth 
samples.  
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Figure 3.18: Man profile for two different lots of biofermentetion in-process broth 
samples.  
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Figure 3.19: HPLC chromatograms obtained for an in-process sample overlaid with 
a standard and a blank. Chromatographic conditions are as described in Figure 3.5. 
Peaks: (1) GlcN, (2) ManN, (3) GalN, (4) excess AA, (5) Gal, (6) Man, (7) Glc, (8) 
Rib, (9) Xyl, (10) Fuc, (11) sialic acid, and (12) blank peak. 
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3.4. Conclusion 
 
A relatively rapid, robust RPLC-FLD based method was developed for 
the determination (both qualitative and semi-quantitative) of up to 10 
monosaccharides (glucosamine, mannosamine, galactosamine, galactose, 
mannose, glucose, ribose, xylose, fucose and sialic acid) in a range of 
complex samples originating from the biofermentation production process 
within the biopharmaceutical industry. Standard analytical performance 
criteria were used for evaluation purposes, with the method having been 
found to be both linear and precise, and with LODs meeting the 
requirements for routine and potentially process monitoring of these 
important solutes, for both process optimisation and quality control. This 
work demonstrates for the first time a single chromatographic method 
directly applicable to analysis of all three sample matrices and provides the 
ever increasing biopharmaceutical industry with a new assay to investigate 
both material quality and complex in-process biochemical processes and 
interactions, currently not fully understood. 
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Chapter 4 
Rapid and sensitive chromatographic 
determination of total sialic acid in bio-pharma 
fermentation media samples 
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4.1. Introduction  
 
Sialic acids are a family of nine-carbon carboxylated monosaccharides and 
are generally found in the terminal position of the carbohydrate chains of 
glycoconjugates (glycoproteins, glycolipids and lipopolysaccharides); they 
are rarely found in free form (3%) [1, 2]. Sialic acids have many biological 
roles and the importance of sialic acids to a glycoprotein’s half-life 
emphasises the need to determine sialic acid content of a glycoprotein when 
examining its function and activity as therapeutic [3]. There are more than 40 
compounds have been associated to sialic acid family [4]. However, the 
main representative and the most abundant forms of sialic acid are the 
acylated compound, which are known as N-acetylneuraminic acid (NANA), 
and N-glycolylneuraminic acid (NGNA), where a glycolyl group is bound to 
the amino group at C5 (Figure 4.1) [5]. 
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Figure 4.1: Chemical structures of N-acetylneuraminic acid and N-
glycolylneuraminic acid. 
 
Sialic acid levels in biological samples have been determined using 
various methods. Traditional determination has been performed by a number 
of colorimetric methods. The most commonly used are the resorcinol-based 
method [6] and the thiobarbituric acid (TBA) method [7]. However, the TBA 
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method is preferable due to its specificity and sensitivity [8]. This method 
determines free sialic acids only; bound sialic acids have to be released first 
utilising acid hydrolysis [9, 10] or enzymatic hydrolysis [11]. The TBA does 
not distinguish the two types of sialic acid because both of them give β-
formylpyruvic acid upon oxidation with periodic acid [12]. Therefore, it 
determines the total sialic acid. The TBA method was first introduced by 
Waravdekar and Saslaw [13] for the determination of 2-deoxyribose which 
produces malonaldehyde upon periodate oxidation, which then reacts with 
TBA to form a red complex with an absorption maximum at 532 nm. The 
method was later modified for the assay of sialic acids as described by 
Warren [7] and Aminoff [14]. The product of sialic acid oxidation is β-
formylpyruvic acid which forms a red complex after derivatisation with TBA 
that has an absorbance maximum at 549 nm.  
Sialic acids have also been determined using several other 
instrumental techniques such as GC [15], HPAEC-PAD [3, 16, 17], CE [18-
20] and HPLC using different detection techniques [12, 21-30] and liquid 
chromatography tandem mass spectrometry (LC-MS/MS). Rohrer et al. [3] 
described a HPAEC-PAD method for the analysis of sialic acid content in 
glycoproteins. However, this technique in general suffers from other sample 
components interfering in complex matrices such as biological samples [31, 
32]. The TBA method has been adapted to HPLC for sialic acid 
determination in biological samples for enhanced sensitivity and reduced 
interference because sialic acids are usually present at trace levels in such 
complex matrices. The derivatised sialic acid was separated from other 
interfering substances on a C18 reversed phase column [12, 21, 22]. 
Anumula [27] reported a HPLC method for the determination of sialic acids 
in which sialic acids were derivatised with o-phenylenediamine (OPD) and 
monitored using fluorescence detection. The method was used for the 
analysis of sialic acid in glycoproteins. Martín et al. [28] also described a 
HPLC method for sialic acid determination in which they used another 
derivatisation agent, i.e. 1,2-diamino-4,5-methylenedioxybenzene (DMB), 
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and the method was applied to determine sialic acid content in infant 
formulas.  
This Chapter describes a rapid, sensitive and reproducible method 
specifically for the quantitative determination of total sialic acid in a range of 
complex biological samples employing TBA as pre-column tagging agent 
after the oxidation of sialic acid with periodic acid. The derivatised sialic acid 
was separated from 2-deoxy-D-ribose and the other components in less than 
90 seconds utilising a short C18 monolithic column. The method was 
successfully applied to quantify sialic acid in a range of complex samples, 
e.g. yeastolate powders, basal media and in-process samples supplied by 
Bristol-Myers Squibb.  
 
4.2. Experimental  
 
4.2.1. Reagents and materials   
 
N-acetylneuraminic acid (NANA, 98 %), 2-thiobarbituric acid (TBA, 98 %), 
periodic acid (98 %), sodium hydroxide (NaOH, 98 %), sodium phosphate 
monobasic monohydrate (98-102 %), sodium phosphate dibasic (99 %), 2-
deoxy-D-ribose (97 %), sodium thiosulfate (98 %) and trifluoroacetic acid 
(TFA, 98 %) were purchased from Sigma-Aldrich (Tallaght, Dublin, Ireland). 
Methanol (MeOH) was of HPLC grade and purchased from Labscan (Dublin, 
Ireland). All chemicals were used as received, without any further 
purification. 
 
4.2.2. Instrumentation  
 
All instrumentation used was as described in Section 3.2.2 with the 
exception of the following. The derivatives were separated on a 4.6 mm × 
100 mm Chromolith Flash RP-18e monolith column (Column A) and a 4.6 
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mm × 25 mm Chromolith Flash RP-18e monolith column (Column B) at flow 
rates of 2.5 mL.min-1 and 4.5 mL.min-1, respectively, and a column 
temperature of 45 oC for both columns. The separation was performed using 
TFA (pH 2.3, 0.05 %) as mobile phase A and MeOH as mobile phase B. The 
separation mode for Column A was isocratic at 20 % mobile phase B, 
whereas for Column B was used with a gradient of: 0-30 seconds (11 % B), 
30-39 seconds (11-35 % B) and 39.6-90 seconds (11 % B). The injection 
volume was 100 µL and the derivatives were monitored at 549 nm.  
 
4.2.3. Sample preparation  
 
All samples described in Section 3.2.3 were analysed for sialic acid utilising 
the method described in this chapter. Here, the samples were dissolved and 
diluted using sodium phosphate buffer (pH 6.5, 10 mmol.L-1). For yeastolate 
powder samples, 15 mg of the sample was dissolved in 1 mL of phosphate 
buffer whereas for the analysis of the liquid samples (basal media and in-
process samples), 150 µL of the sample was diluted by a factor of 2 using 
phosphate buffer.  
 
4.2.4. Sample cleanup by solid phase extraction (SPE) 
 
All samples obtained from Section 4.2.3 were subjected to clean up using a 
C18 SPE cartridge. The cartridge was first conditioned with 1 mL of MeOH 
followed by 1 mL of water. Then 250 µL of the sample was passed through 
the cartridge and collected in a clean polypropylene centrifuge tube, followed 
by a further 80 µL phosphate buffer (pH 6.5, 10 mmol.L-1) which was 
collected and combined with the 250 µL. 
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4.2.5. Labelling of sialic acid with TBA  
 
4.2.5.1. Oxidation of sialic acid 
300 µL of standard/sample collected in Section 4.2.4 was placed in a 
2 mL screw-top polypropylene sample tube. Sialic acid was oxidised by the 
addition of 25 µL of 50 mmol.L-1 periodic acid and 40 µL of 0.22 mol.L-1 HCl. 
The tube was shaken and placed in a water bath at 37 oC for 40 minutes. 
Then the oxidation was terminated by the addition of 60 µL of 2 % sodium 
thiosulfate and shaking the sample tube until the yellow-brown colour 
appeared upon the addition of thiosulfate had vanished. The oxidation is 
shown in Figure 4.2.     
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Figure 4.2: Reaction scheme shows the oxidation of N-acetylneuraminic acid and 
N-glycolylneuraminic acid with periodic acid. 
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4.2.5.2. Derivatisation of sialic acid 
To the oxidised standard/sample obtained from Section 4.2.5.1, 250 
µL of 0.1 mol.L-1 TBA prepared in 70 mmol.L-1 NaOH was added. The 
sample tube was shaken and heated in a water bath at 100 oC for 8 minutes. 
After that the tube was removed and placed in an ice bath for 5 minutes. The 
derivatised sample was then centrifuged and the supernatant was 
transferred to an HPLC vial for injection. 
 
4.3. Results and discussion 
 
4.3.1. Optimisation of chromatographic conditions 
 
Throughout this study, NANA was used as a representative of sialic acid. 
The separation of the sialic acid peak from 2-deoxy-D-ribose peak, which is 
a possible source of interference as described in Section 4.3.4.2, was 
performed on an Agilent 1200 series RRLC chromatograph using a 
monolithic column. One of the advantages of monolithic materials that they 
can be operated at high flow rates with low backpressures due to the porous 
structure of the monolith which leads to rapid sample analysis as achieved in 
this study.  
Initially, the separation was developed using Column A. The effective 
parameters on the separation such as the pH of the mobile phase, the % of 
the organic solvent and the column temperature were investigated.  
 The effect of the mobile phase pH was studied in the range 2.3 to 4.3. 
Even though the range was narrow, the influence of the pH on the retention 
factor of sialic acid was significant. The retention factor of sialic acid 
increased from 0.85 for pH 4.3, to over 4.3 for pH 2.3 at a column 
temperature of 25 oC and 5 % MeOH in the mobile phase. Decreasing the 
pH to 2.3 and thus increasing the retention factor allowed the use of 
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elevated column temperatures and higher organic solvent which lead to 
sharper peaks and lower running times as described below.   
 The effect of the organic solvent in the mobile phase was examined. 
The peaks were eluted earlier using ACN instead of MeOH. However, the 
resolution of sialic acid both from the void peak and 2-deoxy-D-ribose was 
low, thus using less organic solvent in the mobile phase, low column 
temperatures and low mobile phase pH are required to improve the 
resolution. Instead, using MeOH as organic modifier allowed running the 
samples at high column temperatures and high organic solvent ratio which 
sharpened the peaks as indicated in Figure 4.3. 
Figure 4.4 shows the effect of the column temperature upon the 
separation. In general, decreasing the column temperature lead to an 
increase in the retention times and broadening of the peaks. Therefore, the 
column temperature of 45 oC was selected as an optimum temperature. 
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Figure 4.3: The effect of MeOH percentage on the separation between sialic acid 
(1) and 2-deoxy-D-ribose (2). Column: Column A. Mobile phase: 0.05 % TFA, pH 
2.3/MeOH. Elution mode: isocratic. Flow rate: 1 mL.min-1. Injection volume: 10 µL. 
Column temperature: 25 oC. Detection @ 549 nm.  
 
  124 
0
20
40
60
80
100
120
0 3 6 9 12 15
Retention time (minutes)
A
b
s
o
rb
a
n
c
e
 (
m
A
U
)
2
@ 45 
o
C
1
@ 25 
o
C
@ 35 
o
C
 
Figure 4.4: The effect of column temperature on the separation between sialic acid 
(1) and 2-deoxy-D-ribose (2). Chromatographic conditions are as described in 
Figure 4.3 except that the % of MeOH was 20 %. 
 
Using 20% MeOH in TFA pH 2.3 as the mobile phase in an isocratic 
mode at a column temperature of 45 oC resulted in a good separation of 
sialic acid from 2-deoxy-D-ribose in less than 4 minutes as illustrated in 
Figure 4.5. Under the optimised conditions, the column was operated at a 
backpressure of 121 bars.  
In order to achieve a faster run time, the separation was transferred to 
a shorter column (Column B) using the same conditions described above 
except that the separation mode was gradient instead of isocratic. Using 
high MeOH percentages resulted in a good peak shapes but the resolution 
of sialic acid from the void peak was low (retention factor < 1). Therefore, 
gradient elution was used for a combination of good resolution and peak 
shape which resulted in the separation showed in Figure 4.6. Under the 
optimised conditions, the separation obtained was over 70 % faster than the 
previous TBA-HPLC methods [12, 21, 22]. 
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Figure 4.5: HPLC chromatograms show a separation of standard of 0.25 mmol.L-1 
sialic acid (1) and 0.25 mmol.L-1 2-deoxy-D-ribose (2) overlaid with a blank. 
Column: Column A. Mobile phase: 0.05 % TFA, pH 2.3/MeOH (80:20). Flow rate: 
2.5 mL.min-1. Injection volume: 10 µL. Column temperature: 45 oC. Detection @ 
549 nm.  
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Figure 4.6: HPLC separation of 0.01 mmol.L-1 sialic acid (1) and 0.01 mmol.L-1 2-
deoxy-D-ribose (2) overlaid with a blank media which contains all reagents except 
the analytes. Column: Column B. Gradient program: 11 % for 0.5 minute, 0.5-0.65 
minutes (11-35 %) and 0.66-1.5 minutes (11 %). Flow rate: 4.5 mL.min-1. Injection 
volume: 100 µL. Column temperature: 45 oC. Detection @ 549 nm.  
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4.3.2. Labelling of sialic acid with TBA 
 
4.3.2.1. Periodate-oxidation of sialic acid 
The oxidation of sialic acid with periodate leads to form β-
formylpyruvic acid which then reacts with TBA to form a red complex. 
Oxidation of 1 mole of sialic acid using periodic acid yields 1 mole of β-
formylpyruvic acid as illustrated in Figure 4.2. 
 The effect of the periodic acid concentration and volume on the 
oxidation of sialic acid was studied. Figure 4.7 shows that the presence of 
excess oxidising agent lead to a decrease in peak area. This could be 
because (1) the presence of excess oxidising agent oxidised the aldehyde 
formed from sialic acid to carboxylic acid, (2) the presence of excess 
oxidising agent lead to an increase in acidity of the solution causing 
degradation of sialic acid which is acid-labile [14]. 
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Figure 4.7(a): The effect of periodic acid volume on the oxidation of sialic acid. The 
concentratopn of periodic acid was 0.05 mol.L-1. 
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 Figure 4.7(b): The effect of periodic acid concentration on the oxidation of sialic 
acid. The added volume of periodic acid was 25 µL.  
 
Figure 4.8 shows the effect of acidifying the environment of oxidation. 
This was investigated by adding different amounts of HCl with the periodic 
acid. As a result of this study, the peak area of sialic acid was increased by a 
maximum of 36 % compared to the peak area of the derivative obtained from 
the oxidation of sialic acid in which there was no addition of HCl. However, 
increasing the amount of the acid over the optimum concentration caused 
degradation of sialic acid [14]. 
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Figure 4.8: (a) The effect of HCl volume on the oxidation of sialic acid with periodic 
acid. The HCl concentration was 0.22 mol.L-1. (b) The effect of HCl concentration 
on the oxidation of sialic acid with periodic acid. The added volume of HCl was 40 
µL. 
 
The period and temperature of oxidation of sialic acid in the water 
bath was investigated. The results are obtained in Figure 4.9. Generally, 
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increasing the temperature accelerated the oxidation. However, the 
maximum peak area of sialic acid was obtained after the oxidation of sialic 
acid at 37 oC for 40 minutes. This temperature is in agreement with Aminoff 
[14] whereas Warren [7] found that at 37 oC less colour was formed 
compared to room temperature. The sialic acid peak area was increased by 
about 13 % when the time of oxidation increased to 40 minutes against 30 
minutes in the original assay [14]. 
 
Figure 4.9: Effect of reaction time and temperature on sialic acid derivatisation.  
 
The oxidation reaction was terminated by destroying the excess of the 
oxidation agent with sodium thiosulfate. The amount of thiosulfate required 
for this task was investigated and the results are plotted in Figure 4.10. 
Increasing the concentration of thiosulfate resulted in increasing the pH of 
the medium of the reaction, therefore preventing the condensation of β-
formylpyruvic acid with TBA. 
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Figure 4.10(a): The effect of thiosulfate volume on the red complex formation. The 
thiosulfate concentration was 5 %. 
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 Figure 4.10(b): The effect of thiosulfate concentration  on the red complex 
formation. The added volume of thiosulfate was 20 µL. 
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4.3.2.2. Derivatisation of sialic acid 
The red complex is formed from the condensation reaction between 
TBA and β-formylpyruvic acid, which was produced from the oxidation of 
sialic acid (Figure 4.11). This condensation was carried out in acidic 
medium, in which the formed chromophore is stable [7, 8]. The possibility of 
increasing the pH of the solution comes from either adding excess 
thiosulfate as mentioned above or from adding excess TBA, as TBA is only 
soluble in alkaline solution. The addition of excess TBA lead to increase the 
pH of the reaction medium and thus decrease the formation of the red 
complex as shown in Figure 4.12. 
The derivatisation was performed in a water bath at 100 oC. The time 
of the derivatisation was studied to reach completion. As it can be seen from 
Figure 4.13 the maximum absorbance was increased by about 23 % in 8 
minutes compared to 15 minutes in the original assay by Warren [7]. This is 
almost in agreement with Aminoff [14] as he carried out the derivatisation for 
7.5 minutes.   
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Figure 4.11: Reaction scheme show the formation of the red complex resulted from 
the condensation of β-formylpyruvic acid and TBA. 
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Figure 4.12: The effect of adding excess TBA on the peak area of the red complex 
formed from the condensation of β-formylpyruvic acid and TBA. The concentration 
of TBA was 0.1 mol.L-1. 
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Figure 4.13: Effect of derivatisation time on the amount of the red complex formed 
between β-formylpyruvic acid and TBA at 100 oC. The derivatisation conditions are 
as described in Section 4.2.5.  
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4.3.3. Effect of organic solvents on the colour intensity 
 
Extracting the red complex in n-butanol or cyclohexanone or adding water 
miscible solvents, such as MeOH, ethanol (EtOH) and DMSO, to the red 
complex solution after derivatisation are known to enhance the intensity of 
the colour and thus the absorbance of red complex in the UV-Vis detector [7, 
8, 12, 14]. Here, the samples were mixed with different organic solvents after 
derivatisation; i.e. MeOH, EtOH and DMSO. The final concentration of the 
organic solvent in the sample was 20 %. The colour of the samples was 
significantly intensified. However, the use of such organic solvents in this 
study, particularly in the case of MeOH, had an adverse influence on the 
retained sialic acid as shown in Figure 4.14. The obtained results were 
expected because the concentration of the organic solvent added to the 
sample was stronger than the percentage of the organic modifier in the 
mobile phase. Therefore, sialic acid will not be retained in the column. The 
results obtained here is in a disagreement with the results obtained by 
Powell and Hart [12]. Powell and Hart showed in their work that the 
absorbance of the red complex varied by the addition of different amounts of 
MeOH to the sample. They diluted the derivatised sample in a buffer 
containing different amounts of MeOH. For example, the absorbance of the 
red complex was increased by about 15 % when the amount of MeOH 
increased from 5 % to 45 %.  
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Figure 4.14: Effect of organic solvents on signal intensity. Chromatographic 
conditions are as described in Figure 4.6 except the separation mode, it was 
isocratic at 11 % MeOH. Peaks: (1) sialic acid standard.  
 
4.3.4. Method validation 
 
4.3.4.1. SPE recovery study of sialic acid standard 
The recovery of sialic acid standard from SPE (Table 4.1) was studied 
by comparing the peak area of sialic acid produced from two different 
aliquots of the same standard solution. One of the aliquots was passed 
through the SPE cartridge as described in Section 4.2.4, collected, oxidised 
with periodic acid and derivatised with TBA as described in Section 4.2.5, 
whereas the other aliquot was oxidised and derivatised as described in 
Section 4.2.5 without SPE treatment. In order to minimise the dilution of the 
sample or the standard, the volume of the phosphate buffer required for 
rinsing the SPE cartridge after passing the sialic acid solution was also 
investigated. The cartridge was rinsed with 250, 125 and 50 µL phosphate 
buffer and the same volume was added to the non-extracted standards and 
compared. In all cases the recovery was good (111.8, 99.3 and 99.4 % 
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respectively). However, the minimum volume chosen for rinsing the cartridge 
was 80 µL.  
 
Table 4.1  
Analytical performance data 
 Sialic acid 
Area precision % RSD (n = 6) 1.31 %  
RT precision % RSD (n = 6) 0.57 %  
Oxidation/derivatisation precision % RSD (n = 6) 1.71 %  
LOD 842 fmol 
Linear range (µmol.L
-1
) 0.25-25 
Linearity 0.9994 
SPE recovery 99.4 % 
 
4.3.4.2. Selectivity of the method 
Possible interference could arise from monosaccharides or amino 
acids present in the samples tested in this study. Therefore, in order to prove 
the selectivity of the method, the following nine common monosaccharides 
and twenty amino acids were treated through the whole optimised 
procedure: 0.1 mmol.L-1 of galactose, mannose, glucose, ribose, 
galactosamine, mannosamine, glucosamine, xylose, fucose, L-
phenylalanine, L-leucine, D-threonine, L-proline, L-arginine, L-thyrosine, D-
methionine, L-histidine, L-methionine, L-aspartic acid, L-isoleucine, L-valine, 
L-serine, trans-4-hydroxy-l-proline, L-lysine, L-thyreonine, L-alanine, L-
glutamine, L-glutamic acid, L-asparagine, L-typtophan, D-typtophan and D-
valine. As a consequence, all of the nine monosaccharides and the twenty 
amino acids gave no colour confirming the selectivity of TBA. This results in 
agreement with what has been described previously by Warren [7] and 
Aminoff [14] in which they investigated some of the compounds listed above. 
Figure 4.15 shows an illustrative example of one of the twenty amino acids 
(D-methionine) and one of the nine monosaccharides (Gal) after oxidation 
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with periodic acid and derivatisation with TBA in which there is no detectable 
peaks observed. 
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Figure 4.15: HPLC chromatograms of derivatised samples of galactose (ii) and D-
methionine (iii) overlaid with sialic acid standard (i) and a blank (iv). 
Chromatographic conditions are as described in Figure 4.6 except the separation 
mode, it was isocratic at 11 % MeOH. Peaks: (1) sialic acid.  
 
 
2-deoxy-D-ribose is another source of interference [7, 8, 14] as it 
gives malonaldehyde as a product of periodate oxidation. Malonaldehyde 
reacts with TBA to form an intense red complex that has a slightly lower λmax 
(532 nm). This interference has been separated from sialic acid using HPLC 
as described previously [12, 22] and within the present method as well 
(Figure 4.6) 
 
4.3.4.3. Linearity 
A linear curve for sialic acid was established based on duplicate 
injections of each standard solution in the concentration range of 0.25 - 25 
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µmol.L-1 (Figure 4.16) revealing a good correlation between the peak areas 
and concentrations, with the correlation coefficient being > 0.999 (Table 4.1). 
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Figure 4.16: Linearity response of derivatised sialic acid standards.  
 
4.3.4.4. Reproducibility 
Reproducibility of the assay was investigated in two different ways: 
reproducibility of the oxidation/derivatisation steps and reproducibility of the 
chromatographic method. The precision of the oxidation/derivatisation steps 
was studied by derivatising six different standard solutions and the 
supernatants were injected in duplicate. The precision of the instrument was 
confirmed by injecting a single sialic acid six times consecutively and the % 
RSD was calculated using the peak areas and the retention times. From the 
results obtained in Table 4.1 it can be confirmed that the assay is highly 
reproducible. 
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4.3.4.5. Sensitivity 
The sensitivity of the method was obtained by minimising the effect of 
the sample dilution and by increasing the injection volume. The volume of 
the sample that can be injected in the column was investigated. A linear plot 
was obtained from plotting the injection volume in the range against the peak 
area with the correlation coefficient being 0.9999 and good column efficiency 
over the range studied (Figures 4.17 and 4.18). Under the optimised 
conditions, the sensitivity was determined by preparing a series of sialic acid 
standard solutions ranging from 500 nmol.L-1 down to 1 nmol.L-1. The series 
was oxidised and derivatised as described in the Experimental Section, 
followed by a duplicate injection in the HPLC system. The LOD of the assay 
was based on a signal-to-noise ratio of 3 and found to be 842 fmol (Table 
4.1). This method is more sensitive than previously published TBA-HPLC 
based methods. The sensitivities reported by Powell et al. and Romero et al. 
were 2000 fmol and 6500 fmol, respectively [12, 21]. 
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Figure 4.17: HPLC chromatograms of sialic acid injected in the column at different 
volumes. The volumes were: 10, 30, 50, 70 and 100 µL. The concentration of sialic 
acid was 1 µmol.L-1. Chromatographic conditions are as described in Figure 4.6 
except the separation mode, it was isocratic at 11 % MeOH. Peaks: (1) sialic acid. 
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Figure 4.18: Linearity response of sample injection volume of sialic acid.  
 
4.3.5. Quantitative analysis of yeastolate, basal media and in-process 
samples 
 
In order to evaluate the applicability of the developed method, a number of 
yeastolate samples (powder samples) as well as basal media and in-process 
samples (liquid samples) sourced from the biopharmaceutical industry were 
analysed. The condensation reaction between β-formylpyruvic acid and TBA 
is highly pH dependant. For this reason, all of the samples were dissolved 
and diluted using phosphate buffer (pH 6.5, 10 mmol.L-1). The presence of 
sialic acid in the samples was verified by a comparison with a standard 
chromatogram. The samples were prepared and derivatised with TBA as 
described in Sections 4.2.3, 4.2.4 and 4.2.5. Due to the high specificity of the 
TBA method, there was no interference from unknown peaks in all samples 
tested.  
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4.3.5.1. Analysis of yeastolate samples 
The concentration of the sample used for analysis was 15 mg.mL-1. 
This concentration was selected based on the results obtained in Figure 
4.19. Logically, the higher the concentration of the sample used, the greater 
the peak area obtained. However, contrary to expectation, the peak areas 
were inversely proportional to the concentration. This could be due to the 
fact that the pH of the yeastolate sample itself is around seven whereas the 
overall pH of the medium after the addition of the reagents must be acidic in 
which the red complex is formed. However, increasing the concentration of 
the yeastolate sample lead to an increase the overall pH of the medium 
(even though the samples were prepared in a buffer), and thus decrease the 
possibility of the red complex formation. In addition, the peak area of sialic 
acid resulting from the analysis of yeastolate samples at the concentration of 
15 mg.mL-1 was high enough to be quantified. Therefore, it was not 
necessary to prepare the samples in higher concentrations. Moreover, a 
decrease in the retention time of sialic acid was obtained by increasing the 
concentration of the sample. This might be due to column overloading with 
the complex sample matrix.  
Figure 4.20 shows the chromatograms obtained from the yeastolate 
samples. In total, seven yeastolate samples were analysed and sialic acid 
was found in all samples tested and the presence was confirmed by a 
comparison with a standard chromatogram. All samples were injected in 
duplicate and sialic acid was quantified against a linear curve of sialic acid 
standard and the results are listed in Table 4.2. The results showed that the 
variability between samples is low with a % RSD of 6.8 %. The average 
concentration of sialic acid found in the samples was 4.2 ng.mg-1 (S.D. = 0.3 
ng.mg-1) and ranged between 4.76 and 3.98 ng.mg-1. Figure 4.21 shows the 
sialic acid profile in these samples. As it can be seen, sialic acid in all the 
samples is deviated within one standard deviation from the average (except 
Sample 7) indicating that the sialic acid sourced from the yeastolate samples 
is invariable. Interestingly, sialic acid was not detected in the yeastolate 
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samples using the AA method (as described in Chapter 3) which confirms 
the value of developing this method.    
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Figure 4.19: HPLC chromatograms of a yeastolate sample prepared at the different 
concentrations. Chromatographic conditions are as described in Figure 4.6 except 
the separation mode, it was isocratic at 11 % MeOH. Peaks: (1) sialic acid. 
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Figure 4.20: HPLC chromatograms obtained from the analysis of the yeastolate 
samples overlaid with a sialic acid standard. Chromatographic conditions are as 
described in Figure 4.6. Peaks: (1) sialic acid, (2) 2-deoxy-D-ribose. 
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Table 4.2 
Quantitative data of sialic acid in the yeastolate samples. Date of analysis: 
01/07/2008. 
Sialic acid found (ng.mg
-1
) Sample number 
Yeastolate samples 
4.04 Sample 1 
4.02 Sample 2 
4.39 Sample 3 
4.01 Sample 4 
3.98 Sample 5 
4.24 Sample 6 
4.76 Sample 7 
0.3  
(6.8 %) 
S.D.  
(% RSD) 
 
  
Mean-SD: 3.9
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Figure 4.21: Sialic acid profile for the yeastolate samples.  
 
 
  144 
4.3.5.2. Analysis of basal media samples 
Figures 4.22 and 4.23 show an overlay of HPLC chromatograms 
obtained from the analysis of basal media samples. The samples, fourteen 
in total, were sourced from two different manufacturing facilities producing 
the same biotherapeutic as described earlier (Section 3.2.3). The samples 
were pretreated as described in the Experimental section and injected in the 
HPLC system in duplicate. Sialic acid was found in all samples tested. It was 
confirmed by a comparison with a standard chromatogram of sialic acid and 
quantified against a linear curve of sialic acid standard. The results are listed 
in Table 4.3 and the profile of sialic acid is as shown in Figure 4.24. From 
the results obtained, the variation in sialic acid level in Lot B (% RSD = 
110.1 %) is much higher than Lot A (% RSD = 8.2 %). This is because sialic 
acid presented in one of the samples in Lot B (Sample B1) is about five 
times higher than the second highest sample in the same lot. The same 
results from the same sample were obtained in Chapter 3 regarding Glc, in 
which its level was higher in this particular sample compared to the others in 
the same lot. However, this was not the case for sialic acid in Chapter 3. 
Apart from Sample B1, the % RSD of Lot B is about 11 %, which is almost 
the same as Lot A. The average concentration of sialic acid found in the Lot 
A was 19.4 pg.µL-1 (S.D. = 1.6 pg.µL-1) and ranged between 21.8 and 17.5 
pg.µL-1 whereas the average in Lot B was 21.9 pg.µL-1 (S.D. = 2.5 pg.µL-1) 
and the range is between 24.0 and 17.8 pg.µL-1. Sample B1, in particular, 
contains 131.0 pg.µL-1 of sialic acid. 
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Figure 4.22: HPLC chromatograms obtained from the analysis of the basal media 
samples (Lot A) overlaid with a sialic acid standard and blank. Chromatographic 
conditions are as described in Figure 4.6. Peaks: (1) sialic acid, (2) 2-deoxy-D-
ribose. 
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Figure 4.23: HPLC chromatograms obtained from the analysis of the basal media 
samples (Lot B) overlaid with a sialic acid standard and blank. Chromatographic 
conditions are as described in Figure 4.6. Peaks: (1) sialic acid, (2) 2-deoxy-D-
ribose. 
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Table 4.3 
Quantitative data of sialic acid in the two lots of basal media samples. Date of 
analysis: 04/07/2008. 
Sample number Sialic acid found (pg.µL
-1
) 
Basal media samples (Lot A) 
Sample A1 18.4 
Sample A2 18.8 
Sample A3 21.8 
Sample A4 17.5 
Sample A5 18.4 
Sample A6 21.2 
Sample A7 20.1 
S.D.  
(% RSD) 
1.6 
 (8.2 %) 
Basal media samples (Lot B) 
Sample B1 131.0 
Sample B2 22.9 
Sample B3 24.0 
Sample B4 17.8 
Sample B5 24.5 
Sample B6 20.8 
Sample B7 21.4 
S.D.  
(% RSD) 
41.3 
(110.1 %) 
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Figure 4.24: Sialic acid profile for the two lots of basal media samples.  
 
4.3.5.3. Analysis of in-process samples 
Finally, 12 in-process samples were analysed and the 
chromatograms are shown in Figure 4.25. The samples were treated and 
derivatised using the optimised procedure and injected in duplicate. Sialic 
acid was found in all samples tested and the results are listed in Table 4.4. 
Sialic acid in these samples ranges from 30.0 to 93.3 pg.µL-1. These in-
process samples were collected from fed-batch CHO cell cultures at different 
time-points as described in Table 3.1. They were obtained prior to and after 
bioreactor inoculation. The level of free sialic acid throughout the production 
of the biotherapeutic can be monitored in the bioreactor vessel. Figure 4.26 
shows the profile of sialic acid for the 12 samples that have been taken from 
different time-points during the production process of a biotherapeutic. 
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Figure 4.25: Selected HPLC chromatograms obtained from the analysis of the in-
process samples overlaid with a sialic acid standard. Chromatographic conditions 
are as described in Figure 4.6. Peaks: (1) sialic acid, (2) 2-deoxy-D-ribose. 
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Table 4.4 
Quantitative data of sialic acid in the in-process samples. Date of analysis: 
05/07/2008. 
Sample number Sialic acid found (pg.µL-1) 
In-process media samples (Lot A) 
Sample A1 40.7 
Sample A2 30.0 
Sample A3 42.8 
Sample A4 34.2 
Sample A5 45.0 
Sample A6 45.8 
Sample A7 38.1 
Sample A8 53.9 
Sample A9 47.9 
Sample A10 80.9 
Sample A11 93.3 
Sample A12 54.8 
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Figure 4.26: Sialic acid profile for the in-process samples.  
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4.4. Conclusion 
 
In conclusion, a rapid, sensitive and accurate RRLC-UV-Vis method for 
quantitative determination of sialic acid was developed. The method consists 
of pre-column oxidation of sialic acid with periodic acid followed by 
derivatisation with TBA to form a red complex. The sialic acid was separated 
from other components on a short monolithic column within 90 seconds. The 
method was used for sialic acid determination in a range of complex 
samples sourced from the biopharmaceutical industry. The method was 
found to be linear over the range, reproducible and sensitive. The method is 
reliable to use in the quantification analysis of total sialic acid in a variety of 
sample types within the production process and quality assurance of the 
pharmaceutical industry.  
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Chapter 5 
Quantitative analysis of cysteine/cystine in 
chemically defined media utilising a developed 
rapid and sensitive chromatographic assay 
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5.1. Introduction 
 
Since these CD media often contain mixtures of vitamins and amino acids, 
the temporal stability of these components is crucial for the production of a 
therapeutic protein with high yield. Cysteine (Cys) is an important amino acid 
for protein folding and function due to disulphide linkages and is a very 
important component of CD media. However, Cys can be readily oxidised to 
cystine (Cyss) in such complex environments, and this ratio has significance 
as a redox indicating quality assay for CD media which contain Cys.  
 A number of analytical methods such as GC-MS [1,2], CZE [3-6], LC-
MS [7-10] and HPLC with pre- or post-column thiol derivatisation followed by 
UV detection [11-22] or fluorometric detection [23-28], have been reported 
for the separation and determination of Cys in different sample matrices 
such as urine [12, 15, 18, 21, 23], human plasma [4, 8, 11, 16, 17, 20, 22, 
23, 27], human blood [10, 24, 25] and yeast [7]. However, very few 
chromatographic methods are available to quantitate Cys and Cyss in 
complex media, and none that exist can be termed simple or rapid [29]. 
 Cys cannot be detected by UV absorption or fluorescence due to the 
lack of a suitable UV chromophore, therefore, derivatisation is important for 
sensitive and selective detection. Derivatisation also stabilises thiols by 
blocking the labile sulfhydryl group and thus improves chromatographic 
performance [30]. The derivatisation reagents should react rapidly and 
specifically with the thiol group to form stable thiol derivatives with sufficient 
absorption or fluorescent yield for trace concentration detection. 
Furthermore, the derivatisation reaction should be carried out at the lowest 
possible temperatures and weakly acidic pH to prevent oxidation of the 
analytes leading to inaccurate results [30, 31]. Several reagents have been 
used for this purpose, such as 2-chloro-1-methylpyridinium iodide (CMPI) 
[22, 32, 33], 2-chloro-1-methylquinolinium tetrafluoroborate (CMQT) [5, 11–
13, 15-19, 21], 7-fluorobenzo-2-oxo-1,3-diazole- 4-sulfonate (SBD-F) [26, 
34], monobromobimane [3, 23-25], 4-aminosulfonyl-7-fluoro-2,1,3-
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benzoxadiazole (ABD-F) [4], dansyl chloride (DNS-Cl) [14], o-
phthalaldehyde (OPA) [27, 28] and 5,5´-dithiobis(2-nitrobenzoic acid) 
(DTNB, Ellman’s reagent) [9, 35]. Among these, CMQT is preferable as a 
tagging reagent due to the very mild reaction conditions (i.e. immediate 
reactivity at room temperature in neutral medium) and due to its high 
specificity for thiol-containing compounds.  
However, Cyss cannot be derivatised with CMQT directly, since it has 
no free thiol group. Therefore, the reduction of its disulfide bond must be first 
carried out, prior to derivatisation and subsequent separation as CMQT-Cys. 
Reduction of the disulfide bond can be carried out using several reducing 
agents including tri-nbutylphosphine (TNBT) [4, 21, 32, 34], tris(2-
carboxyetyl)phosphine (TCEP) [5, 7, 13, 16-18, 20, 34, 36], sodium 
borohydride (NaBH4) [11, 12, 19], triphenylphosphine (TPP) [3, 24, 25] and 
dithiothreitol (DTT) [37]. However, of the above, TCEP is clearly the most 
suitable to-date, as it is water soluble, odourless, selective towards disulfide 
bonds,  stable in both acidic and basic solutions and, perhaps most 
important, the reduction is quantitative and takes no more than 5 minutes at 
room temperature [34, 38, 39, 40]. 
In this Chapter, the development of rapid, selective and quantitative 
monolithic RPLC and RPLC-MS assays for Cys/Cyss in complex CD media 
is reported. The complexity of the media samples was such that a thiol 
selective pre-separation derivatisation step was essential, with a rapid 
sample reduction step allowing accurate determination of the Cys and Cyss 
ratio in a total analysis time of less than 30 minutes for the monolithic 
RPLC–UV method. The method is based on reducing Cyss (oxidised form) 
to Cys (reduced form) with TCEP and then tagging the total Cys with CMQT, 
followed by ion-pairing reversed-phase LC separation on a narrow-bore C18 
monolithic column and UV detection.  
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5.2. Experimental 
 
5.2.1. Reagents and materials 
 
Cysteine (Cys, 97 %), cystine (Cyss, 99.5 %), trichloroacetic acid (TCA, 99.5 
%), lithium hydroxide (LiOH, 99 %), potassium phosphate monobasic (99 
%), potassium phosphate dibasic (99 %), sodium hydroxide (NaOH, 98 %), 
hydrochloric acid (HCl, 37 %), ammonium acetate (99 %), 2-chloroquinoline 
(99 %), trimethyloxonium tetrafluoroborate (95 %), diethyl ether (99.9 %) and 
nitromethane (99.0 %) were purchased from Sigma-Aldrich (Dublin, Ireland). 
TCEP (98 %) was purchased from Alfa Aesar (Heysham, UK). ACN and 
MeOH were of HPLC grade and purchased from Labscan (Tallaght, Dublin, 
Ireland). Ammonia solution (35 %) was purchased from BDH Laboratory 
Supplies (Poole, England). Acetic acid (96 %) was obtained from Riedel-
deHaen (Seelze, Germany). All chemicals were used as received, without 
any further purification. CMQT was prepared in the laboratory as described 
in Section 5.2.4. 
 
5.2.2. Instrumentation 
 
All instrumentation used was as described in Section 3.2.2 with the 
exception of the following. The sample was mixed using a VX100 vortex 
mixer purchased from Labnet. The derivatisation and reduction were carried 
out in a capped 2-mL polypropylene sample tube (Sarstedt, Germany).  
For LC-ESI-MS analysis, a Bruker Daltonics Esquire~LC (Bremen, 
Germany) ion trap instrument with electrospray interface was employed 
using Bruker Daltonics NT 4.0 software. For direct infusion-MS, a Cole 
Parmer 74900 series threaded screw syringe type pump was filled with 
sample and infused at 250 µL.h-1. Conditions were optimised by direct 
sample infusion of a solution of CMQT (1 µg.L-1) in 80:20 H2O/MeOH and 
the optimised parameters are listed in Table 5.1.  
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Table 5.1 
Optimisation of ESI-MS parameters for CMQT 
Parameter Optimised value 
Capillary (V) 4000 
End plate offset (V) -500 
Capillary exit offset (V) 95.0 
Trap drive 55.0 
Octopole RF (Vpp) 150 
Lens 1 -5.0 
Lens 2 -60 
N2 drying gas flow (L.min
-1
) 8 
Dry gas temperature (
o
C) 300 
Nebulizer pressure (psi) 55 
Scan range (m/z) 50 - 2200 
Averages (spectra) 5 
Ion polarity positive 
 
5.2.3. Chromatographic conditions  
 
5.2.3.1. Isocratic method 
The column used was a 2.0 mm × 50 mm Phenomenex Onyx 
monolithic C18 column. The mobile phase used was (86:14) 50 mmol.L
-1 
TCA/ACN (pH 2.5) delivered isocratically at 1.5 mL.min-1. Column 
temperature was set at 45 oC, the injection volume was 40 µL and detection 
was by UV absorbance at 355 nm.  
 
5.2.3.2. Gradient method 
Using the same column as described above, a LC gradient method 
was developed. Mobile phase A was 10 mmol.L-1 ammonium acetate buffer 
(pH 5) with ACN as mobile phase B, and a gradient program of 0-1 minutes 
(2 % B), 1.1-5 minutes (10 % B), 5.1-7 minutes (2 % B) delivered at 1.5 
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mL.min-1. Injection volume was 100 µL with a column temperature of 25 oC 
and detection at 355 nm. This method was further adapted for ESI-MS 
detection by reducing the flow rate to 0.3 µL.min-1 and modifying the gradient 
program as the following: 0-5 minutes (2 % B), 5.5-25 minutes (10 % B), 
25.1-35 minutes (2 % B). The optimised ESI-MS conditions are listed in 
Table 5.1.  
 
5.2.4. Synthesis of CMQT  
 
CMQT was prepared as described by Bald and Glowacki [15]. Briefly, into a 
standard glass test tube a small stirring bar was placed followed by 1.0 g of 
2-chloroquinoline and 1.0 g of trimethyloxonium tetrafluoroborate. The 
mixture was stirred over a magnetic stirring plate after adding 1.2 mL of 
nitromethane. After the evolution of dimethyl ether had ceased, 4 mL of 
diethyl ether was added slowly in a 1-mL aliquots to precipitate CMQT. The 
white precipitate was filtered off under vacuum. The precipitate was washed 
with a further 4 mL of diethyl ether in two 2-mL aliquots and left under 
vacuum for 60 minutes. CMQT was further recrystallised as described in 
Appendix I. 
 
5.2.5. Derivatisation procedure for Cys/Cyss analysis in standard solutions 
 
In all cases, Cys and Cyss standards were prepared in 1 mol.L-1 HCl in order 
to match the pH of the industry samples provided, which was 1 mol.L-1. For 
sample analysis, samples were divided into two aliquots. The first was 
analysed for Cys after pre-column derivatisation with purified CMQT. The 
second was analysed for Cyss (detected and quantified as Cys by peak area 
subtraction) after an initial reduction step with TCEP followed by pre-column 
CMQT derivatisation. Initial studies were performed with a derivatisation pH 
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of 7.6. Quantitative sample analysis was performed at pH 6.2 in order to 
minimise matrix effects.  
 
5.2.5.1. Cys determination 
A solution containing 75 µL of Cys standard was neutralised with 75 
µL of 1 mol.L-1 ammonium hydroxide followed by the addition of 50 µL of 50 
mmol.L-1 HCl and 75 µL of 1 mol.L-1 ammonium acetate pH 6.2. The addition 
of 10 µL CMQT (50 mmol.L-1) was followed by a 2 minutes incubation after 
which the mixture was acidified with 30 µL of 0.5 mmol.L-1 HCl and injected 
into the chromatograph.  
 
5.2.5.2. Cyss determination 
A solution containing 75 µL of Cyss standard was neutralised with 75 
µL of 1 mol.L-1 ammonium hydroxide followed by the addition of 50 µL of 50 
mmol.L-1 HCl and 10 µL of 50 mmol.L-1 TCEP prepared in 1 mol.L-1 
ammonium acetate (pH 6.2). Following a 3 minutes incubation, 65 µL of       
1 mol.L-1 ammonium acetate (pH 6.2) was added along with 10 µL of 50 
mol.L-1 CMQT and incubated for a further 2 minutes. The solution was then 
acidified with 30 µL of 0.5 mol.L-1 HCl prior to injection.  
 
5.2.6. CD cell culture media samples treatment  
 
A total of 31 CD CHO acid I samples originate from an actual industrial scale 
biofermentation process facility for a commercial biotherapeutic drug were 
supplied by Bristol–Myers Squibb as liquids and they contain mainly amino 
acids. CD media were sampled and aliquotted under sterile conditions and 
shipped from the US to Ireland at low temperature. The samples were 
further transferred from Galway to Dublin at low temperature and stored at    
-70 oC. When analysed, the samples were removed from the freezer and 
defrosted at room temperature (~ an hour). The desired sample volume was 
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aliqotted and then treated as described in Section 5.2.6.1, whereas the 
remaining sample was retuned to the freezer until further use. The samples 
identities are listed in Table 5.5. 
 
5.2.6.1. Sample derivatisation 
CD CHO acid I media samples were first neutralised with 1 mol.L-1 
ammonium hydroxide on a 1:1 volume to volume basis. Then the neutralised 
sample was divided into two aliquots as described in Figure 5.1. For Cys 
determination, 150 µL of the neutralised sample was treated as described 
above, with an additional 1/5 dilution with 10 mmol.L-1 ammonium acetate 
(pH 5) prior to injection. For Cyss determination 10 µL of the neutralised 
sample was diluted to 150 µL with water and treated as described above, 
again with an additional 1/5 dilution with 10 mmol.L-1 ammonium acetate (pH 
5) prior to injection.  
 
 
 
 
Figure 5.1: Schematic diagram showing the analysis of Cys ( ) and Cyss ( ) in 
CD media samples.   
 
 
 
 
 
 
 
TCEP 
CMQT 
CMQT-Cys 
CMQT  
CMQT-Cys 
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5.3. Results and discussion 
 
5.3.1. Labelling of Cys/Cyss with CMQT 
 
Due to the lack of suitable chromophores and fluorophores, Cys was 
labelled with CMQT as a UV-tagging reagent. The reaction between Cys and 
CMQT is rapid, specific for thiol-containing compounds and occurs under 
mild conditions across a pH range of 7-9 [15]. In addition, the λmax of CMQT 
and CMQT-Cys derivative are not the same which leads to less interference 
in the case of using excess reagent. The chemical reaction is shown in 
Figure 5.2 in which it involves a nucleophilic displacement of chlorine atom 
by sulphur atom in the Cys molecule [15]. To ensure the completion of Cys 
labelling with CMQT, the amount of CMQT and the time period required for 
labelling of Cys were investigated. As shown in Figure 5.3 the, effect of 
CMQT concentration on the derivatisation of Cys was studied in the range 
from 10 mmol.L-1 to 150 mmol.L-1. The derivatisation reaction was completed 
within 1 minute using 50 mmol.L-1 of CMQT. However, reaction time was 
chosen to be 2 minutes to ensure the complete conversion. 
 
N
+
Cl
CH3
+
N
+
S
CH3 NH2
O
OH
CMQT CMQT-Cys
pH 6.0 - 9.0
NH2
O
SH OH + HCl
Cys
 
 
Figure 5.2: Reaction scheme of labelling Cys with CMQT.  
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Figure 5.3: Optimisation of CMQT concentration and derivatisation time required 
for Cys labelling with CMQT.  
 
 
Cyss has a disulfide bond and does not have free thiol group and thus 
it cannot be tagged with CMQT. Therefore, the reduction of the disulfide 
bond is demanded. For this task, TCEP was used as reducing agent due to 
the advantages that it has compared to other reducing agents (e.g. sodium 
borohydride, dithiothreitol) since it is water soluble, odour-free, does not 
produce gases during its use (which can lead to poor reproducibility), and 
can be used across a wide pH range (pH 1.5 - 11.1). Reduction of the 
disulfide bond is shown in Figure 5.4. It is worth noting that reducing one 
mole of Cyss gives two moles of Cys. Therefore, the peak area obtained 
from Cyss is double the peak area obtained from the same concentration of 
Cys. 
 
 
  164 
O
O
P
O
OH
OH
HO
+ S
S
R
R
+ OH2 +
SH R
SHR
TCEP Cyss 2 Cys
O
O
O
P
O
OH
OH
HO
TCEP oxide
 
 
Figure 5.4: Reaction scheme of reducing the disulphide bonds using TCEP.  
 
 
 
The influence of TCEP concentration and the time period required for 
Cyss reduction were investigated and the results are shown in Figure 5.5. 
The effect of TCEP concentration was studied in the range from 50 to 250 
mmol.L-1. As it can be seen, increasing TCEP concentration leads to 
decrease the peak area of the CMQT-Cys. This is in agreement with the 
results reported by Kozich et al. [34]. This decrease in the peak area could 
be due to the fact that the TCEP is an acidic solution with a pH of about 2.5 
whereas the derivatisation reaction between CMQT and Cys is carried out at 
pH 7.0 - 9.0. Therefore, increasing the TCEP concentration leads to 
decrease the final pH of the medium, thus decrease the possibility of CMQT-
Cys derivative formation. Moreover, the time period of reduction was also 
studied. The time period investigated ranged from 0.5 to 10 minutes, 
however the peak area of CMQT-Cys was not significant. The peak area 
increased by about 10 % when the time increased from 0.5 to 10 minutes.  
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Figure 5.5: Optimisation of TCEP concentration and reduction time required for 
Cyss reduction.  
 
 
5.3.2. Chromatographic determination of Cys 
 
5.3.2.1. Isocratic monolithic RPLC 
The separation of the CMQT-Cys peak from unreacted CMQT 
reagent and reaction by-product peaks was achieved using the separation 
conditions described by Bald and Glowacki [15] with slight modifications. 
However, here the separation was developed utilising a micro-bore 
monolithic C18 column instead of a conventional particulate column. The 
column temperature was also increased from 25 oC to 45 oC, resulting in a 
reduction in retention of the CMQT-Cys peak by 50 % and improved peak 
shape. The optimised separation is shown in Figure 5.6. Peak efficiency for 
the CMQT-Cys derivative peak was calculated using the equation n = 5.55 
(tR/W½)
2 as 20,250 N/m, with all reagent and standard peaks eluting in under 
2 minutes. 
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Figure 5.6: HPLC chromatograms of Cys and Cyss standards overlaid with a blank. 
Column: 50 mm × 2 mm Phenomenex Onyx C18 monolith. Mobile phase: 50 
mmol.L-1 TCA pH 2.5/ACN (86:14). Flow rate: 1.5 mL.min-1. Injection volume: 40 µL. 
Column temperature: 45 oC. Detection UV at 355 nm. Peaks: (1) excess CMQT, (2) 
CMQT-Cys.  
 
 
 
The isocratic method was applied to the analysis of industry supplied 
CD media fermentation feed-stocks samples. The presence of Cys in the 
sample was confirmed by spiking the sample with a Cys standard as 
illustrated in Figure 5.7. The retention time variation between standard 
solution and diluted complex media sample was approximately 4 % (tR 
greater for the media sample) indicating the column capacity for the sample 
was sufficient and that the complex sample matrix resulted in some small 
‘salting out’ effect for the analyte complex. As can be seen from the sample 
chromatogram shown, the presence of multiple unidentified peaks existed in 
the derivatised sample, greatly exceeding the number of known thiol-
containing species within the CD media sample. However, all peaks were 
sufficiently resolved from the target CMQT-Cys peak and all were eluted 
before 3 minutes and so the method could still be justified as relatively rapid.  
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To determine whether the sample contained unknown components 
which absorbed at 355 nm along with CMQT derivatives, the sample was 
injected directly without derivatisation. This underivatised sample did not 
produce any peaks that absorbed at 355 nm. Furthermore, the extra peaks 
were not seen in derivatised Cys standards, bar the reagent impurity peak 
eluting at 34 seconds (Figure 5.6), and thus were not by-products of the 
CMQT-Cys reaction. Therefore, the additional peaks observed were deemed 
to result from the derivatisation of the sample with CMQT, either being 
derivatised unknown sample components or other specific sample reagent 
reaction artefacts. 
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Figure 5.7: HPLC chromatograms of unspiked CD CHO acid I media sample and 
Cys-spiked CD media sample overlaid with a reagent blank. Chromatographic 
conditions are as described in Figure 5.6.  Peaks: (1) CMQT-Cys. 
 
5.3.2.2. Gradient monolithic RPLC 
Figure 5.8 shows the optimised separation of CMQT-Cys derivative 
from the reagent peak using the gradient mode. The gradient mode was 
developed in order to further improve resolution of the Cys peak from the 
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matrix peaks. Ammonium acetate was used as mobile phase buffer instead 
of TCA in order to facilitate simultaneous ESI-MS detection. The same 
micro-bore monolithic column was utilised as described above, with the 
mobile phase delivered at 1.5 mL.min-1 for simple RPLC, and 0.3 mL.min-1 
for RPLC-ESI-MS.  
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Figure 5.8: HPLC chromatograms of Cys and Cyss standards overlaid with a blank. 
Column: 50 mm × 2 mm Phenomenex Onyx C18 monolith. Mobile phase A: 10 
mmol.L-1 ammonium acetate buffer pH 5. Mobile phase B: ACN. Gradient program: 
0-1 minutes (2 % B), 1.1-5 minutes (10 % B), 5.1-7 minutes (2 % B) delivered at 1.5 
mL.min-1. Injection volume: 100 µL. Column temperature: 25 oC. Detection at 355 
nm. Peaks: (1) excess CMQT, (2) CMQT-Cys. 
 
 
5.3.3. The effect of sample matrices 
 
When the isocratic method was developed and applied to the real samples, 
it was expected to get only one peak for CMQT-Cys due to the selectivity of 
the reagent towards thiol-containing compounds as Cyss is the only thiol-
containing compound in the samples. However, as it can be seen in Figure 
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5.7, unexpected peaks appeared after derivatising the sample with CMQT. 
Unsuccessful attempts were made in order to clean up the samples such as 
passing the samples through solid phase extraction cartridge before and 
after derivatisation with no success. These extra peaks did not occur when 
underivatised samples were injected.  
For the purpose of investigating the origin of interfering sample matrix 
peaks, the separation was further developed to the gradient method. The 
chromatograms shown in Figure 5.9 were obtained for a CD media sample 
which was also spiked with different Cys concentrations. The sample was 
derivatised using the purified reagent. The gradient was complete, with all 
peaks eluted in less than 7 minutes, with the target CMQT-Cys peak now 
very well resolved from all other peaks. However, as shown in Figure 5.9, 
although recrystallisation yielded a cleaner mass spectrum and 1H NMR 
spectrum (Appendix I), many extra such peaks still appeared in sample 
chromatograms, clearly suggesting the peaks observed are indeed CMQT 
derivatives of unknown sample components.  
0
200
400
600
0 1 2 3 4 5 6
Retention time (minutes)
A
b
s
o
rb
a
n
c
e
 (
m
A
U
)
iii
ii
i
1
 
Figure 5.9:  HPLC chromatograms showing (i) a CD media sample derivatised with 
recrystallised CMQT reagent and then spiked with (ii) 6 and (iii) 125 µmol.L-1 Cys 
standard. Chromatographic conditions are as described in Figure 5.8. Peaks: (1) 
CMQT-Cys. 
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In addition, a number of sample preparation parameters were varied 
to investigate their effect upon the resultant chromatograms and overall 
method ruggedness. Firstly, the effect of sample dilution upon quantitation 
was investigated. A CD media sample spiked with Cys was serially diluted 
up to a 1/100 dilution factor prior to derivatisation. As expected, the CMQT-
Cys peak area decreased linearly as the dilution factor increased (R2 = 
0.998). However, this was not the case for many of the unknown sample 
component peaks, which showed decreases but unlike CMQT-Cys, such 
decreases were not linear. For example the peak at ~1.6 minutes in Figure 
5.10 decreased in area by a factor of only 1.3 after a ten-fold dilution of the 
sample. Figure 5.10 shows how the peak area for CMQT-Cys is linearly 
proportional to sample dilution.  
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Figure 5.10: HPLC chromatograms showing the effect of sample dilution prior to 
derivatisation. The sample was diluted by a factor of (i) 0, (ii) 2, (iii) 4, (iv) 6 and (v) 
10.  Chromatographic conditions are as described in Figure 5.8. Peaks (1): CMQT-
cysteine. 
 
Moreover, increasing the amount of CMQT used during the 
derivatisation step also yielded unexpected results. As shown in Figure 5.11, 
the peak area for Cys remained constant as the CMQT volume increased, 
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reflecting the fixed amount of Cys present in the sample. This demonstrated 
the reaction of Cys with CMQT to be quantitative, despite clear competition 
with other sample components. Over a factor of ten increase in CMQT 
concentration, the CMQT-Cys peak varied in peak area by less than 5 %, 
and such variation was not proportional to CMQT concentration. However, 
the extra sample peaks continued to increase in area as CMQT volume 
increased. This indicates such components firstly form less stable 
derivatives than Cys, and secondly that under the initial conditions used the 
reaction of these components with CMQT was not quantitative. For example, 
peaks at ~1.5 and ~2.3 minutes both increased by over 400 % as CMQT 
concentration was increased by a factor of 10.  
As CD media samples were provided from industry in an acidic 
medium, aliquots were first neutralised and then buffered at a selected pH 
prior to derivatisation. Based upon the work of Bald and Glowacki [15], this 
pH was initially selected as pH 7.6. Changing the pH at which sample 
derivatisation was carried out also had a significant effect upon sample 
matrix peaks, whilst the target CMQT-Cys peak remained constant. Figure 
5.12 illustrates that a decrease in derivatisation pH from 7.6 to 6.0 led to a 
significant decrease in the peak area of these peaks. For example, there 
was a 27-fold decrease in peak area for the peak doublet at ~1.5 minutes, 
with other peaks decreasing by similar amounts, even when the pH was 
decreased by a mere 1.6 pH units. Thus the extreme sensitivity of unknown 
sample peaks to small changes in pH allowed for their selective reduction 
while CMQT-Cys sensitivity was only slightly affected (~6 % peak area 
variation over pH range studied). Outside the pH range studied, there was a 
more pronounced decrease in sensitivity. For example, the CMQT-Cys peak 
area decreased sharply by 34 % between pH 6.0 and pH 5.8. Therefore, all 
subsequent determinations of Cys/Cyss in the samples were carried out at 
pH 6.2.  
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Figure 5.11: Selected HPLC chromatograms showing the effect upon extra peaks 
of increasing the amount of CMQT used for derivatisation. A Cys-spiked sample 
was derivatised as described in the Experimental section. Chromatographic 
conditions are as described in Figure 5.8. Peaks (1): CMQT-Cys. 
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Figure 5.12: Selected HPLC chromatograms showing the effect upon extra peaks 
of derivatisation at different pH values. Chromatographic conditions are as 
described in Figure 5.8. Peaks (1): CMQT-Cys. 
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5.3.4. Effect of Cu(II) on Cys determination 
 
Presence of trace metals in the samples, such as Cu(II), may affect the 
determination of Cys as they have a high affinity for thiol groups [26] and 
thus prevent the reaction between the thiol group and the derivatisation 
reagent. Therefore, to investigate the effect of the presence of Cu(II) traces 
on the determination of Cys, 50 µL of Cu(II) solution within the concentration 
range 0 - 30 ppm was added to 150 µL of Cys standard (0.5 mmol.L-1) in  a 2 
mL polypropylene plastic sample tube. The reaction was left for 5 minutes at 
room temperature. Then 150 µL of that was derivatised as described in the 
Experimental section. Figure 5.13 indicates the effect of Cu(II) concentration 
on the formation which shows that increasing the Cu(II) concentration leads 
to decrease the CMQT-Cys derivative. On the other hand, this effect was 
completely prevented by the presence of EDTA as it forms a complex with 
Cu(II). Figure 5.14 shows a separation of derivatised cysteine standard in 
the presence of Cu(II) only and in the presence of both Cu(II) and EDTA 
overlaid with derivatised cysteine standard.   
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Figure 5.13: A study shows the effect of increasing Cu (II) concentration upon the 
reaction between CMQT and Cys standard. Derivatisation reaction was carried out 
as described in the Experimental section.  
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Figure 5.14: HPLC chromatograms showing the effect of Cu(II) on Cys 
determination in the presence and absence of EDTA. Chromatographic conditions 
are as described in Figure 5.8. Peaks: (1) excess CMQT, (2) CMQT-Cys. 
 
5.3.5. Method validation 
 
5.3.5.1. Method selectivity 
In order to evaluate the selectivity of the reagent towards thiol-
containing compounds, the following amino acid standards were prepared 
and subjected to the full derivatisation process as described in the 
Experimental section: 0.1 mmol.L-1 L-phenylalanine, L-leucine, D-threonine, 
L-proline, L-arginine, L-tyrosine, D-methionine, L-histidine, L-methionine, L-
aspartic acid, L-isoleucine, L-valine, L-serine, trans-4-hydroxy-l-proline, L-
lysine, L-threonine, L-alanine, L-glutamine, L-glutamic acid, L-asparagine, L-
tryptophan, D-tryptophan and D-valine. The above listed amino acids were 
also injected in the column without derivatisation. As a result, all the tested 
amino acids gave no detectable peaks which confirm the selectivity of the 
reagent for Cys over other amino acids.  
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5.3.5.2. Linearity 
Linear curves for Cys and Cyss were obtained based on duplicate 
injection of Cys- and Cyss-CMQT derivatives across the range 0.25-500 
µmol.L-1 for Cys (n = 9) and 0.25-250 µmol.L-1 for Cyss (n = 8). The method 
was linear over at least three orders of magnitude with correlation 
coefficients of > R2 = 0.999 obtained for both analytes. At concentrations 
greater than 500 µmol.L-1 for Cys the standard curve deviated significantly 
from linearity. Although the initial intention was to begin the Cys linearity at 
the Cys LOQ (360 nmol.L-1), nevertheless it was found that linearity was 
maintained at a lower limit of 0.25 µmol.L-1. No investigation was made into 
whether linearity was conserved below this range.  
 
5.3.5.3. Precision 
Precision of the method was studied for the reduction/derivatisation 
step and for the chromatographic instrument. The repeatability of the 
reduction/derivatisation step was studied by subjecting six different solutions 
of Cys and six different solutions of Cyss to reduction/derivatisation 
processes and the resultants were injected in the HPLC. The precision of the 
instrument was evaluated by injecting a CMQT-Cys derivative solution in the 
HPLC system six times and the % RSD was calculated for both peak areas 
and retention times and the results are listed in Table 5.2. From the results 
obtained, it can be confirmed that the method was highly reproducible. 
 
5.3.5.4. Sensitivity 
Under the optimised conditions, the sensitivity was determined by 
preparing a series of Cys standard solutions. The LOD of the assay was 
based on a signal-to-noise ratio of 3 and found to be 36 nmol.L-1 (Table 5.2).  
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5.3.5.5. Recovery studies 
The recovery was studied by spiking real samples with three different 
known concentrations of Cys standard. The spiked samples were derivatised 
with CMQT as described in the Experimental section. The recovery values 
were 103, 88 and 97 % for the samples spiked with 5, 10 and 50 µmol.L-1 of 
Cys standard respectively.   
 
Table 5.2  
Method validation data 
 Cys 
Area precision % RSD (n = 6) 1.1 % 
RT precision % RSD (n = 6) 0.1 % 
Derivatisation precision for Cys % RSD (n = 6) 0.55 % 
Reduction/derivatisation precision for Cyss % RSD (n = 6) 0.51 % 
LOD 36 nmol.L-1 
Cys Linear range (µmol.L
-1
), linearity  0.25-500, R2 > 0.999 
Cyss Linear range (µmol.L
-1
), linearity  0.25-250, R2 > 0.999 
Average of Cys recovery from real samples 96 % 
 
5.3.6. Quantitative determination of Cys/Cyss in chemically defined media 
 
Under the optimised sample preparation protocol, the method was applied to 
the analysis of 31 CD media samples sourced from biopharmaceutical 
industry. Figures 5.15 and 5.16 show the HPLC chromatograms obtained 
from the analysis of these samples. Cys/Cyss were found in all samples 
tested and their presence was verified by a comparison with standard 
chromatograms. Cys/Cyss presented in the samples were quantified against 
linear curves of Cys/Cyss standards and the results obtained are listed in 
Table 5.3. The average amount of Cys found in the samples was 1.7 µg.mL-1 
(S.D. = 0.16 µg.mL-1) and ranged between 1.6 and 2.3 µg.mL-1, whereas the 
average of Cyss was 1196.5 µg.mL-1 (S.D. = 80.5 µg.mL-1) and ranged from 
1060 and 1347 µg.mL-1. Moreover, the % RSD values of Cys and Cyss in 
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the samples were 9.4 % and 6.7 %, respectively, which shows low lot-to-lot 
variation. Interestingly, Cys was found in all samples tested although initial 
advice received from the suppliers of the samples was that of the redox pair, 
only Cyss was expected to be present based on the formulation recipe for 
the CD media. Clearly the samples had been inadvertently subjected to 
unwanted redox activity and this method thus has potential as a stability 
indicating assay within the biopharmaceutical industry. The thiol redox status 
is defined in this work as the ratio of the reduced form (Cys) to the oxidised 
form (Cyss) and can be used as an important quality indicator for these raw 
materials used in biofermentation processes. Table 5.3 details the Cys/Cyss 
ratio as well as the percentage of total thiols present as Cys. To our 
knowledge this work represents the first time that Cys/Cyss analysis has 
been performed in CD media samples and so no alternative method was 
suitable for the purposes of cross-validation.  
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Figure 5.15: Determination of Cys in selected CD media samples. Chromatograms 
(ii-x) are selected samples overlaid with (i) a Cys standard. Chromatographic 
conditions are as described in Figure 5.8. Peaks: (1) CMQT-Cys. 
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Figure 5.16: Determination of Cyss in selected CD media samples. 
Chromatograms (ii-ix) are selected samples overlaid with (i) a Cyss standard. 
Chromatographic conditions are as described in Figure 5.8. Peaks: (1) CMQT-Cys. 
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Table 5.3 
Quantitative data of Cys/Cyss in the CD media samples. Date of analysis: 
10/07/2009. 
Sample  Sample ID 
Cys 
(µg.mL
-1
) 
Cyss 
(µg.mL
-1
) 
% Cys 
Cys/Cyss 
ratio 
Sample 1 ITP-2007-000066 1.7 1165.4 0.15 0.0015 
Sample 2 ITP-2006-000637 1.6 1179.7 0.14 0.0014 
Sample 3 ITP-2006-000062 1.6 1183.9 0.14 0.0014 
Sample 4 ITP-2007-000007 1.8 1139.3 0.16 0.0016 
Sample 5 ITP-2006-000102 1.7 1341.5 0.13 0.0014 
Sample 6 ITP-2007-000054 1.6 1164.1 0.14 0.0014 
Sample 7 ITP-2006-000532 1.6 1167.9 0.14 0.0014 
Sample 8 ITP-2006-000595 1.6 1168.4 0.14 0.0015 
Sample 9 ITP-2007-000089 1.6 1346.5 0.12 0.0014 
Sample 10 ITP-2006-000591 1.8 1170.2 0.15 0.0014 
Sample 11 ITP-2007-000081 1.7 1147.2 0.14 0.0017 
Sample 12 ITP-2006-000538 1.6 1154.2 0.14 0.0017 
Sample 13 ITP-2007-000019 2.0 1173.2 0.17 0.002 
Sample 14 ITP-2006-000534 2.0 1157.6 0.17 0.0015 
Sample 15 ITP-2006-000408 1.8 1322.4 0.14 0.0015 
Sample 16 ITP-2006-000599 2.3 1147.8 0.20 0.0015 
Sample 17 ITP-2006-000106 1.6 1060.4 0.15 0.0014 
Sample 18 ITP-2006-000611 1.6 1066.9 0.15 0.0015 
Sample 19 ITP-2006-000603 1.9 1212.9 0.15 0.0015 
Sample 20 ITP-2007-000085 1.6 1147.6 0.14 0.0013 
Sample 21 ITP-2007-000023 1.6 1317.1 0.12 0.0015 
Sample 22 ITP-2007-000084 1.6 1336.5 0.12 0.0014 
Sample 23 ITP-2007-000063 1.8 1197.2 0.15 0.0015 
Sample 24 ITP-2007-000032 1.8 1175.6 0.15 0.0018 
Sample 25 ITP-2006-000607 1.6 1171.2 0.13 0.0013 
Sample 26 ITP-2007-000057 1.7 1142.5 0.15 0.0012 
Sample 27 ITP-2007-000027 1.6 1179.0 0.14 0.0014 
Sample 28 ITP-2006-000098 1.7 1340.9 0.12 0.0012 
Sample 29 ITP-2007-000015 1.6 1320.9 0.12 0.0012 
Sample 30 ITP-2006-000068 1.6 1130.3 0.15 0.0012 
Sample 31 ITP-2007-000002 2.1 1161.9 0.181 0.0012 
S.D.  
(% RSD) 
 
0.16 
(9.4 %) 
80.5 
(6.7 %) 
--- --- 
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5.3.7. LC-ESI-MS qualitative sample analysis 
 
For the confirmation of the presence of Cys/Cyss, the samples were 
analysed by LC-ESI-MS using the optimised conditions described in the 
Experimental section. This is the first use of ESI-MS detection with this 
specific derivatisation chemistry. Under the LC conditions used, the CMQT-
Cys peak eluted at 9.5 minutes, as verified by comparison with a standard. 
Figures 5.17 and 5.18 show representative extracted ion chromatograms 
(EICs) of a derivatised Cys standard and a derivatised CD media sample 
before and after reduction. The product ion spectra of the CMQT-Cys 
derivative shows a fragment ion at m/z 185.4, which corresponds to 
[M−C2O2NH7]
+, therefore this fragment ion was used to confirm the presence 
of the CMQT-Cys derivative. The LC-ESI-MS chromatograms confirm that 
the method is indeed specific to Cys and Cyss in the complex media 
samples. In addition, the sample was spiked with Cys standard and the 
results are shown in Figure 5.19. 
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Figure 5.17: Extracted ion chromatogram (EIC) of derivatised Cys standard. Peak 
eluted at 9.5 minutes with m/z 185.4 corresponds to CMQT-Cys derivative. 
Chromatographic conditions as in Figure 5.8 with flow rate reduced to 0.3 mL.min-1. 
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Figure 5.18: Extracted ion chromatograms (EICs) of (a) CD media sample and (b) 
reduced CD media sample. Peaks eluted at 9.5 minutes with m/z 185.4 correspond 
to CMQT-Cys derivative. Chromatographic conditions as in Figure 5.8 with flow rate 
reduced to 0.3 mL.min-1. 
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Figure 5.19: Extracted ion chromatograms (EICs) of a CD media sample (unspiked 
and spiked with Cys standard). Peaks eluted at 9.5 minutes with m/z 185.4 
correspond to CMQT-Cys derivative. Chromatographic conditions as in Figure 5.8 
with flow rate reduced to 0.3 mL.min-1. 
 
 
5.4. Conclusions 
 
 Two pre-column derivatisation methods for determination of Cys and Cyss 
by monolithic reversed-phase LC and LC-ESIMS were developed. Samples 
were divided into two aliquots and analysed for Cys first, followed by the 
determination of Cyss after its reduction to Cys using tris(2-
carboxyethyl)phosphine (TCEP). The reagent used (CMQT) is thiol selective 
and the detection wavelength negated any possible interference from other 
potential interfering sample components such as monosaccharides or other 
amino acids. The method performance data reveal that the methods are 
linear, sensitive and precise. The developed methods are useful for routine 
analysis for large numbers of CD media samples due to their reduced 
sample handling steps, quantitative nature, ruggedness and non-harsh 
conditions.   
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Chapter 6 
Lectin-modified gold nano-particles 
immobilised on a monolithic pipette-tip for 
selective enrichment of glycoproteins  
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6.1. Introduction 
 
In general, SPE is a simple effective and most versatile technique. It is 
applied to the selective capture and preconcentration of the target analyte 
and/or the removal of potentially interfering components from the sample 
matrix [1-4]. Micro-scale SPE devices consist of a selective adsorbant 
material encased within a housing, such as a column, capillary, the channels 
of a micro-fluidic device, or in commercial pipette-tips when working with 
small volumes. The advantages of SPE in pipette-tip format include ease of 
use, small sample and solvent volumes, as well as the possibility to process 
many samples simultaneously, using either multi-channel hand-held pipettes 
or robotic liquid handling systems [5-7]. 
Packed SPE in micro-pipette tips have been applied for the 
enrichment, purification, desalting and fractionation of different biological 
samples using either home-made or commercially available tips [8-14]. For 
example, Kussmann et al. used a home-made tip that was prepared by filling 
a bottom-end squeezed GelLoader tip (Eppendorf, Hamburg, Germany) with 
a suspension of Poros materials (PerSeptive Biosystems, Framingham, MA, 
USA) to form a purification column [10]. However, there are some difficulties 
and drawbacks associated with the preparation of these kinds of tips [8, 15-
17], most notably the requirement for inclusion of retaining frits. As an 
alternative, many packed sorption material related drawbacks can be 
overcome through the use of monolithic sorption beds. 
Great attention has been paid recently to the monolithic sorption beds 
due to the various features they possess [18, 19], as discussed in Chapter 1. 
Silica monoliths are manufactured by sol-gel technology with phase 
separation and have been used for ‘in-tip’ SPE previously [16, 20-23]. For 
example, Miyazaki et al. prepared a monolithic silica bed fixed in a 200 µL 
pipette-tip in which the silica surface was modified with a C18 phase or 
coated with a titania phase and applied to the selective extraction, 
concentration, desalting and purification of phosphorylated peptides [16]. 
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Organic polymer monoliths are produced by the one-step 
polymerisation of a mixture consisting of organic monomers, cross-linkers, 
porogenic solvents and initiators. The mixture is typically sonicated, purged 
under nitrogen, filled into the tip itself and in most cases polymerised using 
UV irradiation. Monolithic materials have shown excellent utility as support 
for affinity chromatography of bimolecules. Different bioligands have been 
immobilised on monolithic surface such as Protein A for biospecific 
separation of immunoglobulins  [24], mannan for separation of mannose-
binding proteins [25], concanavalin A (Con A) and wheat germ agglutinin 
(WGA) for isolation and preconcentration of glycoconjugates [26], 
carbohydrate for affinity of lectins [27] and trypsin immobilised a monolithic 
pipette-tip for rapid proteins digestion [28]. Several studies have described 
the preparation and application of polymer monoliths in such tips in the 
analysis of the biological samples [15, 29-34]. For example, Rainer and co-
workers fabricated a divinylbenzene-based extraction tip for selective 
enrichment of phosphorylated peptides and successfully applied this to the 
study of in vitro phosphorylation [29].  
Despite of all the advantages of monoliths, the low surface area of the 
polymer materials, relative to silica monoliths, somewhat restricts the 
applicability of these materials. However, the surface of the polymer 
monolith can be modified with nano-particles to increase the surface area 
simultaneous with the introduction of new chemistry to the surface for 
specific applications. This modification could be utilised in two different 
strategies: either embedding nano-particles within the polymerisation mixture 
during the fabrication of the monolith in one step [15, 29, 34-36] or 
immobilising the nano-particles on the surface of the pre-formed monolith 
[37-39]. Following the first strategy, Hsu et al. [15], for example, 
encapsulated C18 and IMAC beads into a methacrylate monolith formed 
within the confines of a pipette-tip, either for desalting of protein solutions 
(using the C18 monolith) or enrichment of phosphopeptides (using the IMAC 
bead monolith). Building upon this work, Hsieh et al. [34] and Rainer et al. 
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[29] formed a polymer monolith within a pipette-tip which incorporated 
titanium dioxide nano-particles for the selective enrichment of 
phosphopeptides. However, this strategy is inherently flawed since rather 
than all nano-particles being presented at the monolith surface, the majority 
of nano-particles will either be located deep within the bulk polymer or will be 
only partially exposed at the polymer surface, leading to limitations on 
binding capacity. Therefore, a preferred strategy for the preparation of nano-
structured monoliths is the coating of an activated monolith surface with 
selected nano-particles resulting in higher surface coverage. Recently, 
Connolly et al. produced a high-density Au-immobilised monolith in which 
the AuNPs were immobilised on the surface of the preformed monolith 
utilising azlactone chemistry surface modification [40]. Moreover, Xu et al. 
prepared a GMA-co-EDMA monolithic capillary column which was aminated 
prior to the in-situ generation of citrate-stabilised gold nano-particles for the 
selective capturing of cysteine-containing peptides [41]. This work was 
quickly followed by Cao et al. [42] who used the same gold modified 
monolith as an “exchangable” surface, which could be readily functionalised 
with either reversed-phase or ion-exchange functionalities for the separation 
of selected peptides and proteins.  
In this Chapter, the significant enhancement of the surface area of a 
polymer monolithic phase fabricated in a pipette-tip was achieved by 
immobilising AuNPs on the surface of the monolith. Then, a selective lectin 
was immobilised upon the attached AuNPs via a cross-linker for lectin-
affinity extraction of target glycoproteins from samples of varying complexity. 
 
6.2. Experimental 
 
6.2.1. Reagents and materials 
 
BP (99 %), 2,2-dimethoxy-2-phenylacetophenone (DPA, 99 %), EDMA (98 
%), lauryl methacrylate (LMA, 96 %), 1-decanol (99 %), ethylenediamine 
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(SigmaUltra), gold(III) chloride trihydrate (HAuCl4.3H2O, ≥ 99.9 % trace 
metals basis), 3,3′-dithiodipropionic acid di(N-hydroxysuccinimide ester) 
(DTSP), transferrin (human, 98 %), ribonuclease B (≥ 80 %), insulin (bovine 
pancreas), insulin chain B (oxidised from bovine pancreas), enolase 
(S. cerevisiae), thyroglobulin from porcine thyroid gland, carbonic anhydrase 
(bovine), cytochrome c (equine), manganese (II) chloride tetrahydrate (≥ 99 
%), calcium chloride hexahydrate (98 %), D-(+)-galactose (Gal), 1,4-
butanediol, 1-propanol, Trizma hydrochloride (≥ 99.0 %), sodium citrate, 4-
(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES, ≥ 99.0 %), DMSO 
and trifluoroacetic acid (TFA, 99 %) were all purchased from Sigma-Aldrich 
(Dublin, Ireland). Trizma base (≥ 99.0 %), sodium chloride (NaCl, ≥ 99.5 %) 
and bovine serum albumin were from Fluka (Buchs, Switzerland). 4,4-
Dimethyl-2-vinyl-2-oxazolin-5-one (Vinyl azlactone, 95 % GC) was 
purchased from TCI Europe (Zwijndrecht, Belgium). Unconjugated Erythrina 
cristagalli lectin (ECL) was provided by Vector Laboratories (Peterborough, 
UK). Clostridium perfringens neuraminidase and Flavobacterium 
meningosepticum PNGase F were purchased from New England BioLabs 
(Hitchin, UK). The 20-µL polypropylene (PP) tips used for in-situ fabrication 
of the monolith were from Brand (Wertheim, Germany). MeOH, EtOH, 
acetone and ACN were of HPLC grade and purchased from Fisher Scientific 
(Dublin, Ireland). All chemicals were used as received and without any 
further purification. Teflon-coated fused silica capillary (100 µm i.d.) was 
supplied by Composite Metal Services (Shipley, England). 
 
6.2.2. Instrumentation 
 
Photo-polymerisation and photo-grafting were carried out using a 
Spectrolinker XL-1000 UV Crosslinker at 254 nm (Spectronics Corp., 
Westbury, NY, USA). The balance used was a Sartorius Extend (Sartorius, 
Goettingen, Germany).  The sonication bath used was from Branson 
Ultrasonics Corporation (Danbury, CT, USA). A KD Scientific syringe pump 
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(KDS-100-CE, KD Scientific Inc, Holliston, MA, USA) was used for all 
washing and functionalisation of monoliths within pipette-tips, as well as for 
the trap/release of protein mixtures. SEM was performed on a 1 mm long 
cross-section of the unmodified monolith using a Hitachi S-3400N instrument 
(Hitachi, Maidenhead, UK), after sputtering the sample with gold using a 
SputterCoater S150B (BOC Edwards, Sussex, UK). To visualise the 
coverage of AuNPs on cross-sections of gold-modified monoliths previously 
removed from their housings (as described later) and mounted on carbon 
grids, a Hitachi S-5500 field emission SEM (Hitachi, Maidenhead, UK) was 
used.  
 Chromatography was performed using a Dionex Ultimate 3000 
capillary LC system (Dionex, Sunnyvale, USA) at a flow rate of 2 µL.min-1. 
The injection volume was 1 µL, with detection by UV at 214 nm using a 3 nL 
flow-cell. Mobile phase A was 0.1 % TFA in water and mobile phase B was 
0.1 % TFA in 90 % ACN. For the separation of ribonuclease B and 
desialylated transferrin a 10 minute gradient of 5 % B to 100 % B was 
applied at 25 oC. All other separations involved a 9 minute gradient (5 % B to 
100 % B) at 40 oC. The monolithic column used was prepared by filling a 
100 µm x 15 cm vinylised [43] fused silica capillary with a deoxygenated 
mixture of 24 wt % LMA, 16 wt % EDMA, 14.5 wt % 1,4 butandiol, 45.5 wt % 
propanol and 1 wt % DPA (w.r.t monomers), followed by irradiation with 2 
J.cm-2 UV energy at 254 nm. The resulting monolith was washed with MeOH 
for 2 hours at the flow rate of 2 µL.min-1 to remove the porogen and 
unreacted monomers.  
 
6.2.3. Fabrication of a monolith in a pipette-tip 
 
6.2.3.1. Modification of the polypropylene tip inner-wall 
Prior to in-situ fabrication of the monolith, the inner-wall of the 
polypropylene tip was modified with grafted chains of EDMA. Firstly, the tip 
was washed with 10 µL EtOH (10 times) and 10 µL acetone (10 times) and 
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dried using nitrogen to remove any impurities on the surface of the 
polypropylene. A solution of BP in MeOH (5 %) was prepared and 
deoxygenated with nitrogen for 10 minutes. Then the tip was filled with 10 µL 
of BP and placed in a capped 5-mL polypropylene UV transparent sample 
tube irradiated with 1 J.cm-2 UV energy at 254 nm, followed by a thorough 
MeOH rinse. The tip was then filled with deoxygenated 15 % EDMA in 
MeOH and irradiated using the same conditions. Finally, the tip was washed 
thoroughly with MeOH and dried with nitrogen before use. 
 
6.2.3.2. In-situ fabrication of the polymer monolith within the modified 
pipette-tip housing 
A polymerisation mixture consisting of EDMA (40 wt %), 1-decanol 
(60 wt %) and DPA (1 wt %, w.r.t monomer) was prepared, sonicated for 30 
minutes and deoxygenated with a nitrogen flow for 10 minutes. In order to 
ensure a constant and repeatable bed volume for each monolith, a 2-mm 
o.d. guide ring of polypropylene was slipped over the outside of the modified 
tip, which was subsequently filled by capillary action until the meniscus 
reached the bottom of the guide ring as shown in Figure 6.1. The filled tip 
was placed upright in a coned centrifuge tube (polypropylene) and irradiated 
with 3 J.cm-2 UV energy at 254 nm. The resulting monolith was washed 
thoroughly with MeOH at flow rate of 100 µL.h-1 to remove the porogen and 
any unreacted monomers.  
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Figure 6.1: Schematic description of the monolithic tip preparation. 
 
In some instances, an attempt was made to prepare a main channel 
through the centre of the monolith to facilitate lower operating 
backpressures. This was achieved by inserting a section of either 150 µm 
o.d. or 360 µm o.d. fused silica capillary down the bore of the monomer-filled 
tip prior to polymerisation followed by the removal of this template afterwards 
as described by Hsu et al. [15]. 
 
6.2.4. Modification of the preformed monolithic surface with gold nano-
particles (AuNPs) 
 
6.2.4.1. Preparation of citrate-stabilised AuNPs  
 AuNPs (20 nm) were prepared using the citrate reduction method as 
described by Frens [44]. All glassware was acid-washed with 1 mol.L-1 HNO3 
prior to use followed by copious rinsing with deionised water. Gold chloride 
(50 mL, 5 mmol.L-1) was added to a stirred 425 mL volume of boiling 
deionised water. While the solution was boiling, 25 mL of 30 mmol.L-1 
sodium citrate was rapidly added during vigourous stirring. After the 
 
 
Filled up with 
polymerisation 
mixture 
  
Wall-
pretreated 
blank tip  
Monolithic  
tip  
Top-end 
Bottom-end 
Bed-size 
guide ring 
UV @ 254 
nm 
For 3 J.cm-2 
  196 
evolution of a deep red wine colour, (< 3 minutes), boiling and stirring were 
continued for 5 minutes, followed by stirring for an additional 30 minutes at 
room temperature. Finally upon cooling, the solution was made up to 500 mL 
with water and stored at 4 oC until use.  
 
6.2.4.2. Immobilisation of AuNPs on the monolithic surface 
Attachment of AuNPs to the monolith surface first involved the 
amination of the monolith surface as described by Connolly et al. [40]. The 
monolith was first conditioned with 50 µL MeOH followed by flushing the 
monolith with a deoxygenated solution of 5 % BP in MeOH for 30 minutes. 
The monolith was then irradiated with 3 J.cm-2 UV energy at 254 nm 
followed by washing with MeOH for 30 minutes. The monolith was then 
flushed with a deoxygenated solution of 15 % vinyl azlactone in MeOH for 30 
minutes and subjected to the same irradiation cycle. After a preliminary 
wash with MeOH, the monolith was washed with H2O for 30 minutes prior to 
flushing with 1 mol.L-1 ethylenediamine for a nominal time of 4 hours. The 
monolith was again washed with water (until monolith rinsings were pH 
neutral) to remove free ethylenediamine. Finally, the aminated monolith was 
flushed with AuNPs (approx. 2 mL). Immobilisation of AuNPs was 
considered to be complete after the entire monolith bed had turned a deep 
red colour. The Au-modified monolith was washed with 1 mL water to 
remove unbound AuNPs. The axial homogeneity of AuNPs coverage along 
the monolith bed was readily evaluated using an optical microscope. The 
density of coverage of AuNPs on the monolith was examined using FE-SEM. 
 
6.2.5. Functionalisation of Au-modified monolith with ECL for affinity 
extraction of glycoproteins  
 
The Au-modified monolith prepared above was conditioned with 50 µL of 
DMSO and then flushed with 25 mmol.L-1 coupling agent, DTSP in DMSO 
for 4 hours. The monolith was then washed with DMSO for 30 minutes to 
remove any unreacted DTSP, followed by deionised water for 30 minutes. 
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Subsequently, the monolith was conditioned for 30 minutes with 10 mmol.L-1 
HEPES buffer pH 8.2 containing 1 mmol.L-1 Ca2+ and 1 mmol.L-1 Mn2+, 
followed by flushing a 1 mg.mL-1 solution of ECL prepared in the same buffer 
for 4 hours at room temperature. Finally, in order to block any unreacted 
succinimidyl groups, the resulting ECL-Au-modified monolith was flushed 
with a primary amine (1 mol.L-1 Tris buffer pH 7.4) followed by a 100 µL 
deionised water wash. When not in use, the ECL-Au-modified monolith was 
kept immersed in 10 mmol.L-1 Tris buffer pH 7.4 containing 150 mmol.L-1 
NaCl, 1 mmol.L-1 Ca2+ and 1 mmol.L-1 Mn2+ at 4 oC. For the sake of clarity, 
this monolith shall be referred to hereafter as Monolith A. 
 In order to investigate the effect of immobilising AuNPs on the 
monolith surface, a comparison monolith (Monolith B) was also prepared 
which did not incorporate immobilised AuNPs. Instead, the monolith was 
grafted with vinyl azlactone as described, and then ECL was immobilised 
onto the resulting pendant azlactone moieties using the same immobilisation 
buffer, followed by blocking with 1 mol.L-1 Tris buffer. 
 
6.2.6. Non-specific binding studies  
 
In order to investigate the origin of unwanted non-specific interactions 
between test proteins and the Au-modified substrate, a further four monoliths 
were prepared (referred to as “blank” monoliths in that they did not include 
immobilised ECL). Blank Monolith 1 did not include immobilised AuNPs, 
but was grafted with polymer chains of vinyl azlactone and blocked with 1 
mol.L-1 Tris buffer. Blank Monolith 2 was modified with AuNPs which were 
not blocked with 1 mol.L-1 Tris buffer. Blank Monolith 3 was modified with 
AuNPs which were subsequently blocked with 1 mol.L-1 Tris buffer. Blank 
Monolith 4 was modified with AuNPs, functionalised with DTSP and the 
resulting succinimidyl groups blocked with 1 mol.L-1 Tris buffer. Figure 6.2 
illustrates a schematic diagram of the different monoliths prepared and Table 
6.1 summarises them. 
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Figure 6.2: Schematic diagram of all affinity monoliths and blank monoliths 
prepared in this study.  
 
Table 6.1 
Summary of different monoliths prepared throughout this study 
Monolith  Surface chemistry Expected protein retention 
Monolith A ECL immobilised on AuNPs Galactosylated proteins 
Monolith B 
ECL immobilised on azlactone 
moieties (no AuNPs) 
Galactosylated proteins 
Blank monolith 1 Azlactone blocked with Tris buffer None 
Blank monolith 2 Bare AuNPs Amines and thiols 
Blank monolith 3 AuNPs blocked with Tris buffer None 
Blank monolith 4 
AuNPs functionalised with DTSP 
and then blocked with Tris buffer 
None 
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6.2.7. Desialylation of transferrin and thyroglobulin 
 
Desialylated transferrin and thyroglobulin was prepared by treating each with 
Clostridium perfringens neuraminidase and following supplier instructions. 
Briefly, 100 µg of the protein was prepared in 50 mmol.L-1 sodium citrate, pH 
6.0, mixed with 50 U neuraminidase and left to react at 37 oC for overnight. 
 
6.2.8. Deglycosylation of transferrin 
 
Transferrin was deglycosylated using Flavobacterium meningosepticum 
PNGase F, following supplier instructions. Briefly, 100 µg of the protein was 
prepared in 50 mmol.L-1 sodium phosphate, pH 7.5, mixed with 500 U 
PNGase F and left to react at 37 oC for overnight. 
 
6.2.9. Bind and elute studies  
 
A number of selected proteins were used to study the binding affinity of all 
fabricated monoliths and also to evaluate the blocking strategies used to 
eliminate non-specific interactions (i.e. binding which was not due to sugar-
lectin interactions). All lectin affinity monoliths and blank monoliths were 
tested using the syringe pump at a flow rate of 50 µL.hour-1. The monolith 
was first conditioned with 20 µL of loading buffer (10 mmol.L-1 Tris, pH 7.4, 
containing 150 mmol.L-1 NaCl, 1 mmol.L-1 Ca2+ and 1 mmol.L-1 Mn2+). A test 
mix of selected proteins (total volume: 20 µL) was prepared in loading buffer 
and loaded from the top-end, pumped through the monolith and collected in 
a clean 1.5 mL centrifuge tube, followed by a 20 µL buffer wash which was 
collected in the same tube and combined with the extracted mixture. 
Preliminary binding studies and all evaluations of “blank monoliths” (Blank 
Monoliths 1 to 4) involved the use of a simple mixture of two glycoproteins: 
desialylated transferrin and ribonuclease B (20 µg.mL-1 each) and denoted 
as Standard A. Further more rigourous testing of the affinity monoliths 
involved the use of a more complex protein mixture containing up to nine 
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proteins as described later and denoted as Standard B. Finally, an 
Escherichia coli (E. coli) cell lysate spiked with transferrin was also used to 
test the affinity monolith. In all cases, to elute any retained glycoprotein, 40 
µL of 0.8 mol.L-1 galactose prepared in buffer solution was flushed through 
the monolith and collected for analysis by nano-LC. All affinity monoliths 
prepared in this study could be re-used numerous times after a rinse with 
loading buffer. 
 
6.3. Results and discussion 
 
The fabrication of porous polymer monoliths within pipette-tips has been 
reported before [15, 29-34], however in the work described herein, it is 
reported for the first time the in-situ covalent attachment of AuNPs to the 
polypropylene-encased monolith, resulting in two distinct benefits. Firstly, the 
surface area can be significantly increased, resulting in increased loading 
capacity when a selected lectin is immobilised onto the gold surface. 
Secondly, the use of a gold surface and a commercially available bi-
functional linker (DTSP) means that the extraction device is readily suited for 
the immobilisation of any bio-recognition molecule via the reaction between 
pendant succinimidyl groups and native lysine residues (ranging from 
Protein A for trapping immunoglobulins, to enzymes such as trypsin or 
PNGase for off-line enzymatic digestion). In this study however, a galactose-
selective lectin (ECL, Figure 6.3) was elected to be immobilised on the gold 
surface as a simple test-case, in order to examine the trap-and-release of 
various selected glycoproteins with terminal beta-galactose. Terminal beta-
galactose is of concern in biopharmaceuticals since proteins with these 
structures get cleared from the bloodstream by the liver [45]. ECL is a well-
characterised commercially available lectin [46]. The performance of the 
resulting ECL affinity monolith was also compared directly with that of an 
ECL affinity monolith which did not incorporate AuNPs, but rather where the 
lectin was instead immobilised directly onto the lower surface area 
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monolithic substrate itself via grafted chains of amine-reactive poly(vinyl 
azlactone). 
 
 
 
Figure 6.3: The structure of ECL dimer. The N-linked carbohydrate, lactose bound 
at the combining site and HEPES molecules are shown. The manganese and 
calcium ions bound in the vicinity of the combined site are shown as small spheres 
[47]. 
 
6.3.1. Fabrication of porous polymer monoliths within pipette-tips 
 
In the study described here, an EDMA monolith was in-situ fabricated within 
the confines of a commercial 20 µL plastic pipette-tip. Pipette-tips used in 
this study were manufactured from polypropylene as polypropylene is 
resistant to all solvents employed in this study and was found to be 
appropriate for all UV-initiated photo-grafting and polymerisation events. In 
addition, polypropylene is highly suited as a substrate for the photo-grafting 
of selected monomers as it contains easily abstractable hydrogens (photo-
grafting is mediated by BP and proceeds due to hydrogen abstraction from 
the surface of the substrate [48-50]). Therefore, as illustrated in Figure 6.4, 
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the surface chemistry of the tip inner-wall was modified by grafting EDMA 
chains for subsequent attachment to the monolith. 
 
 
 
 
Figure 6.4: Schematic diagram of pipette-tip inner-wall modification. 
 
 
The inner-wall surface of the tip was modified to ensure covalent 
attachment between the EDMA monolith and the tip. This monolith/wall 
attachment is significant (i) to increase the rigidity of the monolithic bed to 
withstand high backpressures and thus prevent the bed from slipping out of 
the tip either during the tip fabrication and surface modification (i.e. grafting, 
Au-immobilisation and ECL-modification) or during the sample analysis as 
some of the tips are not tapered enough at the bottom-end to hold the 
monolithic bed, and (ii) to prevent unwanted voids between the wall and the 
monolithic bed that occur due to the shrinkage of the monolith during the 
polymerisation, which could has an impact on the recovery and thus the 
sample to pass through the monolithic bed. In addition, there is no need for 
supporting frits when the monolithic bed is bonded to the wall. 
The monolith/wall attachment evaluation was carried out by flowing a 
stream of nitrogen from the bottom-end of the tip. The monolithic bed was 
easily detached from the unmodified pipette-tip whereas the resistance of 
the monolith prepared in the modified tip was significantly higher which 
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indicates the strong covalent attachment between the inner-wall of the tip 
and the monolithic bed. As a result of this attachment, the tip could be 
operated at high flow rates. Figure 6.5 shows SEM images of an EDMA 
monolith fabricated in a pipette-tip, with and without wall modification. As it 
can be seen, the monolith fabricated in a wall-modified tip was covalently 
attached to the tip inner-wall (Figure 6.5(i-iv)), whereas the monolith 
fabrication in the unmodified tip resulted in a void between the monolith and 
the tip inner-wall (Figure 6.5(v) and (vi)). 
Unlike capillary fused silica or microfluidic channels, the in-situ 
fabrication of the monolith in a pipette-tip is technically challenging. For 
example, because the tips are not sealable, polymerisation can not be 
carried out thermally (i.e. in a water bath). Moreover, some of the porogens 
can not be used due to the volatility issues. Another issue is how to control 
the bed size for a reproducible preparation of the monolithic tips. 
Unsuccessful attempts were made to adjust the monolith bed size utilising a 
photomask as illustrated in Figure 6.6(i) because some of the monolith was 
partially polymerised underneath the mask which was over the requested 
bed size. Also, other studies have reported the placement of guide ring 
inside the tip for this purpose [15]. However, this strategy was avoided due 
to the possible generation of a void volume between the top of the monolith 
bed and the ring. 
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Figure 6.5: Scanning electron microscopy images of a porous polymer monolith 
formed within a polypropylene pipette-tip, which was modified by photo-grafting (i-
iv) and unmodified (v, vi) prior to monolith polymerisation. 
 
 
Therefore, the monolithic bed size was adjusted during the fabrication 
using a 2-mm guide ring as described in the Experimental section. The guide 
ring was placed outside the tip and removed when the polymerisation was 
completed (Figure 6.6(ii-iii)). The monolith bed length was measured under 
an optical microscope using a vernier caliper and a % RSD of 8 % was 
achieved for 11 separately prepared monoliths. In addition, different bed size 
could be prepared by changing the ring size, as illustrated in Figure 6.6(iv). 
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Figure 6.6: Images of a monolith bed size adjustment using a photomask (i) and a 
guide ring (ii-iii). (iv) preparation of different bed size. 
 
 
To facilitate aspirating and expelling the sample during analysis and 
to reduce operating backpressures and thus facilitate the use of laboratory 
auto-pipettes, previous studies have suggested creating a main flow-through 
channel through the monolithic bed [15, 34]. However, two issues occurred 
during the fabrication and modification process of the monolithic tip when the 
channel was created. Firstly, the channel was close to the tip wall and it was 
difficult to have it right in the centre of the monolithic bed. This could 
negatively affect the trap-elution of the sample analytes due to uneven fluid 
flow through the monolithic bed (Figure 6.7(ii)). Secondly, which was more 
significant in this study, the subsequent immobilisation of AuNPs on 
monoliths incorporating a main channel did not occur evenly throughout the 
entire monolith. Rather, the coverage of AuNPs was centred around the bore 
of the main channel such that the radial homogeneity of immobilised AuNPs 
was poor (Figure 6.7(iii-iv)). This is because the fluid followed the path of 
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least resistance through the channel rather than flowing through the pores of 
the monolith. Thus, the preparation of the monolithic bed without the main 
flow-through channel was unavoidable even though it lead to high 
backpressures during operation, which prohibited the use of hand-held auto-
pipettes for sample loading and rinsing and obliged the use of a syringe 
pump.  
Unsuccessful attempts were made to reduce the backpressure by 
varying the monomer concentration between 20 % and 40 % prior to 
polymerisation, but all monoliths with < 40 % EDMA had very poor 
mechanical rigidity. However the main focus of our efforts in this work was to 
demonstrate the use of Au-modified monoliths in pipette-tips for affinity 
applications and thus the means by which the monolith was flushed (i.e. via 
syringe pump or auto-pipette) was considered incidental at this stage of the 
project.  
 
 
 
Figure 6.7: Optical microscope images of (i) empty pipette-tip, (ii) bottom-end of 
monolithic tips with a 150 µm o.d. flow-through channel, and (iii-iv) monolithic tips 
with flow-through channel after AuNPs immobilisation.  
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6.3.2. Modification of the monolith surface with AuNPs 
 
The focus of this Chapter was to increase the capacity of the monolithic 
extraction device by increasing the number of extraction active sites (ECL in 
this case). The surface of the preformed monolith was modified utilising 
photografting since it is one of the techniques used to modify the chemistry 
of the surface of synthetic polymers [51] and it does not require re-
optimisation of the polymerisation conditions for each new monolith (as 
discussed in Chapter 1) [52]. 
Therefore, the surface area of the monolithic substrate, which had a 
high surface density of primary amine groups, was increased by 
immobilising 20 nm citrate-stabilised AuNPs. The immobilisation of AuNPs 
onto the polymer monolith with a high density of coverage was achieved 
using a protocol originally described by Connolly et al. [40] with minor 
modifications. Figure 6.8 illustrates the scheme of the monolith surface 
modification with AuNPs. The immobilisation procedure was divided into two 
main steps: amination of the monolith surface by flushing the vinyl azlactone 
photo-grafted polymer monolith with ethylenediamine and then the resulting 
aminated monolith was flushed with the 20 nm citrate-stabilised AuNPs 
subsequently.  
One particular matter of concern was the possibility that the UV 
radiation (during grafting of azlactone) might not penetrate through the entire 
bulk of the monolith (due to the screening effect of UV absorbing monomers, 
solvents and the monolith itself) leading to an unwanted radial gradient of 
graft density. Rohr et al. have previously demonstrated that homogeneous 
grafting can be achieved through a 200 µm thick layer of monomer and also 
investigated the effect of rotating the substrate during grafting events [50]. In 
their study, they used electron probe microscopy to evaluate the 
homogeneity of graft density (for sulphonated polymer grafts) [53]. 
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Figure 6.8: Reaction scheme showing the surface modification of the pre-formed 
monolith with AuNPs. 
 
 
However, in the work described here, FE-SEM was used to image the 
high coverage of the monolith surface with the AuNPs, which was indicative 
of graft homogeneity since each nano-particle was strongly attached by 
multi-point interactions to the grafted surface, via primary amine lone-pair 
electrons [40-42]. Figures 6.9 and 6.10 show images of an Au-modified 
monolith which have been taken under optical microscope and FE-SEM, 
respectively. As it can be seen in Figure 6.9, the monolith colour turned from 
white to dark red indicating the complete radial and axial coverage with 
AuNPs. The images (i-iii) in Figure 6.10 were taken using the FE-SEM for a 
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piece of monolith that was prepared in a pipette-tip that had not been 
treated. These images illustrate the excellent coverage of AuNPs 
represented by the white dots. This high surface coverage of AuNPs clearly 
confirmed the achieved significant increase in surface area even though it 
was not specifically measured here due to the very small bed volume (which 
prevents the use of Brunauer-Emmett-Teller (BET) surface area analysis to 
accurately quantitate the surface area increase).  
The image (i) in Figure 6.10 shows that the edge of the monolith 
close to the wall of the tip had rather a sparse coverage of AuNPs. It is 
believed that the poor coverage in this very narrow zone (representing about 
3.5 % of the entire 400 µm monolith radius) was due to poor convective fluid 
flow at the extremities of the monolith compared with flow through the 
remaining monolith bulk. In relation to the work of Rohr et al. [50, 53] 
regarding the radial homogeneity of grafting, for the work presented here, no 
gradient of grafting density was observed, either axially or radially even 
though the monolith here was of considerably larger dimensions.  
 
 
 
 
Figure 6.9: Optical microscope images showing the monolithic tips before and after 
coverage with AuNPs. 
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(i)
(ii)
(iii)
 
 
Figure 6.10: Field emission scanning electron microscopy images showing dense 
coverage of AuNPs. (i) 8,000X magnification, (ii) 13,000X magnification and (iii) 
60,000X magnification. The white dots on the globule surfaces represent the 
immobilised AuNPs. 
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6.3.3. Modification of the Au-modified monolith with ECL 
 
For the preparation of a lectin-affinity extraction phase, ECL was chosen due 
to its commercial availability as well as that its bind/release mechanism is 
well known [46]. Therefore, the Au-immobilised monolith was subsequently 
modified with ECL for the preparation of the lectin-affinity extraction monolith 
for selective enrichment of galactosylated proteins.  
The immobilisation of ECL on the Au surface can be carried out 
utilising different strategies. The easiest and quickest method would be to 
flush the Au-modified monolith with a solution of ECL as suggested by Storri 
et al. [54], such that the lectin is physically adsorbed on the bare gold 
surface. However, this interaction is known to be weak and the adsorbed 
lectin could be easily detached from the Au surface during the subsequent 
use of the extraction device [54]. 
An alternative method that resulted in a strong covalent attachment 
between the ECL and the Au surface involved the use of a bi-functional 
linker, DTSP, as described by Katz [55] and illustrated in Figure 6.11. The 
Au surface modification was carried out utilising a two-step strategy in which 
the Au-modified monolith was first flushed with DTSP to form self-assembled 
monolayers (SAM) of N-succinimidyl-3-thiopropionate (NSTP) [55-57], via 
strong gold-sulphur bonds. Since disulphides are known to interact with gold 
surfaces via dissociative chemisorption, thus NSTP monolayers are formed 
from the dissociation of the DTSP disulfide bond on the gold surface [58]. 
NSTP has an exposed active NHS group that is reactive towards primary 
amines. Covalent immobilisation of ECL was achieved by flushing a solution 
of ECL as a second step and the attachment took place by the nucleophilic 
attack of the lysine primary amine group of the ECL [56]. The final step was 
to block any possible remaining active NHS groups or bare gold by flushing 
the ECL-Au-modified monolith with amine-containing buffer. This blocking is 
crucial to eliminate non-specific binding of sample components to the SAM 
or the bare gold surface as illustrated in Figure 6.12. 
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The Au surface could also be modified with ECL in a faster way 
utilising a one-step immobilisation strategy in which ECL is mixed with the bi-
functional linker first and then the resultant solution is flushed through the 
Au-modified monolith. However, the two-step immobilisation strategy was 
preferred to the one-step because unspecific adsorption of the ECL on the 
Au surface was prevented by the pre-formed NSTP SAM [57].  
The immobilisation buffer was selected to have a pH of 8.2, which 
was close to the optimum pH for lectin/glycan binding as dictated by the 
vendor. The buffer also incorporated 1 mmol.L-1 of Ca2+ and 1 mmol.L-1 of 
Mn2+, which are known to play a role in maintaining the spatial arrangement 
of the carbohydrate binding site residues [59]. By maintaining optimum 
buffer conditions for ECL during immobilisation and subsequent testing of 
the affinity monoliths, the risk of deactivation of ECL was minimised. 
 
 
 
O
O
N
O
O
N
O
S
O
O
S
O
+ 
DTSP 
OH
O
O
N+ 
O
O
N
O
S OAu 
Au 
O
O
N
O
S OAu 
O
S NHAu 
H2N ECL 
 ECL 
N-hydroxysuccinimide ECL-Au-modified tip 
 
 
Figure 6.11: Reaction scheme showing the adsorption of NSTP via the dissociation 
of the DTSP disulphide bond, followed by the subsequent immobilisation of ECL. 
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Figure 6.12: Reaction scheme showing the blocking of remaining unreacted NHS 
groups and bare gold sites with Tris buffer. 
 
6.3.4. Trap-elute studies of a simple standard mixture of glycoproteins  
 
ECL is known to be selective towards glycoproteins with terminal galactose 
residues. Therefore, a simple mixture (Standard A) consisting of two test 
glycoproteins were chosen both for selectivity studies and evaluation of non-
specific protein binding. The mixture consisted of ribonuclease B as the 
negative control since it contains high mannose glycan structures [60], and 
thus this glycoprotein is not expected to be retained by the ECL affinity 
monolith. Transferrin was selected as the positive control protein since the 
glycan of transferrin is terminated by neuraminic acid residues, [61] which 
were removed by neuraminidase to expose galactose residues and thus 
maximise the transferrin extraction. To validate the extraction efficiency and 
selectivity of the extraction monoliths, all samples treated with the extraction 
monoliths were injected in a capillary HPLC and separated on a reversed-
phase monolithic column as described in the Experimental section.  
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6.3.4.1. Investigation of non-specific interactions  
In order to insure that the retention of the galactosylated proteins was 
due to sugar-lectin interactions which prove the specificity of ECL and to 
investigate non-specific binding, several monolithic tips containing no 
immobilised ECL were used as blank comparisons. The unwanted non-
specific binding of proteins could occur, either due to hydrophobic 
interactions with the polymer monolith, gold-sulphur/gold-amine interactions 
with the immobilised AuNPs, or via the covalent attachment between the 
proteins and the exposed unreacted succinimidyl groups. Therefore, four 
blank monoliths were prepared as described in Section 6.2.6 and illustrated 
in Figure 6.2 and summarised in Table 6.1. The test mixture, Standard A, 
was used for the evaluation purposes. Note: different batch of Standard A 
was used for each of the following experiments. Figure 6.13(a) shows 
chromatograms obtained for Standard A before and after flushing through 
Blank Monolith 1 in which the hydrophobicity of the EDMA base monolith 
was modified by photografting azlactone moieties, followed by blocking with 
Tris buffer. This modification increased the hydrophilicity of the monolith 
surface, which then minimised any unwanted hydrophobic interactions, as 
evidenced by the complete lack of retention of either test protein on the 
monolith surface after Standard A passage. 
Conversely, as it can be seen in Figure 6.13(b), both test proteins 
(both glycosylated) were retained on Blank Monolith 2 which incorporated 
bare unfunctionalised AuNPs, presumably due to adsorption of protein on 
the gold surface as described by Storri et al. [54].  
The % relative areas of the two test proteins before and after 
treatment with the Blank Monolith 1 are listed in Table 6.2.  
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Figure 6.13: HPLC chromatograms of Standard A before (blue) and after (pink) 
passage through: (a): Blank Monolith 1 showing the elimination of non-specific 
protein adsorption and (b): Blank Monolith 2 showing adsorption of the two-test 
proteins on the bare AuNPs. Chromatographic conditions: Column: 100 µm x 15 cm 
LMA-co-EDMA monolith, Gradient: 10 minute gradient from 5 % B to 100 % B at 2 
µL.min-1, Column temperature: 25 oC, Injection volume: 1 µL, Detection: UV at 214 
nm. Peaks: (1) ribonuclease B, (2) desialylated transferrin. 
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Table 6.2  
Peak areas of the two-test proteins and the deglycosylated transferrin before and 
after treatment with the different monoliths. 
% Peak area* 
Monolithic tip Test-protein 
Before extraction After extraction 
Ribonuclease B 48.4 % 52.0 % 
Blank Monolith 1 
Desialylated transferrin 51.6 % 48.0 % 
Ribonuclease B 60.9 % 62.6 % 
Blank Monolith 3 
Desialylated transferrin 39.1 % 37.4 % 
Ribonuclease B 37.1 % 39.1 % 
Blank Monolith 4 
Desialylated transferrin 62.9 % 60.9 % 
Monolith A Deglycosylated transferrin 1.085** 1.086** 
*Relative peak area expressed as a percentage. 
**Actual peak areas rather than percentage. 
 
However, no detectable retention of either test protein was observed 
when the bare AuNPs were blocked with Tris to produce Blank Monolith 3 
(Figure 6.14) as well as when AuNPs were functionalised with DTSP and 
then blocked with Tris (Blank Monolith 4) as indicated in Figure 6.15. This 
is suggesting that Tris, as a small hydrophilic amine, was well suited to 
providing efficient blocking of unreacted succinimidyl groups. The % relative 
areas of the two test proteins before and after treatment with the Blank 
Monolith 3 and Blank Monolith 4 are listed in Table 6.2.  
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Figure 6.14: HPLC chromatograms of Standard A before (blue) and after (pink) 
passage through Blank Monolith 3 showing the effect of blocking the bare AuNPs 
with Tris buffer. Chromatographic conditions are as in Figure 6.13. Peaks: (1) 
ribonuclease B, (2) desialylated transferrin. 
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Figure 6.15: HPLC chromatograms of Standard A before (blue) and after (pink) 
passage through Blank Monolith 4 showing the effect of blocking the DTSP-
functionalised AuNPs with Tris buffer. Chromatographic conditions are as in Figure 
6.13. Peaks: (1) ribonuclease B, (2) desialylated transferrin. 
  218 
In addition, Figure 6.16 shows that no retention was observed when a 
deglycosylated transferrin was passed through Monolith A as it did not 
contain galactose residues indicating the specificity of Monolith A towards 
galactosylated proteins. The peak area of the deglycosylated transferrin 
before and after treatment with Monolith A is listed in Table 6.2. As a 
consequence of all of the results obtained above, the retention of the 
galactosylated transferrin was due to the specific sugar-lectin interactions 
and all other possible interactions were eliminated.  
 
0
7
14
21
28
35
0 3 6 9 12 15
Retention time (minutes)
A
b
s
o
rb
a
n
c
e
 (
m
A
U
)
1
 
 
Figure 6.16: HPLC chromatograms of deglycosylated transferrin before (blue) and 
after (pink) passage through Monolith A showing its specificity towards 
galactosylated proteins. Chromatographic conditions are as in Figure 6.13. Peaks: 
(1) deglycosylated transferrin. 
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6.3.4.2. Investigation of affinity extraction of ECL-functionalised monoliths 
Due to the specificity of ECL towards galactose residues, the 
extraction efficiency of the ECL-functionalised monoliths (Monolith A and 
Monolith B) was evaluated by examining its ability in extracting desialylated 
transferrin (e.g. a protein terminated with galactose residues). The 
evaluation of the monoliths involved loading 20 µL of Standard A from the 
top-end of the affinity monoliths followed by a buffer rinse as described in 
Section 6.2.9. All fractions and combined monolith rinsings were collected 
and subjected to capillary LC analysis to determine if selective binding had 
occurred. 
The aim of immobilising AuNPs on the monolithic surface was to 
increase the area of that surface and therefore increase the extraction 
capacity of the affinity monolithic tip by increasing the available lectin 
immobilised on the gold surface (Monolith A). Therefore, for comparative 
purposes, Monolith B was prepared in which the ECL was immobilised on a 
monolith containing no AuNPs (ECL covalently attached via amine-reactive 
azlactone polymer grafts) as illustrated in Figure 6.17.  
 
 
O NH
NHO
( ) 
NO
O
( ) 
Azlactone-grafted 
monolithic tip 
+ 
n n 
H2N ECL 
ECL 
Monolith B 
 
 
Figure 6.17: Reaction scheme showing the immobilisation of ECL on the surface of 
the pre-formed monolith for the preparation of Monolith B.  
 
As mentioned above, 20 µL of Standard A was passed through both 
affinity monoliths and the chromatograms obtained are in Figure 6.18. As it 
can be seen, in both affinity monoliths, ribonuclease B was not retained as 
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expected whereas desialylated transferrin was retained by both Monolith A 
and Monolith B. This is clearly indicative of the selective retention of 
desialylated transferrin over ribonuclease B due to galactose-lectin 
interactions. Moreover, using relative peak areas in standard Chromatogram 
(i) as a reference, ~ 95 % more desialylated transferrin was retained on 
Monolith A relative to Monolith B, clearly showing the advantage of Au-
modified monoliths as substrates which lead to much more immobilised ECL 
lectin for affinity extraction. The relative peak area of desialylated transferrin 
before extraction was 1.6 and decreased to 1.28 after treatment with 
Monolith B, whereas the treatment with Monolith A lead to a decrease to 
0.55. The loading capacity is estimated to be 138 ng/monolith. A subsequent 
monolith rinse of Monolith A with 40 µL of 0.8 mol.L-1 galactose in loading 
buffer revealed that the bound desialylated transferrin could be readily 
recovered, appearing as a single peak in Chromatogram (iv).  
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Figure 6.18: HPLC chromatograms of (i) untreated Standard A, (ii) Standard A 
after passage through Monolith B, (iii) Standard A after passage through 
Monolith A, (iv) release of bound transferrin from Monolith A with a galactose 
rinse. Chromatographic conditions are as described in Figure 6.13. Peaks: (1) 
ribonuclease B, 2- desialylated transferrin. 
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6.3.5. Application of affinity monoliths to complex protein mixtures 
 
The extraction efficiency of Monolith A was further evaluated by applying 
the affinity monolith to extract two galactosylated proteins from a complex 
mixture of proteins. The complex mixture (Standard B1) consisting of nine 
selected proteins in which six of them are non-glycosylated proteins (insulin 
chain B, insulin, cytrochrome C, BAS, enolase and carbonic anhydrase) as 
well as glycoproteins which had either terminal mannose (ribonuclease B), 
or terminal galactose (desialylated transferrin and desialylated 
thyroglobulin). In order to mimic a real sample, the non-glycosylated proteins 
were specifically selected to span a wide range of molecular masses from 
insulin chain B (3.5 kDa) to enolase (82 kDa to 100 kDa, depending on the 
isoform).  
For the evaluation purposes, a chromatographic method was 
developed for the separation of the nine proteins. The effect of the column 
temperature on the separation was investigated on the range between 25 oC 
and 75 oC at 5 oC intervals and the results are shown in Figure 6.19. As it 
can be seen, there was no significant influence on the retention times across 
this range as the retention time of the last eluted peak was decreased by 
only 0.4 minutes when the column temperature increased from 25 oC to 75 
oC. However, the remarkable effect was upon selectivity, particularly for 
three adjacent peak pairs. Resolution between Peak 2 and 3 increased from 
0.9 at 25 oC to 2.5 at 75 oC, resolution of Peak 3 and 4 decreased from 3.6 
at 25 oC to 1.2 at 75 oC and resolution of Peak 7 and 8 decreased from 2.0 
at 25 oC to complete co-elution at 75 oC. As a compromise, a column 
temperature of 40 oC was selected which resulted in resolution between 
Peaks 2/3, 3/4 and 7/8 of 1.4, 2.5 and 1.7 respectively.  The optimised 
gradient conditions resulted in a peak capacity of 102 which was calculated 
based on the following equation [62]. 






+=
w
t
1Pc
g
                                                                (Eq. 6.1) 
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where tg is the gradient time and w is the average peak width measured 
13.4% above the baseline. The concentration of enolase and desialylated 
thyroglobulin in Standard B1 was higher than the others due to the lower 
absorbance at 214 nm. 
0
60
120
180
240
300
0 3 6 9 12 15
Retention time (minutes)
A
b
s
o
rb
a
n
c
e
 (
m
A
U
)
@ 25 
o
C
@ 65 
o
C
@ 55 
o
C
@ 45 
o
C
@ 40 
o
C
@ 35 
o
C
@ 75 
o
C
1 4
7
6
9
8
5
32
 
Figure 6.19: Selected HPLC chromatograms showing the effect of column 
temperature on the separation of Standard B1 proteins. Chromatographic 
conditions are as described in Figure 6.13 except: Gradient: 9 minute gradient from 
5 % B to 100 % B. Peaks: (1) 20 µg.mL-1 ribonuclease B, (2) 20 µg.mL-1 insulin 
chain B, (3) 20 µg.mL-1 insulin, (4) 20 µg.mL-1 cytrochrome C, (5) 25 µg.mL-1 
desialylated transferrin, (6) 25 µg.mL-1 BSA, (7) 20 µg.mL-1 carbonic anhydrase, (8) 
40 µg.mL-1 enolase, (9) 80 µg.mL-1 desialylated thyroglobulin. 
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Figure 6.20 shows chromatograms of Standard B1 before and after 
its passage through Monolith A. The results show that all of the non-
glycosylated proteins (Peaks 2-4 and 6-8) were unretained as well as Peak 1 
(ribonuclease B) since this glycoprotein has high mannose glycans. On the 
other hand, significant retention (i.e. significant decrease in their peak areas) 
was observed for both desialylated transferrin and desialylated thyroglobulin 
(Peaks 5 and 9) and subsequently recovered with a galactose wash step. 
The lack of interfering peaks in the galactose wash is indicative of the 
specificity of binding. Interestingly, the affinity monolith was demonstrated to 
simultaneously extract both transferrin and thyroglobulin even in the 
presence of other proteins and glycoproteins. This was despite the 
considerable difference in size of both target glycoproteins (80 kDa and 670 
kDa, respectively) and also the difference in glycan structure and coverage. 
Specifically, thyroglobulin has 25-30 N-linked glycans having both high-
mannose- and complex structures, some of which are teminated in 
galactose [63]. Other complex glycans on thyroglobulin are terminated in 
sialic acid and so treatment with neuraminidase revealed underlying 
galactose residues in order to maximise the ECL binding of the protein. 
Conversely, transferrin contains only 2 N-linked glycans, both of which have 
the same complex-type structure [61]. 
 
  224 
0
9
18
27
36
45
54
0 3 6 9 12
Retention time (minutes)
A
b
s
o
rb
a
n
c
e
 (
m
A
U
)
1
Before extraction
9
8
7
6
5
4
32
Galactose wash
After extraction
 
 
Figure 6.20: HPLC chromatograms of Standard B1 before and after extraction with 
Monolith A8. Chromatographic conditions and peak assignment are as described 
in Figure 6.19. 
 
 In a further effort to verify that transferrin had indeed been retained 
due to sugar-lectin interactions, rather than non-specific protein-protein 
interactions, two further complex mixtures (Standard B2 and B3) were 
prepared. Both mixtures do not contain galactosylated proteins; therefore no 
retention was expected from any of the proteins presented in these two 
mixtures. Standard B2 consists of the six non-glycosylated proteins (insulin 
chain B, insulin, cytrochrome C, BSA, enolase and carbonic anhydrase) in 
addition to ribonuclease B (terminated with mannose) and asialotransferrin 
(terminated with sialic acid). The proteins presented in Standard B3 are the 
same as Standard B2 except that it does not contain asialotransferrin. The 
two mixtures were treated with Monolith A and the results obtained are in 
Figure 6.21. As expected, the retention of the target proteins was due to the 
sugar-lectin interaction.  
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Figure 6.21: HPLC chromatograms of: (a) Standard B2 and (b) Standard B3 
before and after extraction with Monolith A8. Chromatographic conditions and 
peak assignment are as described in Figure 6.19. 
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6.3.6. Evaluation of transferrin extraction repeatability on Monolith A 
 
The % of desialylated transferrin extracted during the loading step was 
calculated using relative peak areas with ribonuclease B as an internal 
standard. Three repeat extraction cycles were performed on a Monolith A 
(regenerated each time with a galactose rinse). The average % extraction for 
desialylated transferrin for a single selected affinity monolith (n = 3) was 31 
% which suggests that either (a): the affinity monolith was overloaded at the 
employed sample concentration (20 µg.mL-1; equivalent to 400 ng of protein 
loaded per 20 µL aliquot of test mix) or (b): the loading flow-rate and thus 
contact time was not optimum. The % RSD for the three repeat extractions 
using the stated loading conditions on a single extraction monolith was 4.3 
%, indicating that the affinity monolith could be reused for repeat extractions.  
Although a rigourous study of the stability of prepared affinity 
monoliths was not conducted, it was observed that affinity monoliths could 
retain their extraction capabilities after numerous consecutive periods of 
storage at 4 oC and re-use at room temperature. For example, immediately 
after preparation, a particular monolith was stored for 12 hours at 4 oC, used 
for one extraction cycle (bind/elute), stored for a further 5 days at 4 oC, re-
used for 6 consecutive extraction cycles, stored for 36 hours at 4 oC and 
finally used for three extraction cycles. In all cases, the extraction device 
was able to retain galactosylated proteins. More detailed stability testing 
should be the subject of future studies. However, the extraction performance 
dropped off significantly after prolonged storage (> 1 month). For example, 
the peak areas of the ribonuclease (i.e. non-galactosylated protein) B before 
and after extraction were 0.54 and 0.53, respectively. Also, the peak area of 
the desialylated transferrin (i.e. galactosylated protein) before and after 
extraction were 0.84 and 0.83, respectively. 
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6.3.7. Repeatability of nano-agglomerated affinity monolith fabrication 
procedures 
 
During the course of this work, a total of eight nano-agglomerated affinity 
monoliths were prepared (denoted A1 to A8) and their extraction 
performance was evaluated as described. For six of the eight monoliths, 
(Figure 6.22) the average extraction of transferrin (from 20 µL of Standard 
A) was again 31 %, with a % RSD between monoliths of 14.0 %. This level 
of agreement between separate affinity monoliths is acceptable considering 
that each individual monolith was subject to no less than 11 discrete steps 
during fabrication (2 steps for polypropylene wall modification, 2 steps for 
monolith polymerisation (critical for control of base-monolith surface area 
and bed volume), 4 steps for nano-agglomeration with gold and 3 steps for 
protein immobilisation/blocking procedures). Two of the eight affinity 
monoliths (A7 and A8) displayed disproportionately high % extraction of 
desialylated transferrin (72 % and 65 %) relative to the other six monoliths. 
The most likely reason for higher extraction of transferrin is (a): an 
erroneously higher surface area for the base monolith due to the human 
error involved in preparing the monomer mixture or (b): a larger bed volume 
due to inaccurate filling of the tip with monomer mixture. 
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Figure 6.22: Repeatability of extraction of desialylated transferrin from Standard A 
on multiple nano-agglomerated affinity monoliths. 
 
6.3.8. Extraction of glycoprotein from spiked real samples: E. coli 
 
Finally, the extraction performance of the affinity monolith tip (Monolith A) 
was examined with real sample matrices similar to those typical of a 
biofermentation process reaction. An E. coli cell lysate sourced from a KRX 
strain (filtered and passed through a 10 kDa ultrafiltration unit) was spiked 
with 20 µg.mL-1 desialylated transferrin. The cell lysate was from E. coli, 
which is a prokaryotic organism and so does not have the type 
of glycosylation system that produces the complex glycoproteins that ECL 
interacts with. Thus, 20 µL of the spiked sample was passed through the 
monolith and the results before and after are shown in Figure 6.23. The peak 
of the desialylated transferrin decreased significantly as a result of extraction 
despite the presence of unknown matrix protein. Indeed the peak profile of 
the E. coli proteins was unchanged before and after extraction, as expected, 
which indicates that unwanted non-specific protein binding or protein-protein 
interactions were largely eliminated. In addition, the retained transferrin was 
recovered from the extraction phase with an extraction recovery of about 83 
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% and there was a marked absence of interfering proteins in this galactose 
elution step. 
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Figure 6.23: HPLC chromatograms of spiked E. coli cell lysate before and after 
passage through Monolith A. Chromatographic conditions are as described in 
Figure 6.20. Peaks: (1) desialylated transferrin. 
 
6.4. Conclusions 
 
A novel affinity monolithic extraction phase has been described which 
incorporates covalently attached AuNPs, providing a significant increase in 
surface area. By using the well studied bifunctional coupling agent DTSP, a 
selected lectin was successfully immobilised on the gold surface, while 
retaining its activity. The obvious advantage of this new Au-modified 
substrate is that using DTSP chemistry, any bio-recognition molecule 
(lectins, enzymes, Protein A etc) can be immobilised depending upon the 
required application while taking full advantage of the excellent mass-tranfer 
characteristics afforded by the underlying porous polymer monolith. Although 
a comprehensive quantitative assessment of extraction and recovery was 
not performed, nevertheless enhanced capacity and excellent phase 
selectivity was clear.  
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The effectiveness of biotherapeutic drugs for the treatment of different 
diseases, e.g. cancer, diabetes, etc., has accelerated their development and 
manufacturing. The production processes of such drugs are strictly regulated 
to ensure the consistency of the processes and to produce high quality 
drugs. Therefore, the aim of this project was to develop rapid and efficient 
chromatographic methods for the analysis of real samples sourced from the 
biopharma industry and to evaluate lot-to-lot variability. The samples 
included complex and CD cell culture media, raw materials (i.e. yeastolate) 
and in-process samples. The samples were complex and comprised a 
variety of components. The challenge was to develop methods for the 
determination of the target analytes with minimal interference from sample 
matrices.  
 The results in Chapter 3 showed the development of a relatively rapid 
and efficient RPLC-FLD based method for the qualitative and semi-
quantitative determination of up to ten common monosaccharides. The 
method involved a sample pretreatment step using a C18 SPE cartridge to 
trap hydrophobic peptides and vitamins, with recovery of all test 
monosaccharides exceeding 90 %. The selectivity of the method was also 
achieved by the pre-column derivatisation of monosaccharides with 
anthranilic acid. The derivatives were efficiently separated on a C18 particle-
based column packed with sub-2 µm particles. The method used 
considerably less mobile phase while running at lower flow rates. Standard 
analytical performance criteria were used for evaluation purposes, with the 
method found to exhibit LOD’s as low as 10 fmol, and be linear and precise 
(% RSD < 2.2 % (n = 7). The method was applied to the analysis of different 
lots of complex biopharmaceutical production samples, including yeastolate 
powders, cell culture media and in-process fermentation broth samples in 
order to estimate lot-to-lot variability. 
 The second developed method, as described in Chapter 4, showed 
the successful application of a rapid, sensitive and specific RRLC-UV-Vis 
assay for the quantitative determination of total free sialic acid in the same 
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sample matrices analysed in Chapter 3. The method also involved a sample 
pretreatment step utilising a C18 SPE cartridge. It also involved a pre-column 
derivatisation step employing thiobarbituric acid as pre-column tagging agent 
followed the oxidation of sialic acid with periodic acid. However, the 
derivatives here were separated on a short C18 monolithic column in less 
than 90 seconds. The separation was carried out at high flow rates showing 
the advantage of using such columns. The method was linear over a wide 
range (0.25 - 25 µmol.L-1), reproducible (average % RSD = 1.2 (n = 6) and 
sensitive (LOD = 842 fmol based upon a 100 µL injection volume). 
 Monolithic columns were also effectively used for the development of 
a rapid and sensitive method for the quantitative determination of the Cys 
and Cyss ratio in CD media feedstock as presented in Chapter 5. Cys was 
pre-derivatised with purified CMQT and separated from other derivatisation 
products on a narrow-bore C18 monolithic column and monitored with UVD at 
355 nm and MS. The derivatisation reagent (CMQT) is thiol selective and the 
detection wavelength negated any possible interference from other potential 
interfering sample components such as monosaccharides or other amino 
acids. The treatment of the samples consisted of dividing them into two 
aliquots, the first aliquot was analysed for Cys and the second aliquot is 
analysed for Cyss after its quantitative reduction to cysteine using TCEP. 
The method performance data revealed that the method w linear, sensitive 
and precise. Samples (n = 31) of an industry-supplied CD media feedstock 
were analysed, finding Cys ranging from 1.56 to 2.26 µg.mL-1 (S.D. 0.2 
µg.mL-1) and Cyss from 1062.02 to 1348.13 µg.mL-1 (S.D. 80.5 µg.mL-1). The 
developed methods are useful for routine analysis for large numbers of 
samples due to their minimal sample handling steps, quantitative nature and 
fast analysis.   
 The final section of this project, which is presented in Chapter 6, 
demonstrated a novel affinity monolithic extraction phase for selective 
enrichment of galactosylated proteins. The inner-wall of pipette-the tip was 
pretreated by grafting methacrylate anchor sites to ensure a subsequent 
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attachment between the tip and the extraction phase (i.e. EDMA porous 
polymer monolith), which was then photopolymerised in-situ within the 
confines of 20 µL polypropylene pipette-tips. Then the surface of the 
monolith was significantly enhanced by immobilising AuNPs. AuNPs were 
immobilised onto the monolith after surface amination (via an azlactone 
grafting step) and coverage was verified using FE-SEM. The obvious 
advantage of this new Au-modified substrate is that any bio-recognition 
molecule (lectins, enzymes, Protein A etc) can be immobilised by using the 
bifunctional coupling agent DTSP. However, ECL was selected in this study 
since it is commercially available and its bind/elute mechanism is well known 
[1]. Therefore, the immobilised AuNPs were functionalised with ECL. The 
ECL-modified tip was successfully applied for the enrichment of 
galactosylated protein (desialylated transferrin) versus a non-galactosylated 
protein (Ribonuclease B) due to the specificity of ECL. Reversed-phase 
capillary HPLC was used to validate the efficiency and selectivity of the 
developed extraction device which resulted in an increase in extraction 
recovery of ~95 % due to the AuNPs enhanced surface area. Further 
specificity of the ECL-modified tip was demonstrated with a complex mixture 
of non-glycosylated and glycosylated proteins with differing terminal sugar 
structures. Although the affinity monolith was not applied to industry-supplied 
complex samples, it was applied to a galactosylated protein spiked E. coli 
cell lysate to successfully demonstrate matrix tolerance.  
The primary focus in the work presented in Chapter 6 was a 
qualitative assessment of the selectivity of the affinity monolith for 
galactosylated glycoproteins (e.g. transferrin) over non-glycosylated 
glycoproteins (e.g. ribonuclease B) rather than a comprehensive quantitative 
assessment of extraction/recovery. The preliminary results obtained were 
extremely promising in terms of the development of a novel AuNP-modified 
monolithic substrate for affinity applications. The enhanced capacity and 
excellent phase selectivity of the affinity monolith were clear. Future work 
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shall involve a more detailed examination of extraction/recovery, loading 
flow-rates and stability testing of the affinity monolith tip. 
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Appendix I: Recrystallisation of CMQT 
 
Experimental 
 
Instrumentation 
 
1H NMR spectra of CMQT before and after recrystallisation were 
collected with a Bruker Avance 400 UltraShield spectrometer (Fällanden, 
Switzerland). Accumulation parameters are listed in Table I.1. The chemical 
shifts were referenced with respect to deuterium oxide (D2O), used as 
internal reference.  
 
Table I.1  
Experimental acquisition conditions for 1H NMR spectroscopy 
Scans 
Spectral 
width (ppm) 
Pulse 
duration (s) 
Recycle delay 
time (µs) 
Frequency 
(MHz) 
State 
16 20.68 3.95 60 400 Liquid 
 
 
Recrystallisation of CMQT 
 
1.3 g of CMQT produced in Section 5.2.4 was dissolved in 3 mL ACN and 
placed in a 25-mL beaker, which was in turn placed within a larger beaker 
containing 25 mL diethyl ether. The system was made airtight and left 
overnight. The resulting crystals in the inner beaker (formed due to solvent 
exchange) were isolated and dried by vacuum filtration for 60 minutes. The 
recrystallisation yield was calculated as 93.9 %.  
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Results and discussion 
 
Recrystallisation of the prepared CMQT reagent was carried out in order to 
minimise unknown reagent components that were observed when the CMQT 
was injected in the HPLC which possibly lead to increase chromatogram 
complexity. 
Choosing the proper solvent for recrystallisation is the most critical 
point. Unsuccessful attempts have been made to use single-solvent or hot-
filtration recrystallisation due to either the solubility of CMQT at room 
temperature in the more polar solvents or due to insolubility of CMQT in the 
less or non polar solvents. The only two solvents that CMQT was insoluble 
in at room temperature and soluble at boiling point were ethanol and 1-
propanol. Figure I.1 shows chromatograms of CMQT-Cys using CMQT 
recrystallised in three different solvents; diethyl ether, ethanol and 1-
propanol. As it can be seen, CMQT was successfully recrystallised from 
ACN:diethyl ether. Purified CMQT crystals were verified using HPLC (Figure 
I.2), mass spectrometry (Figure I.3) and 1H NMR (Figure I.4). 
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Figure I.1: HPLC chromatograms showing Cys standard drivatised with CMQT that 
was recrystallised in different solvents. Chromatographic conditions are as 
described in Figure 5.8. Peaks: (1) excess CMQT, (2) CMQT-Cys.  
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Figure I.2 shows HPLC chromatograms of Cys standard derivatised 
with CMQT before and after recrystallisation in diethyl ether. The 
chromatograms were obtained using a gradient method. As it can be seen, 
the recrystallisation of CMQT lead to disappearance of the extra peaks 
eluted after the excess CMQT reagent peak.  
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Figure I.2:  HPLC chromatograms showing the CMQT-Cys standard before and 
after recrystallisation of CMQT. Chromatographic conditions are as described in 
Figure 5.8. Peaks: (1) excess CMQT, (2) CMQT-Cys. 
 
 
CMQT purification was also confirmed using MS. Figure I.3 shows the 
mass spectra of CMQT before and after recrystallisation. The spectra was 
obtained from direct infusing of a solution of CMQT (1 µg.L-1) prepared in 
H2O/MeOH (80:20). Apart from CMQT signal at m/z of 178, which remained 
relatively constant, other signals at m/z 174, 159 and 131 were present. The 
intensities of these signals were decreased by over 96 % after 
recrystallisation. A characteristic mass spectral isotope pattern was 
produced by CMQT corresponding to the chlorine natural isotopic 
abundance. The molecular ion of CMQT at m/z 178 shows a +2 amu peak 
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with about 30 % intensity, which corresponds to the 37Cl isotope contribution 
as illustrated in Figure I.3. (It should be noted that this characteristic pattern 
is not produced by the CMQT-Cys derivative since the chlorine atom is 
replaced by the thiol.)  
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Figure I.3: Mass spectra of CMQT (1 µg.L-1) before and after recrystallisation.  
 
 
To identify the origin of these peaks, CMQT was further analysed 
using 1H NMR. Figure I.4 shows the 1H NMR spectra of CMQT before and 
after recrystallisation. Both spectra exhibit 6 different NMR signals located at 
7.9, 8.03, 8.15, 8.17, 8.3 and 8.9 ppm. Apart from signals located at 7.9 and 
8.15, which are triplet signals, all other signals are doublet. This 
demonstrates that CMQT structure consisted of four different protons having 
one single neighbouring proton, and two different protons having two 
neighbouring protons. Moreover, the triplet signal observed around 8.15 ppm 
is composed of a superposition of two triplet signals translating the presence 
of two different protons of similar electronical environment. According to 
these observations, the 1H NMR spectra show the presence of seven 
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different protons within the structure of CMQT. This is in a perfect agreement 
with the theoretical expectation as CMQT is consisting of nine protons in 
which three of them (within the methyl group, -CH3) have an identical 
electronical environment and thus appearing with the same NMR signal 
(Figure I.4(a)). Assignments of the different chemical shifts are summarised 
in Table I.2.  
 
           Table I.2 
Assignment of 1H NMR signals obtained from CMQT 
Chemical shift (ppm) Attribution 
7.9 H6 
8.03 H7 
8.15 H4,5 
8.17 H3 
8.3 H2 
8.9 H1 
 
 
Even if both spectra (before and after recrystallisation) show the 
same number of signals at closely related chemical shifts, it is important to 
highlight the slight shift toward the lower chemical shifts of CMQT 
characterised before recrystallisation, as indicated by the dash-lines in 
Figure I.4(a). This shift could be caused by the presence of strong 
nucleophilic groups such as oxygenated or fluorinated groups, which could 
be present in the reagent before purification. 
In addition, Figure I.4(b) shows the disappearance of several signals 
in the 3 - 4.5 ppm region, where methoxy- protons (CH3-O) linked to either 
aliphatic or aromatic groups usually appear. Thus, it is very likely that 
unpurified CMQT contains methoxy groups covalently linked to the aromatic 
skeleton in place of the chloride group. Furthermore the presence of a peak 
at m/z 174 in the mass spectrum of the material before recrystallisation 
suggests the presence of a methoxy group on the aromatic skeleton rather 
than the intended chloride atom. 
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Figure I.4(a and b): 1H NMR spectra of CMQT (20 mg/1 mL D2O) before and after 
recrystallisation 
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